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Phytoestrogens are perceived as a safer alternative to conventional hormone replacement therapy 
(HRT) for the alleviation of menopausal symptoms as they present a decreased side-effect profile. 
The Cyclopia subternata (honeybush) methanol extract, SM6Met, displays estrogenic attributes 
desirable for the development of an phytoestrogenic nutraceutical, namely, estrogen receptor (ER) α 
antagonism, ERβ agonism, and antagonism of 17β-estradiol (E2)-induced breast cancer cell 
proliferation.  
Activity-guided fractionation was employed in an attempt to isolate and identify the compounds 
inducing the specific estrogenic profile of SM6Met. Fractions were evaluated for estrogenic 
attributes and major polyphenols present. Initial liquid-liquid fractionation of SM6Met yielded a 
polar fraction (PF) and a non-polar fraction (NPF), with the estrogenic attributes of interest retained 
and concentrated in NPF. Subsequent high performance counter-current chromatography (HPCCC) 
fractionation of NPF yielded three fractions (F1-F3). Interestingly, the fractions revealed separation 
of the previously demonstrated positive estrogenic attributes of NPF into separate fractions, with F1 
and F2 acting as ERα antagonists, only F2 inducing antagonism of E2-induced breast cancer cell 
proliferation and only F3 retaining ERβ agonist activity. Although ERβ agonism displayed by F3 
was robust and significantly higher than that of 10
-11
 M E2, it also displayed weak ERα agonism. 
Fractionation also for the first time in the study revealed ERβ antagonism, as induced by F1. In 
terms of major polyphenols HPCCC fractionation resulted in a divergence with F1 emerging as the 
dihydrochalcone-rich fraction and F2 as the flavanone and benzophenone-rich fraction, while the 
xanthones, flavones and phenolic acids were retained in F3.  
In addition, a preliminary absorption study was conducted using the ex vivo flow-through diffusion 
assay whereby the permeability of porcine small and large intestine for polyphenols in SM6Met was 
evaluated. The major compounds present in SM6Met were not able to penetrate the large intestinal 
mucosa, but small intestinal permeation of all major compounds in SM6Met ensued, with apparent 








, indicative of good 
intestinal absorption. Open source programs used for theoretical prediction of absorption gave 
conflicting results, emphasising the need to confirm predictions experimentally. ACD/Labs 
predicted poor intestinal absorption of SM6Met compounds based on physicochemical profiling, 
while OSIRIS and ChemAxon anticipated good absorption.  
In conclusion, activity-guided fractionation results suggest that retention of all the positive 
estrogenic attributes of the original SM6Met in one fraction is not an attainable goal. This suggests 
that several of the polyphenols present in SM6Met or NPF, through antagonistic, synergistic, or 
additive effects, may together be conferring these desired estrogenic traits. Thus production or 
isolation of a mixture of compounds, i.e. an ―intelligent‖ mixture, should serve as a superior 
strategy in designing a nutraceutical product tailored to user demand of estrogenic activity. 
  





Fitoestrogene word beskou as ‗n veiliger alternatief vir konvensionele hormoon-vervangingsterapie 
(HVT) vir die verligting van simptome geassosiaeer met menopause aangesien dit ‗n verminderde 
newe-effek profiel vertoon. Die metanol ekstrak van Cyclopia subternata (heuningbos), SM6Met, 
vertoon estrogeniese eienskappe wat wenslik is vir die ontwikkeling van ‗n fitoestrogeen 
nutraseutiese middel, naamlik, estrogeen reseptor (ER) α antagonisme en ERβ agonisme, asook 
antagonisme van 17β-estradiol (E2) geïnduseerde proliferasie van borskankerselle. 
Aktiwiteit-begeleide fraksionering (ABF) is gebruik om die verbindings wat die spesifieke 
estrogeniese profiel aan SM6Met verleen te probeer isoleer en identifiseer. Fraksies is ge-evalueer 
vir estrogeniese eienskappe, asook vir die hoof polifenole teenwoordig. Aanvankilike vloeistof-
vloeistof fraksionering van SM6Met het ‗n polêre fraksie (PF) en ‗n nie-polêre fraksie (NPF) 
opgelewer met behoud en konsentrering van die wenslike estrogeniese eienskappe in NPF. 
Daaropeenvolgende hoë werkverrigting teen-vloei chromatografie (HPCCC) van NPF het drie 
fraksies (F1-F3) opgelewer.  Interessant genoeg het hierdie fraksies ‗n verdeling van die wenslike 
estrogeniese eienskappe van NPF in die individuele fraksies teweeggebring, deurdat F1 en F2 ERα 
antagonisme getoon het, F2 E2-geïnduseerde proliferasie van borskankerselle antagoniseer het, en 
net F3 ERβ agonis-aktiwiteit behou het. Alhoewel die ERβ agonis-aktiwiteit van F3 betekenisvol 
hoër was in vergelyking met die aktiwiteit van 10
-11
M E2, het dit ook swak ERα agonisme getoon.  
Verder het fraksionering, vir die eerste keer in hierdie studie, ERβ antagonisme meegebring soos 
getoon deur F1.  HPCCC het ook ‗n skeiding van die hoof polifenole veroorsaak, waarvolgens F1 
as die dihidrogalkoon-ryke fraksie, F2 as die bensofenoon-ryke en flavanoon-ryke fraksie, en F3 as 
die xantoon-, flavoon- en fenoliese suur-ryke fraksie tevoorskyn gekom het. 
‗n Voorlopige absorpsie studie, wat gebruik gemaak het van die ex vivo deurvloei diffusie 
toetssisteem, is uitgevoer om die deurlaatbaarheid van vark dik- en dunderm vir SM6Met polifenole 
te evalueer.  Die hoof verbindings van SM6Met kon nie die dikderm mukosa penetreer nie, maar die 




deurlaatbaarheid van die dunderm vir alle SM6Met hoof polifenole is aangetoon, met skynbare 





ooreenstemmend met goeie intestinale absorpsie. Oopbron programme, wat gebruik is vir die 
teoretiese voorspelling van absorpsie deur gebruik te maak van fisiese-chemiese profilering van 
verbindings, het teenstellende resultate opgelewer wat daarop dui dat hierdie voorspellings 
eksperimenteel bevestig moet word. ACD/Labs, wat van die fisiese-chemiese eienskappe van die 
verbinding gebruik maak, het swak intestinale absorpsie van die polifenole voorspel, terwyl OSIRIS 
en ChemAxon goeie absorpsie voorspel het. 
Ten slotte, resultate van aktiwiteit-begeleide fraksionering het getoon dat behoud van al die 
gewensde estrogeniese eienskappe van SM6Met in een fraksie nie ‗n haalbare doelwit is nie. 
Hierdie bevinding dui daarop dat verskeie van die polifenole teenwoordig in SM6Met of NPF saam, 
deur middel van antagonistiese, sinergistiese of additiewe effekte, die wenslike estrogeniese 
eieskappe verleen. Die ontwikkeling of isolering van ‗n mengsel van verbindings, met ander 
woorde‗n ―intelligente‖ mengsel is dus ‗n beter strategie vir die ontwerp van ‗n estrogeniese 
nutraseutiese produk om die verbruikers-aanvraag van estrogeniese aktiwiteit te voorsien.  
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Nutraceuticals have become a multi-billion dollar industry in the global marketplace with sales in 
the USA alone reported to be $57.2 billion in 2012 [1]. In 2004 the major contributors to the global 
market were USA, Japan, and Europe, comprising an estimated 90% of the total market [2]. 
Defined as non-toxic food extract supplements, with health benefits likely arising from biochemical 
and cellular interactions [3], nutraceuticals are believed to have fewer side-effects than synthetic 
drugs [4]. Consumers have shown increased interest in nutraceuticals as a consequence of increased 
public health consciousness, increasing health costs of modern medicines [5], and also as 
nutraceuticals are seen as ‗safer‘ alternatives to conventional therapies [6]. Africa is currently not 
seen as a competitive market for nutraceuticals, however an emerging market is establishing itself 
in South Africa [7,8], which opens the door for the development of a uniquely South African 
nutraceutical. 
Cyclopia species (family Fabaceae) are endemic to the Western and Eastern Cape provinces of 
South Africa [9], and the aerial parts of the bush have been harvested for more than a century for 
the production of a herbal tea known as honeybush tea [10], produced from oxidised plantmaterial. 
Re-discovery of honeybush in the 1990‘s led to the production of green or unfermented honeybush, 
in order to prevent oxidative breakdown of potentially health-promoting polyphenols, as this 
transpires in the case of fermented honeybush [11]. As consumers world-wide demonstrated an 
increased demand for health-promoting foods, and especially antioxidants, the export market for 
honeybush grew from 50 to 200 tonnes from 1999 to 2006 [9]. In 2010, the major importers were 
the Netherlands, Germany, USA, and the United Kingdom (UK) [9] and at this stage several in vitro 
and in vivo studies had already shown that Cyclopia species had antimutagenic, antioxidant, 
anticancer and also phytoestrogenic properties [10]. 
Menopausal women have shown great interest in phytoestrogenic nutraceuticals as an alternative to 
conventional hormone replacement therapy (HRT) due to the extensive side effect profile of HRT 
[12-24], with breast cancer as a primary adverse outcome [23,24]. Initially, epidemiological studies 




found a correlation between the consumption of phytoestrogen-rich food and a lowered incidence of 
breast, prostate, and endometrial cancer, as well as cardiovascular disease [25,26]. More recent 
studies, however, have shown that known phytoestrogens can not only alleviate menopausal 
symptoms, but they can also aid in the prevention of numerous diseases such as osteoporosis and 
cardiovascular disease, and also hormone dependent cancers, such as amongst others, breast cancer 
[27-35]. 
The possibility of Cyclopia as a phytoestrogen source was first raised in two studies by Verhoog et 
al. [36,37] in 2007. In the initial study [36] it was found that extracts from both C. genistoides and 
C. subternata displayed phytoestrogenic activity, and it was also shown that optimal extract 
estrogenicity was generated by using methanol extracts from unoxidised plantmaterial rather than 
fermented plantmaterial. In the second study [37] a dried methanol extract (DME) of C. genistoides, 
P104, was identified as binding the estrogen receptor (ER), transactivating an estrogen response 
element (ERE) containing promoter reporter construct predominantly via ERβ, and also 
antagonising 17β-estradiol (E2)-induced breast cancer cell proliferation. Subsequent screening of 
extracts produced from C. genistoides and C. subternata species for extraction-enhanced estrogenic 
activity in 2008 by Mfenyana et al. [38], resulted in the identification of SM6Met, a sequential 
methanol extract of a C. subternata harvesting, M6. Mfenyana et al. [38] also demonstrated that 
SM6Met was estrogenically the most potent of the screened Cyclopia extracts, with a potency 
comparable to commercially available phytoestrogenic nutraceuticals. More recently, investigation 
into the estrogenic specificity of SM6Met revealed that the extract displays three desirable 
estrogenic traits for future development of a possible phytoestrogenic nutraceutical, namely, ERα 
antagonism, ERβ agonism, and also antagonism of E2-induced breast cancer cellular proliferation 
[39]. This suggested that SM6Met contains a compound or compounds conferring subtype specific 
estrogenic activity [40], which could play a key role in the development of a future nutraceutical, as 
it has been shown that ERα antagonism results in the inhibition of cellular proliferation, whilst ERβ 
activation inhibits ERα mediated breast cancer cell proliferation [41]. A phytoestrogenic 




nutraceutical with these traits would thus alleviate menopausal symptoms through ERβ activation, 
whilst as a positive side effect it would prevent the development of breast cancer through ERα 
antagonism. 
For the future development of a possible phytoestrogenic nutraceutical, the candidate formulation, 
as for any new nutraceutical, should meet important prerequisites for the marketing of health 
claims. An important prerequisite is formulation standardisation, which includes efficacy, quality 
and safety data, however, equally important prerequisites include identification of the active 
compound(s), and elucidation of the molecular mechanism of action, which covers amongst others 
absorption, distribution, metabolism and excretion of the active compound(s) [42-45]. Identification 
of active compounds is not only important for the manufacturing process of a quality-assured 
phytoestrogenic nutraceutical, but it will also prove to be important in screening and selective 
breeding of Cyclopia plants for effective isolation and/or purification of these compounds.  
The remainder of this dissertation consists of four chapters. Chapter 2 provides a literature review 
discussing the importance of E2, sources of E2, its molecular mechanism of action, and its use in 
conventional HRT. The literature review also includes a section on E2-associated diseases, and why 
most phytoestrogens are perceived as safer alternatives to conventional HRT. Furthermore, the 
literature review includes a section on Cyclopia, followed by a section discussing techniques 
available in identifying estrogenic compounds from an extract. Lastly, the literature review will 
focus on the intestinal absorption and metabolism of known phytoestrogens and Cyclopia-
associated polyphenols, and also techniques available to evaluate intestinal permeation of 
compounds. The literature review aims to validate our decision of identifying and isolating 
compounds conferring phytoestrogenic activity to Cyclopia extracts and establishing whether these 
compounds are intestinally absorbed. In addition, the literature review aims to enlighten the reader 
about the potential of phytoestrogens, and Cyclopia extracts as a potential source of phytoestrogenic 
compounds. Chapters 3 and 4 will each address one of our main aims. Chapter 3 focusses on the 




isolation of compounds conferring specific phytoestrogenic activity to SM6Met, using activity-
guided fractionation of SM6Met combined with two in vitro assays to monitor estrogenic activity. 
The two in vitro assays to be used are a cell proliferation assay investigating the effect of fractions 
on breast cancer cell proliferation, and a promoter reporter assay investigating ERα/ERβ 
transactivation via an ERE-containing promoter reporter construct. In an attempt to predict human 
intestinal absorption of SM6Met compounds, chapter 4 investigates small and large intestinal 
permeation of SM6Met compounds using an ex vivo flow-through diffusion assay. Chapter 5 
integrates and contextualises the obtained results in terms of the available literature, and discusses 
how these results fit into the ‗bigger picture‘. Furthermore, chapters 3 and 4 are written in 
manuscript format, and as such, each contains an introduction, materials and methods, results, and 
discussion section, and therefore the occurrence of repetition between chapters are inevitable. We, 
however, have found the outcomes of the current study to be of a rewarding nature, and in sharing 
this we hope to enrich the scientist in the reader. 
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Menopause is characterised by a decrease in estrogen production from the ovaries due to a decrease 
in ovarian function [1]. Menopausal symptoms may be divided into climacteric symptoms, such as 
night sweats, and psychosomatic symptoms such as poor concentration and memory loss [2], 
however, long term problems such as osteoporosis, Alzheimer‘s disease and coronary heart disease 
(CHD) are also common [3-5]. 
To supplement the deficit in estrogen, menopausal symptoms are traditionally treated with HRT. 
Conventionally, estrogen or estrogen and progestin are used in HRT, however, estrogen 
supplementation has been linked to an increased risk of various diseases, amongst others [6-9], 
cardiovascular disease [9-11] and also various cancers [9,10,12-18], of which breast cancer is 
considered the primary adverse outcome [9,10]. 
As a result of adverse effects women have become reluctant to make use of traditional HRT [19] 
and this has consequently initiated the search for a safer alternative. Phytoestrogens were 
subsequently identified as a safer alternative [20] as these plant constituents are structurally and or 
functionally similar to mammalian estrogen [21]. Phytoestrogens, however, present a subtle 
uniqueness in their mechanism of action that not only supplements the estrogen deficit in 
menopausal women, but as a side effect may result in the prevention of certain hormone-dependent 
cancers [22,23], such as hormone dependent breast cancer. 
Studies have shown that Cyclopia species, better known as honeybush, serve as a possible 
phytoestrogen source [24-26]. Cyclopia forms part of the fynbos kingdom of the Western and 
Eastern Cape provinces of South Africa [27], and has traditionally been marketed and consumed as 
a herbal infusion. In addition to findings supporting Cyclopia as a possible phytoestrogen source, a 
specific C.subternata extract was shown to be comparable to commercially available 
phytoestrogenic nutraceuticals in terms of its estrogenic potency [26]. Subsequent estrogenic 
specificity evaluation of this extract in a recent review identified three estrogenic attributes 




desirable for the development of a possible phytoestrogenic nutraceutical [28], which will be 
discussed in this review. 
Prerequisites in the development of an oral phytoestrogenic nutraceutical from a plant extract 
include, amongst others, identification of the active compounds, and also whether these compounds 
can become bioavailable in the human body in order to exert a desired therapeutic effect [29-32]. 
The most obvious choice in the isolation and identification of desired active compounds from 
extracts is activity-guided fractionation, as this technique is most frequently and successfully 
employed for this purpose [33,34]. Identified compounds will not only be important in screening of 
harvestings and selective breeding of plants for isolation and purification purposes, but they will 
also allow bioavailability analyses, and furthermore serve as quality control parameters of the final 
product.  
This literature review will focus on the molecular mechanism of estrogen as traditional HRT source 
and how it translates to both the positive and the negative effects associated with estrogen 
supplementation. Cyclopia poses as a possible phytoestrogen source and as such phytoestrogen 
related topics, covering commercially available phytoestrogenic nutraceuticals and its popularity 
amongst menopausal women, as well as the rationale for the increased interest in Cyclopia as 
possible phytoestrogen source will be discussed. For the isolation and identification of active 
compounds from an extract, activity-guided fractionation is regarded as the most successfully 
employed technique, therefore, this literature review will provide background on this technique and 
its practise as well as discussing the various estrogenic tests available to test for activity. 
Furthermore, factors influencing absorption and metabolism of compounds will also be discussed as 
active compounds have to become bioavailable to elicit a therapeutic effect. The literature review 
will be concluded with a research rationale for the current study, from which the aims of the thesis 
will be formulated. 




2.2 Estrogens  
2.2.1 Sources of estrogen 
Estrogens may be classified into two groups namely endogenous and exogenous estrogens. These 
two groups of estrogens not only differ in terms of source and estrogenic potency, but also in terms 
of the biological response they elicit.  
2.2.1.1 Endogenous estrogens 
Four different endogenous estrogens have been identified, with the three predominant estrogens 
being estrone (E1), E2 and estriol (E3), and the less common estetrol (E4). The three predominant 
estrogens are all steroids consisting of 18 carbon atoms and characterised by an aromatic A-ring 
[35]. The hydroxy groups at positions 3 and 17 and the aromatic A-ring are considered crucial for 
the specific estrogen effect [35] (Fig. 1B). The individual potencies of the endogenous estrogens 
vary, with E3 the least potent and E2 the most potent [36,37].  
E1, E2 and E3 are the main estrogens in non-pregnant women, and are synthesized by the aromatase 
enzyme (estrogen synthase) in the ovarian granulosa cells, various extraglandular sites like the skin 
and brain fibroplasts, and also, adipose tissue [38]. In the ovaries, the main site of estrogen 
biosynthesis in premenopausal women [39], the initial movement of cytosolic cholesterol into the 
mitochondrion is facilitated by the steroidogenic acute regulatory protein (StAR1) (Fig. 1A). Six 
enzymes are then involved in the conversion of cholesterol to E2 [40] (Fig. 1A&B). The aromatase 
enzyme, located in the endoplasmic reticulum of estrogen-producing cells, is responsible for 
estrogen formation from C19 androgens [41,42]. The enzyme is comprised of two polypeptiteds, 
namely, the flavoprotein, NADPH-cytochrome P450 reductase and the aromatase cytochrome P450 
(encoded for by CYP 19) [38]. E2 is converted to E1 by the activity of 17β-hydroxysteroid 
dehydrogenase in a reversible reaction forming part of the E2 biosynthesis pathway [35]. The 
principal product of the ovaries is the potent E2, while the estrogenically weak E1 is formed in large 
quantities in adipose tissue where at least half of it is converted to E2 in extraovarian tissues [43]. 




In post-menopausal women E2 levels are low as the ovaries cease to produce E2. Consequently, the 
primary site for estrogen biosysnthesis is no longer the ovaries but the adipose tissue and the skin. 
In post-menopausal women the predominant estrogen is E1, which originates from androstenedione 
[40,44]. The adrenal cortex is the primary source of androstenedione which serves as immediate 
precursors of E1 [35]. E1 serves as the primary source of E2 synthesis in post-menopausal women, 
however, androstenedione can also be converted testosterone to form E2. Even though 
adrostenedione is predominantly produced by the adrenal glands, some androstenedione is also 
produced by the ovaries. In addition, the adrenal gland and the ovaries also supply other androgenic 
precursors that are suitable for estrogen production [45,46]. 
During pregnancy, the predominant estrogen is E3 which is formed from androgenic precursors 
provided by the mother and the fetus [35]. Androgenic precursors then undergo fetal liver 
hydroxylation, where after the placenta is responsible for the conversion of hydroxylated 
androgenic precursors to E3 [47]. E4 (Fig. 2A) is exclusively formed during human pregnancy [48], 
where fetal liver hydroxylation reactions are a necessity in E4 synthesis from its precursors [49-51] 
(Fig. 2B). Produced E4 then reaches the maternal circulation through the placenta [48]. E4 synthesis 
can occur from phenolic E2, E3, 15α-hydroxyestradiol, or from neutral androgenic precursors (Fig. 
2B) with sulfo-conjugation preceding hydroxylation where present [48,52-54].  
Numerous biological roles of estrogens have been identified. During fetal life E3 is responsible for 
cerebral development, leads to breast swelling and endorses uterine growth. E2 promotes the 
advance of female sex characteristics, and also stimulates uterine growth and breast development. 
During menopause circulating estrogen levels decline and the estrogenically less potent E1 becomes 
the predominant estrogen [35,56,57]. Consequently, this leads to atrophy of the genitalia and also 
many other menopause associated symptoms and diseases [35]. Uterine cell-differentiation, in 
contrast to the growth induced by E2, has been identified as a biological role of E4 [48]. 





Figure 1. Biosynthesis of E1-E3 (Adapted from Wright et al. [55] and Bulun et al. [40]. (A) In the ovaries 
the StAR protein facilitates the main step of estrogen biosynthesis by enabling the entry of cholesterol into 
the mitochondrion which leads to progesterone and subsequent dehydroepiandrosterone. (B) Several 
enzymes are then responsible for the conversion of dehydroepiandrosterone to E1-E3.  
Levels of endogenous estrogens can act as determining factors or markers for the detection of 
physiological abnormalities. E2, with circulating levels between the pM to nM range in pre-
menopausal women, is the physiological estrogen most frequently connected with the female 
reproductive phase function as well as the initiation and progression of cancers in the female 




reproductive tissues [58]. E1 ranges from 0.5-1 nM in reproductive and from 150 pM-200 pM in 
postmenopausal women, whilst E3 is higher in pregnant, than in non-pregnant women (10-100 nM 
vs 7 nM). Low levels of E3 in pregnancy have been correlated with the incidence of Down‘s 
syndrome in offspring [59] and complications of eclampsia [60]. E4 levels in late pregnant females 
are approximately in the 3 nM range [48], and studies have shown that E4 does not represent a 
unique marker for the identification of fetal abnormalities [48]. 
 
Figure 2. (A) E4 chemical structure and (B) biosynthesis pathways as adapted from Holinka et al. [48]. 
Abbreviations used: E3 = estriol; E2 = 17β-estradiol; E4 = estetrol; 15α-OHE2 = 15α-hydroxyestradiol; 15α-
OHAD = 15α-hydroxyandrostenedione; 16α-OHAD = 16α-hydroxyandrostenedione; 15α-OHDHEA = 15α-
hydroxydehydroepiandrosterone; 16α-OHDHEA = 16α-hydroxydehydroepiandrosterone; 16α-OHDHEAS = 
16α-hydroxydehydro- epiandrosterone sulfate; DHEAS= dehydroepiandrosterone sulfate. 
In summary, four different endogenous estrogens, E1-E4 have been identified. E1-E3 are the only 
circulating estrogens in non-pregnant women, with E2 as the predominant estrogen. During 
menopause the ovaries cease to produce E2 which leads to a decline in circulating E2-levels. 
Consequently E1 is the predominant estrogen in post-menopausal women, and serves as the main 
source of E2 synthesis. In pregnant women E1-E4 are all present, with E3 as the predominant 
estrogen. Apart from the structural differences between E1-E4, they differ in their estrogenic 
potencies, and they have different biological roles. These endogenous estrogens, however, are not 




solely responsible for all estrogen-induced biological responses, as exogenous dietary estrogens, 
upon absorption by the host, also play a role. 
2.2.1.2 Exogenous estrogens 
Dietary estrogens may be classified into two main groups, namely, naturally occurring estrogens 
and synthetic contaminant estrogens (Fig. 3) [61], where naturally occurring estrogens are divided 
into ovarian steroids, phytoestrogens and mycoestrogens, and synthetic contaminant estrogens are 
divided into pharmaceutical estrogens and xenoestrogens (Fig. 3) [61]. As ovarian steroids have 
already been discussed in section 2.2.1.1 this section will focus on phytoestrogens, mycoestrogens, 
pharmaceutical estrogens, and xenoestrogens. It is important to bear in mind that phytoestrogens 
form the largest part of dietary estrogens, and that they are also more common in the human diet, 
consequently they will be discussed in more detail. 
 
Figure 3. Assembly of dietetic estrogen groups [61]. 
Phytoestrogens are plant-derived compounds that are structurally similar to mammalian E2 and as 
such promote estrogenic actions in mammals [62,63]. They may be classified into isoflavones such 




the aglycones genistein and daidzein or the glycones genistin and daidzin, coumestans such as 
coumestrol and 4‘-methoxycoumestrol, flavones such as apigenin and luteolin, flavanones such as 
eriodicytol and naringenin [61], flavonols such as fisetin, catechins such as proanthocyanidins, 
lignans such as secoisolariciresinol and matairesinol and chalcones, such as phloretin. Although 
flavanols and catechins form part of the flavonoids this is not indicated in Fig. 3. In addition, 
stilbenes such as resveratrol [64] and the terpenoids and saponins (Fig. 3), such as tschimganidine 
and diosgenin [65], respectively, are also classified as phytoestrogens. The most studied sources of 
phytoestrogens include black clover, red cohosh, flax, licorice, hops and dong quai [65]. The main 
phytoestrogenic sources will be discussed in the next section of this literature review, where they 
will be assessed terms of their historical usage, and the benefits they may offer. 
Even though mycoestrogens are metabolites of fungal species and not plant compounds, they are 
frequently discussed as part of the hierarchy and classification of phytoestrogens [61]. The naturally 
occurring mycoestrogen, zearalenone, is frequently found in food as a result of grain infection by 
Fusarium moulds [66]. Zeranol and zeranlenol are derived from zearalenone, they share weak 
estrogenic activity, and are collectively known as β-resorcylic acid lactones (RALs). Zeranlenol, a 
metabolite of zearalenone, is likely to be found in animal tissues, and it is known to compete with 
E2 for ER binding and subsequent activation [67]. 
Synthetic contaminants also form part of dietary estrogens, and may be classified into two groups, 
namely pharmaceutical estrogens and xenoestrogens (Fig. 3). These estrogens will be briefly 
discussed in the following two paragraphs. 
Xenoestrogens are considered synthetic non-steroidal small lipophilic compounds that copy the 
action of endogenous estrogens [68]. They originate from urban waste or consumer products, 
agricultural spraying, and industrial processes [69]. Xenoestrogens may be divided into two groups, 
namely, environmental pollutants such as fungicides and pesticides, which includes lindane, 
chlordecone, dichloro-diphenyl-trichloroethane (DDT) and atrazine, and the second group, 




industrial chemicals such as surfactants and plasticizers, which includes polychlorinated biphenyls 
(PCBs), alkylphenols, bisphenol A and phthalate esters [70-73] 
Pharmaceutical estrogens are also a class of synthetic estrogens, however, they were designed with 
an intended medicinal use. Ethinyl estradiol is an example of a pharmaceutical estrogen most 
commonly used in contraceptives such as Generess
®
. Another commercially available product 
containing ethinyl estradiol is Quinestrol
®
, which is used in hormone replacement therapy [74,75]. 
Selective estrogen receptor modulators (SERMS) such as tamoxifen [76], and selective estrogen 
receptor downregulators (SERDS) such as fulvestrant, both designed for the use in treatment of 
breast cancer [77], also form part of pharmaceutical estrogens, eventhough some phytoestrogens are 
also often referred to as natural SERMS [78].  
In summary, exogenous estrogens may be divided into two main groups namely naturally occurring 
estrogens and synthetic contaminants, where phytoestrogens form the predominant group of 
naturally occurring estrogens, however, the estrogenic contribution of the other groups should not 
be discounted. Even though endogenous and exogenous estrogens differ in source, chemical 
structure and estrogenic potency, all estrogens mediate their effects through a similar signalling 
transduction pathway, and as such the next section will focus on the molecular mechanism of 
estrogen action. 
2.2.2 Molecular mechanism of action 
The signalling transduction pathway of all estrogenic compounds are similar to that of E2, and as E2 
is the major endogenous estrogen in non-pregnant premenopausal women, the following section 
will in detail discuss the molecular mechanism of E2 action. 
E2 action is mediated via the ER, which forms part of the superfamily of nuclear receptors 
functioning as ligand-activated transcription factors [79]. ERs are divided into two main subtypes, 
namely, ERα and ERβ (Fig. 4). Both contain two highly conserved regions, the E/F or ligand-
binding domain (LBD), found at the carboxyl-terminal end, which binds estrogen, and also the C or 




DNA-binding domain, found in the middle of the ER, which is involved with DNA interaction [79]. 
The LBD also has other functions such as nuclear localisation, dimerization, heat shock protein 
association, and hormone dependent activation function (AF-2). In contrast, the amino-terminal end 
(A/B domain) contains a ligand independent activation function (AF-1) [80]. ERα comprises a fully 
functional AF-1 and AF-2 domain, whereas ERβ lacks a functional AF-1 domain, but retains a 
functional AF-2 domain [81]. 
 
Figure 4. Diagram illustrating the % homology between human ERα (595 amino acids) and human 
ERβ (530 amino acids) [82]. DNA refers to the DNA-binding domain; Ligand refers to the ligand binding 
domain; AF-1 and AF-2 refers to the two transcriptional activation functions  
Estrogen-dependent transcriptional activation (Fig. 5, point 1) occurs when E2 diffuses across the 
plasma and nuclear membranes and consequently binds the ER. In the absence of E2, the ER is in its 
inactive form bound to heatshock proteins within the nucleus [80]. Upon binding of E2 to the ER, 
the ER transforms into its active state by facilitating the dissociation of the heatshock proteins and 
permitting dimerization of receptor proteins [83]. Following homodimerization, the ERs bind the 
ERE (estrogen response element), which is frequently situated in the 5‘-flanking region of estrogen-
responsive genes [80]. The DNA-bound receptor then either directly or indirectly interacts with the 
general transcription machinery via cofactors [84], such as PPARγ coactivator-1 (PGC-1), CREB 
binding protein (CBP)/p300, amplified in breast cancer-1 (AIB1), steroid receptor coactivator 
1(SRC-1) and glutamate receptor-interacting protein 1(GRIP1), steroid receptor RNA activator 
(SRA), and p68 RNA helicase [85]. The receptor-cofactor-transcriptional machinery interaction 




aids in the disturbance of chromatin at the ERE by stabilising the transcription preinitiation complex 
in order to exert either a positive or negative effect on the expression of target genes [81].  
 
Figure 5. Schematic illustration of the ER mode of actions [86]. 1. classical ligand dependent actions, 
where E2-induced ER in the nucleus binds to EREs in the promoter region of target genes, 2. ERE-
independent actions, where nuclear E2-ER complexes are bound to transcription factor complex (TF) that 
binds to the promoter region of target genes, 3. ligand independent actions, where nuclear ERs are activated 
via phosphorylation (P) by protein kinase cascades, initially activated by growth factors (GF), 4. non-
genomic actions, where protein kinase cascades are activated by membrane E2-ER complexes resulting in 
altered gene expression or protein function. 
Activation or repression of genes can also occur in the absence of an ERE-site (Fig. 5, point 2) [81]. 
This mechanism is referred to as transcriptional cross talk or tethering [87] and covers E2- induced 
activation or repression of several genes which commonly occur through binding of the ERs to 
other transcription factors. These E2-ER-transcription factor complexes elicit an effect by binding to 
the promoter region of the target genes. Transcriptions factors include Fos and Jun proteins that 
bind AP-1 (activating protein-1) binding sites, ER-specificity protein-1 (Sp1), nuclear factor κB 
(NF-κB), CCAAT/enhancer binding protein β (C/EBPβ), or GATA binding protein 1 (GATA-1). 
Genes activated by E2 through the interaction of ERs with Fos and Jun proteins at AP-1 binding 
sites include collagenase [88], ovalbumin [89], IGF-I [90] and cyclin D1 [91,92], however, E2 




activated ERs also repress certain genes such as the choline acetyltransferase gene [93] via ER-AP-
1 complexes. ER-Sp-1 complexes are known to regulate genes that contain GC-rich promoter 
sequences [94] with genes such as c-fos [95], cyclin D1 [96], and low-density lipoprotein receptor 
(LDL-R) [97] known to be activated by E2-induced ER-Sp-1 complexes. Interaction of the E2-
induced ERs with NF-kB and C/EBPβ represses the IL-6 gene [98,99], whilst the interaction of E2-
induced ERs with the GATA-1 transcription factor represses erythropoiesis [100]. Even though 
ERE-independent genomic actions do not involve DNA-ER receptor interactions, it does involve 
the DNA binding domain (DBD) of the receptors [88-91,93,99,101-103], and even though DNA 
binding does not occur, it is speculated that the DBD might be necessary for proper protein-protein 
interactions, or for the recruitment of additional co-regulator proteins to the promoter region [86]. 
ER function can also be modulated by extracellular signals in the absence of E2 i.e. ligand-
independent (Fig. 5 point 3) activation. It was proposed that ligand-independent ER actions might 
either serve as a mechanism to stimulate growth factor pathways and consequently amplify 
mitogenesis in ER-positive tissues, or alternatively, it serves as a mechanism of ER activation in the 
presence of low E2 levels as found in males [81]. Ligand-independent activation and subsequent 
increase in expression of ER target genes predominantly takes place in the presence of insulin-like 
growth factor-1 (IGF-1), polypeptide growth factors such as epidermal growth factor (EGF) and 
also 8-bromo-cyclic adenosine monophosphate [104]. It has been shown that alteration of the 
phosphorylation state of the ER by cellular kinases is important in ligand-independent activation. 
For example, mitogen activated protein kinase (MAPK) phosphorylates the serine 118 residue of 
the human ERα AF-1 upon administration of IGF or EGF, resulting in activation of target gene 
transcription [105]. In addition, for ERβ, the MAPK encourages the recruitment of SRC-1 to the N-
terminus, thereby stimulating activation of target gene transcription [106]. 
The non-genomic actions of E2 (Fig. 5, point 4), which likely occurs through cell surface ERs that 
are linked to intracellular signal transduction proteins, was suggested due to the rapid biological 




effects of E2 observed in the breast, vasculature, bone and nervous system [81]. These actions 
include the activation of the MAPK signalling pathway, studied in bone [107,108], endothelial 
[109], breast cancer [110], and neuroblastoma [111] cells, and the phosphoinositol (PI) 3kinase 
signalling pathway in liver [112], breast cancer [113] and endothelial cells [109]. The non-genomic 
actions of E2 also include the stimulation of cyclic adenosine monophosphate (cAMP) production 
[114,115] and the mobilisation of intracellular calcium [116]. Controversy exists on whether ERs 
responsible for non-genomic actions are classical or non-classical ERs, situated at the plasma 
membrane [116-118]. ERs have been found in the caveolae of cells, where endothelial nitric oxide 
synthase (eNOS) is activated through protein kinase-mediated phosphorylation [119,120]. It, 
however, seems that the LBD of plasma membrane ERα is sufficient for mediating non-genomic 
activities of E2 [121], and that the activity is induced by the interaction of the ERs and various 
scaffold or signalling molecules [86]. Membrane ERs also activates the membrane tyrosine kinase 
receptors in various cell types, as in the case where E2-induced ERα directly interacts with IGF-1, 
leading to an increase in MAPK signalling [122]. In addition, E2-induced ERα stimulates the EGF 
receptor by a mechanism that involves activation of Src kinase, G proteins, and matrix 
metalloproteinases, thus activating protein kinase B (Akt) and MAPK activities [123]. 
In summary, E2 mechanism of action may be divided into four categories, namely classical ligand 
dependent actions, ERE-independent actions, ligand independent actions, and non-genomic actions. 
In general estrogen-induced biological responses are tissue specific due to a differential ER-subtype 
expression. 
2.2.2.1 ER subtype expression 
Some homology exists between the two ER-subtypes (Fig. 4), however, both ERs have distinct 
functions in estrogen action. Tissue localisation of ER-subtypes is thus not only important in 
understanding the molecular mechanism of estrogen action, but it is also important in understanding 
the initiation and progression of various estrogen-related diseases.  




Even though ERs are co-expressed in various tissue types such as the breast, vascular, ovary [124], 
and bone [125] (Table 1), ERα is predominantly expressed in the classical estrogen target tissues 
such as the cardiovascular systems, uterus [126], mammary gland and bone, whereas ERβ is mainly 
expressed in non-classical estrogen target tissues such as the urinary tract, prostate and ovary 
[124,127,128]. Interestingly, even though both ERs are expressed in the human brain [125], ERβ is 
predominantly expressed in the cerebral cortex and the basal forebrain [129,130], whilst ERα is 
predominantly expressed in the hippocampus region [131]. Similarly, in rats, both receptors are co-
expressed in the brain with some regions indicating selective expression, however, in contrast to 
humans, ERα is predominantly expressed in the ventromedial hypothalamic nucleus and subfornical 
organ [132], whereas ERβ is predominantly expressed in the cortex and the hippocampus [132,133].  
Table 1 Tissue specific expression of human ER subtypes [125]. 
Organ/Tissue ER subtype Organ/Tissue ER subtype 
 Erα ERβ  ERα ERβ 
Heart   Adrenal  ‾ 
Lung ‾  Kidney   
Vascular   Prostate ‾  
Bladder ‾  Testes ‾  
Epididymus ‾  Brain   
Pituitary ‾  Thymus ‾  
Liver  ‾ Breast   
Muscle  ‾ ‾ Uterus   
Fat ‾ ‾ Endometrium   
Gastointestinal tract ‾  Vagina  ‾ 
Colon ‾  Fallopian tube ‾  
Small intestine ‾  Ovary   
Bone      




As for humans, ERα is predominantly expressed in the mouse hippocampus [134], indicating not 
only tissue specific, but also species-specific ER expression. 
Reliant upon whether the ERs are co-expressed or expressed separately in a tissue type, 
homodimers (ERα/ERα or ERβ/ERβ) or heterodimers (ERα/ERβ) can be formed for activation of 
gene expression [135,136], with the ERα/ERα or ERα/ERβ dimers demonstrating a greater binding 
affinity to EREs [135]. Changes in the selective expression of the ERs have been observed in 
certain tumour types [125], for instance an increased ratio of ERα/ERβ mRNA has been observed in 
ER-positive breast carcinoma [137] and ovarian tumours compared to the normal tissue [138]. 
Due to the high degree of sequence divergence in the N-terminus between ERα and ERβ, together 
with the fact that studies have shown that the AF-2 domain functions independently in ERβ [139], 
the two ER subtypes functions differently [139,140]. This was confirmed in a study where ERβ was 
shown to interact with EREs in a ligand independent manner and also to attenuate the ligand-
activated transcriptional activity of ERα [139]. Co-expression of ERα and ERβ in vitro showed 
preferential formation of hetero-dimers [135], implying a convergence between ERα and ERβ 
pathways. It has thus been proposed that in cells co-expressing ERα and ERβ, the overall estrogen 
responsiveness may be determined by the ERα:ERβ ratio [139]. 
The differential ER subtype function and expression has become increasingly important in the 
pharmaceutical industry as side effects of HRT in menopausal women is a significant health issue. 
The selective action of estrogens in different tissues may not only be explained by the distribution 
of ERs in the different tissues, but also by the differential binding affinities of the individual 
receptors [124]. Therefore, in light of the fact that ERα is known to be pro-proliferative and ERβ 
anti-proliferative, focus has shifted to the development of estrogens that are not only subtype 
specific, but also to incorporate natural alternatives such as phytoestrogens that have higher 
affinities for ERβ than ERα [141]. 




2.2.3 Estrogen related diseases 
Estrogen-related diseases may be divided into two categories, namely diseases resulting from the 
presence of E2 or diseases resulting from a deficiency in E2. The next section will focus mainly on 
menopause as the primary E2-deficient condition, and the use and outcomes of conventional 
therapies used for menopause. As the primary adverse outcome of conventional HRT is breast 
cancer [9,10], we will discuss the role of E2 in breast cancer, and also breast cancer treatments 
currently in use, followed by a benefit and risk analysis of HRT in E2 deficient associated diseases. 
Menopause is defined as the point in the life of women when 12 successive months of amenorrhea 
is experienced, without an obvious intervening cause, such as surgical removal of the ovaries or 
dietary deficiencies [142,143]. The average age of natural menopause has been estimated as 50-51 
years [144,145], where the cessation of menstrual cycles are ascribed to the loss of ovarian follicles 
resulting in an estrogen deficiency [146]. It is estimated that women are born with one to two 
million primordial follicles, and at age 40 only a few thousand remain [147], followed by a further 
depletion with time resulting in menopause [148]. 
Menopausal symptoms are experienced by 67 % of menopausal women and these symptoms are 
usually more severe after abrupt cessation of ovarian function as per oophorectomy [2]. Symptoms 
can be classified into climacteric and psychosomatic symptoms. Climacteric symptoms include 
night sweats, hot flushes, atrophic vaginitis and insomnia, whereas psychosomatic symptoms 
include emotional instability, poor concentration, and memory impairment [149]. Apart from the 
relatively short term symptoms of menopause, long-term and also more serious diseases include 
osteoporosis, CHD and Alzheimer‘s disease [2]. 
Conventional HRT to treat menopausal symptoms include estrogen for women without an intact 
uterus, or estrogen plus progestin for women with an intact uterus [150]. Common E2 deficiency 
diseases include osteoporosis, obesity, cardiovascular disease and neurodegenerative diseases 
[2,151]. Although HRT alleviates or prevents some menopause associated diseases such as 




osteoporosis, CHD and possibly Alzheimer‘s disease [152], HRT usage is accompanied by an array 
of increased risks including breast cancer, endometrial cancer, increased incidence of gall bladder 
disease [153,154], and an increased risk of venous thromboembolic events [155,156]. The best 
established benefit from HRT usage is the reduced risk of osteoporotic fractures, as the therapy 
results in increased bone density [157]. In contrast, the most adverse and important risk of HRT is 
the increased incidence of breast cancer, where animal studies have shown that exogenous estrogens 
can induce breast cancer [158]. 
E2 exposure is associated with breast cancer development as risk factors associated with breast 
cancer mirror increased exposure of breast tissue to E2 [159]. Currently there are two hypotheses 
postulated to describe the above mentioned relationship [160]. The first hypothesis states that 
binding of E2 to the ER stimulates the proliferation of breast tissue. Increased cell division and 
DNA synthesis thus results in an increased risk of replication errors, which may involve mutations 
that result in abnormal functioning of cellular processes such as apoptosis and DNA repair [151]. In 
the second hypothesis the metabolism of E2 results in the formation of by-products that are able to 
damage DNA, which again results in mutations [151]. 
Although 67 % of all breast cancers have ERα, mutations within ERα are uncommon, as it occurs in 
only roughly 1 % of primary tumours [161]. However, it has been suggested that the mutation 
frequency is higher in metastatic breast tumours, where some mutations have been correlated with 
estrogen independence and tamoxifen resistance [162,163]. Even though mutation frequencies are 
low in primary tumours and increases in metasteses, many single mutations have been shown to 
influence breast cancer cell behaviour [164].  
It is estimated that roughly 7-10 % of the epithelial cells in normal breast tissue express ERα, the 
receptor correlated with proliferation [165], and it has been shown that the expression varies with 
the menstrual cycle [166-168]. In contrast to ERα expression, ERβ expression is considerably 
higher in normal breast tissue (80-85 %), it does not fluctuate during the menstrual cycle [169], and 




is inversely correlated with proliferation of cells [170,171]. It has been shown that ER-positive 
breast cancers have a higher ERα:ERβ ratio, compared to normal breast tissue, and also that 
estrogen-independent breast cancers have low ERα:ERβ ratios [172]. Furthermore, high grade 
ductal carcinoma in situ, and invasive breast carcinomas contain reduced levels of ERβ 
[169,173,174]. This indicates that the ratio of ERα:ERβ may affect the course of tumorigenesis 
[164].  
Various treatments have been used in clinical practice to kerb and eliminate breast cancer. These 
treatments are all premised on reducing levels or signalling by estrogens. Chemotherapy used in the 
treatment of breast cancer causes ovarian suppression [175,176], however, it has a toxic effect on 
the patient, resulting in a decreased quality of life [177]. In addition, resistance to chemotherapy is 
the main problem in the treatment of cancer patients [178]. Resistance can be either innate, which 
occurs prior to drug treatment, or it can be acquired, which occurs following drug exposure [178].  
It has been shown that approximately one third of breast cancer patients respond well to endocrine 
ablation such as in the case of oophrectomy [179], however oophorectomy does not completely 
remove the source of endogenous estrogens [180]. Compounds named SERMs such as tamoxifen 
was initially used to reduce estrogen signalling [181]. Tamoxifen acts as an ER antagonist, thus 
inhibiting binding of E2 to ERs [182] in breast tissue, and as such serves as a less invasive, but also 
more efficacious method than oophorectomy [182]. Tamoxifen, however, also has estrogen agonist 
activities in other tissues [183,184], which can result in, for example, an increased risk in uterine 
cancer [185] and thromboembolism [186]. Also, tamoxifen resistance can develop as a result of 
tamoxifen treatment [187]. Abovementioned factors led to the development of a SERD, fulvestrant, 
an ER antagonist also aimed at inhibiting the binding of E2 to ERs, however, with no agonist 
activities [188]. Currently, aromatase inhibitors are the most effective treatments available in the 
treatment of estrogen-dependent breast cancer [40], as it has been shown to be better than 




previously used ER antagonists [189,190] by blocking estrogen formation at its source of synthesis, 
resulting in a more targeted effect [40]. 
HRT-induced breast cancer is of great concern for women in menopause as it is considered the 
primary side effect associated with conventional HRT use. Thus the recent move toward using 
phytoestrogens instead of conventional HRT to treat menopausal symptoms has been spurred by the 
fact that more and more women perceive phytoestrogens as a ‗natural‘ alternative [191,192] with 
less side-effects compared to conventional HRT [153-156].  
2.3 Phytoestrogens 
2.3.1 Phytoestrogens as an alternative to traditional HRT 
In the next section phytoestrogens as a source of estrogen and possible attributes arising from its 
consumption will be discussed. We will also discuss why most phytoestrogens are considered 
important candidates for the development of an alternative HRT. 
Epidemiological studies have shown that the incidence of breast cancer is lower in Asian than in 
Western populations and that this may be attributed to the consumption of soy isoflavones [61]. In 
addition, studies have shown that high soy consumption during childhood is correlated with a 
reduced risk of breast cancer [193-196]. Phytoestrogen consumption in general may also have a 
protective effect on some other E2-related conditions such as osteoporosis [197], breast cancer 
[198], prostate cancer [199], cardiovascular disease [200] and menopausal symptoms [201], 
however there are some concerns regarding the possible hazards involved in high level consumption 
of phytoestrogens [202]. 
Phytoestrogens primarily bind both ERα and ERβ and transactivates via ERE, however, they 
generally bind ERβ with higher relative binding affinity than ERα [203,204]. For example, 
genistein binds ERβ with a 20 greater affinity than it binds ERα, resulting in a 30 times greater 
estrogenic potency for ERβ [204]. Phytoestrogens has a mechanism of action different from 




classical estrogen and act similar to SERMs, which has tissue specific ER agonist and antagonist 
properties [205]. The biological importance of the potent ERβ activation by phytoestrogens is of 
clinical importance as it is known that a group of genes responsible for cell cycle suppression and 
the retardation of proliferation are up-regulated by ERβ activation [206]. For this effect to take 
place, however, cells must express ERβ. 
Apart from primarily binding the ERs, phytoestrogens also have other mechanisms of action which 
could beneficial to the host. Genistein, the best characterised phytoestrogen [207] and the most 
active and abundant phytoestrogen in soy [208], inhibits protein tyrosine kinases (PTKs) in tissues 
such breast cancer and prostate cancer cells [209,210], which slows the growth rate of these cells. In 
addition, inhibition of PTKs in other tissues is responsible for the neuroprotectant [211] and 
cardiovascular improving effects of genistein [212]. Apart from the inhibition of PTK‘s, genistein 
can also inhibit DNA replication enzymes that are involved in carcinogenesis such as matrix 
metalloprotein, matrix metallopeptidase 9 (MMP9), and DNA topoisomerases I and II [213,214]. 
In summary, phytoestrogens are generally considered as a plausible source for the development of a 
nutraceutical that will serve as an alternative to conventional HRT due to the specific molecular 
mechanism of phytoestrogen action [205,206]. Literature available on phytoestrogen consumption-
associated advantages also supports their use as an alternative to conventional HRT [215]. 
Consequently, a range of phytoestrogenic nutraceuticals are currently commercially available.  
2.3.2 Phytoestrogenic nutraceuticals 
Botanical sources of phytoestrogens include soy, black cohosh, red clover, flax, licorice, hops, don 
quai, kudzu root [65], evening primrose oil, ginseng, alfalfa, chasteberry, [216-219], and even 
coffee [220]. Soy has received the most attention in terms of research [221-223], followed by red 
clover (Trifolium pratense, Fabaceae) [219,224] and black cohosh (Cimicifuga racemosa, 
Ranunculaceae) [225,226]. In the following section these three main and most investigated sources 
will be discussed briefly [65]. 




The most abundant source of isoflavones in food is soybeans, a legume consumed worldwide, but 
most commonly by Asian countries. Soybeans are rich in genistein and daidzein [227,228]. Apart 
from the use of soy in the alleviation of menopausal symptoms [229], various studies have shown 
an association between the intake of soybeans and other health benefits, such as reduced risk of 
breast cancer, prostate cancer, cardiovascular disease, and atherosclerosis [198,230-237]. 
Investigation of the bioavailability of the two predominant isoflavones in soy, genistein and 
daidzein, revealed that initial hydrolysis of the sugar moiety, which is performed by intestinal β-
glucosidases, is required for their uptake into the peripheral circulation [238]. In addition, it has 
been shown that isoflavone absorption occurs efficiently, but varies considerably among individuals 
[223,239,240]. Studies have, however, shown that the levels of the isoflavones in soybeans may 
vary up to 3 fold in the same cultivar from different geographical locations, and over time [228]. 
The variability in isoflavone levels is attributed to environmental conditions [228,241] such as 
variations in temperature, nutritional status or drought, light conditions or pest attacks [228]. A 
standardised commercially available soy extract originating from soybean, for the treatment of 





 contains 17.5 mg of isoflavones, consisting of 50 % daidzein, 30 % 
glycitein, 20 % genistein [242]. 
Red clover is a herb traditionally used by the Native Americans in the treatment of whooping 
cough, cancer and gout [243], and is also traditionally consumed in parts of Asia [244,245]. Red 
clover is also used in the treatment of menopausal symptoms as a result of its composition [229]. It 
contains genistein and daidzein and two other estrogenic compounds, formononetin and biochanin 
A [243]. Studies have shown contradictory data regarding the potential of red clover as 
cardioprotectant, as some studies showed no effects, whereas other studies showed an increase in 
HDL cholesterol and a reduction in tryglycerides [246-251]. Furthermore, Tice et al. [252] reported 
that red clover extracts were not effective in alleviating the amount of hot flushes experienced by 
menopausal women, concluding that, even though the standardised extract investigated in the study 




displayed estrogenic activity in vitro, it did not translate to the relief of menopausal symptoms. 
Other studies have, however, showed a positive correlation with red clover consumption and an 
increase in bone mineral density [246,250] and formation of bone mineral markers [250]. In 
addition, it has been shown that red clover does not affect the endometrium, whereas soy-related 
isoflavones have been reported to have an effect in some studies [253,254], but not in other studies 
[255]. In vitro studies of soy and red clover indicate no effect on breast cancer cell proliferation 
[256,257]. Red clover-derived isoflavones are regarded as well absorbed in the gut as they are 
predominantly in the aglycone form [258]. An example of a standardized commercially available 
red clover extract supplement is Menoflavon
®
, which contains 64 % red clover extract with an 
average isoflavone content of 11 % [259]. 
Black cohosh grows in Eastern North America and belongs to the buttercup family 
(Ranunculaceae). Native Americans used the rhizomes and roots of the black cohosh plant for a 
variety of conditions including treatment of diarrhoea, stimulation of menstrual flow, childbirth, 
dymenorrhea and suppression of cough [225]. In a study four randomised, controlled trials 
investigating Remiferim
®
, which is a black cohosh extract containing triterpene glycosides such as 
27-deoxyacetain [260], phenolic acids (isoferulic acid, fukinolic acid), flavonoids, volatile oils and 
tannins [225,261], in the treatment of menopausal symptoms [262], it was found that three of the 
four trails indicated that black cohosh relieved hot flashes. Black cohosh is not classified as a 
phytoestrogen [263], but its compounds act synergistically to augment an estrogenic effect [263]. 
The exact mechanism of action of black cohosh is not known, and as such no studies have been 
performed on the bioavailability of the extract [264]. Adverse effects associated with black cohosh 
extract consumption are deemed mild by some authors [265], whereas other authors have reported 
cases of induced muscle damage and cutaneous pseudolymphoma, respectively [266,267]. 
In general, women in menopause have shown great interest in commercially available 
phytoestrogenic nutraceuticals as an alternative to conventional HRT. These nutraceuticals have 




mostly been effective in alleviating menopausal symptoms together with additional positive effects 
not seen with conventional HRT. In the next section we propose an exclusively South African 
source for the future development of a possible phytoestrogenic nutraceutical.  
2.4 Honeybush (genus Cyclopia) 
To date, various studies have demonstrated that Cyclopia may pose as a candidate source for the 
future development of a possible phytoestrogenic nutraceutical as extracts of some Cyclopia species 
displayed desirable phytoestrogenic attributes [24-26,268-272]. In the next section we will discuss 
the epidemiology, and the potential health benefits associated with Cyclopia. In addition, we will 
discuss previous studies performed on the evaluation of the estrogenicity of Cyclopia extracts. 
Furthermore, known polyphenols present in a candidate Cyclopia extract will be evaluated for the 
prospective biological activities they may induce. 
The genus Cyclopia, which forms part of the leguminous Fabaceae family, is a member of the 
Podalyriea family [273]. The Cyclopia genus was discovered in 1808, and today, some studies 
ascribe 23 [274], whilst other studies approximate 24 species [275] to this genus. Cyclopia, also 
known as honeybush, is widespread in the fynbos biome (Fig. 6) and as such the plant grows in the 
mountainous regions and on the coastal plains of the Western and Eastern Cape Provinces of South 
Africa [27]. Cyclopia species have a low leaf to stem ratio and have adapted to frequently occurring 
fires in their natural habitats by either being sprouters or non-sprouters, where sprouters produce 
new coppice shoots after fires, and non-sprouters lack lignotuber, but are re-seeders [276]. The 
seeds only germinate upon scarification, brought upon by the fire [273].  
Aerial parts of Cyclopia species, such as C. subternata, C. genistoides, C. intermedia, and C. 
sessiliflora have long been used in the manufacturing of a herbal tea [277-279], which is known to 
have a distinctive brown colour and a sweet honey-like aroma [269]. The sensory attributes of 
honyebush tea together with the fact that the tea is low in tannins and caffeine-free contributed to 
the popularity of this tea [269]. The potential health benefits from the consumption of polyphenol-




rich beverages such as tea dates back 5000 years, and evidence relating polyphenol consumption 
with health benefits are renowned [280-282]. Since polyphenols are heat-labile, and as such degrade 
during the ‗fermentation‘ step in classical fermented tea, more recent studies have included research 
on the health benefits of unfermented (green) honeybush tea [269].  
 
Figure 6 Natural distribution of Cyclopia species across the fynbos biome in South Africa [273]. 
Various in vitro and in vivo studies have validated the fact that Cyclopia has antimutagenic, 
antioxidant, anticancer and phytoestrogenic properties [269]. In the investigation of Cyclopia as a 
phytoestrogen source, Cyclopia extracts have been studied for estrogenic activity and its phenolic 
composition [24-26,268-272].  
In a study by Verhoog et al. [24] in 2007, four different Cyclopia species C. genistoides, C 
subternata, C. intermedia and C. sessiliflora, were screened for phytoestrogenic activity, where 
Cyclopia extracts generally indicated a preferential binding to ERβ. ERα activation is associated 
with an increase in cellular proliferation, whereas ERβ activation inhibits ERα-mediated cell 
proliferation [165], thus it has been suggested that compounds, which antagonise ERα and/or 




activate ERβ may be useful in the prevention and treatment of breast cancer [283-285]. Preferential 
binding to ERβ is thus a desirable trait in a phytoestrogenic nutraceutical, as it can allow alleviation 
of menopausal symptoms, whilst as a side-effect it may prevent breast cancer formation, the 
primary adverse outcome of conventional HRT [9,10]. Verhoog et al. [24] also demonstrated that 
methanol extracts from ‗unfermented‘ (unoxidised) plant material, rather than aqueous extracts 
from fermented and/or unfermented plant material, generally displayed superior ER binding. 
Cyclopia genistoides and C. subternata extracts were examined for ER-binding, and it was found 
that unfermented extracts of both C. genistoides and C. subternata bound preferentially to ERβ. 
Also, binding of naringenin, formononetin, eriodictyol and luteolin, which are known 
phytoestrogens, and mangiferin, narirutin, eriocitrin (eriodictyol-7-O-rutinoside), hesperidin 
(hesperetin-7-O-rutinoside) and hesperetin, which were previously shown to be present in Cyclopia 
species [275,286], were screened for binding to ERα and ERβ. It was found that naringenin, 
formononetin and luteolin bound to both ERα and ERβ, however, preferentially to ERβ, with the 
order of radiolabeled E2 displacement in a competitive binding assay being 
luteolin>naringenin>formononetin. Narirutin, eriocitrin and eriodictyol bound only to ERβ, whereas 
mangiferin, hesperidin and hesperetin did not bind to either receptor subtype. As the 
phytoestrogens, eriodictyol, luteolin, formononetin and naringenin, were not detected in any of the 
investigated extracts, accompanied by the fact that narirutin and eriocitrin, which binds ERβ, where 
present in only trace amounts (which could not fully convey extract estrogenic activity) led 
investigators to believe that further research might reveal novel compounds in Cyclopia mediating 
its estrogenic activity [24]. 
In another study by Verhoog et al. [25] DMEs from unfermented C. genistoides harvestings (P104, 
P105 and P122), and also polyphenols known to be present in Cyclopia species (luteolin, 
formononetin, mangiferin and naringenin), were evaluated for estrogenic activity [25]. P104 was 
the only extract that bound to the ER subtypes, however, unlike the phytoestrogens investigated, it  
indicated preferential binding of ERα. Nevertheless, P104 only transactivated an ERE containing 




promoter reporter construct via ERβ, with a potency similar to the known phytoestrogen, genistein, 
and also E2. In addition, although this extract induced breast cancer cell proliferation to a similar 
extent as genistein, but significantly (p < 0.001) lower than E2, it could significantly antagonise E2-
induced proliferation of breast cancer cells [25]. 
In 2008 Mfenyana et al. [26] investigated four sequential and non-sequential extracts from different 
Cyclopia harvestings for phytoestrogenic activity. In the initial screening phase it was found that 
DMEs from M6 (C. subternata) and M7 (C. genistoides) plant material exhibited an appreciable 
degree of phytoestrogenic activity with M6 on average being quantitatively more efficacious than 
M7. In the next phase additional extractions of M6 and M7 were prepared and tested. Firstly, it was 
found that the M6-derived extracts, SM6EAc and NM6EAc, were the most efficacious of all other 
M6 and M7 extracts and also surpassed the efficacy of the original M6 and M7 DMEs. Secondly, it 
was found that two other M6-derived extracts, SM6Met and SM6Eth, were significantly more 
potent than all other M6 and M7 extracts, with SM6Met having the highest estrogenic potency of all 
extracts.  
As SM6Met, a sequential methanol extract of a C. subternata harvesting, M6, showed the highest 
estrogenic potency of all the investigated extracts, it was investigated further in phase 3 of the study 
[26]. Phase 3 consisted of benchmarking SM6Met estrogenicity against commercially available 









though the efficacy of SM6Met was significantly lower than some of the commercial products in 
the promoter reporter and E-screen assays, the potency of SM6Met was not significantly different 
from Phytopause Forte or Femolene, while it was significantly higher than Promensil in the E-
screen assay. In an attempt to identify compounds responsible for the estrogenic activity of 
SM6Met, selected extracts including SM6Met were analysed by means of HPLC and liquid-
chromatography mass spectrometry (LC-MS). Narirutin, naringenin and formononetin, which have 
previously been shown to be present in some Cyclopia species [270], were not present in SM6Met, 




however phytoestrogens such as eriocitrin and luteolin, were present. Even though eriocitrin were 
present in relative high quantities in the M6 extract, it appeared unlikely that eriocitrin was the sole 
cause of the estrogenic activity, as it could only partly displace 
3
H-E2 from ERβ, but not ERα [25], 
while the M6 dried methanol extract was able to fully displace 
3
H-E2 in MCF7-BUS cells. Luteolin 
also did not explain the estrogenic activity of the extract due to low quantities thereof in the 
SM6Met extract [26], thus the investigators suggested that other unidentified compounds possibly 
confer the observed estrogenic activity in SM6Met [26]. 
2.4.1 SM6Met and associated polyphenols 
To date, two Cyclopia extracts have displayed sufficient estrogenic activity for future 
investigations. Firstly, P104, has been shown to bind to both ERα and ERβ, to transactivate only via 
ERβ in an ERE-containing promoter reporter assay, and to induce breast cancer cell proliferation, 
but at a significantly lower level than E2, while antagonising E2-induced breast cancer cell 
proliferation [25]. Secondly, SM6Met has been shown to have the highest estrogenic potency 
amongst other investigated Cyclopia extracts [26]. P104 plant material was, however, only available 
in small quantities, and as such SM6Met, which is available in bulk, seemed the most plausible 
candidate for future investigations. In the next section SM6Met estrogenic attributes will thus be 
discussed in further detail. 
In vitro assays have shown that SM6Met transactivates via ERβ, and antagonises ERα activity in an 
ERE-containing promoter reporter assay [268], while it antagonises E2-induced breast cancer cell 
proliferation [268]. In addition to the in vitro work, an immature rat uterotrophic assay was 
performed, which revealed that SM6Met, unlike E2, did not increase uterine weight, and like the ER 
antagonist, ICI 182,780, antagonised E2-induced uterine growth, which is indicative of ERα 
antagonism as seen in the in vitro assay [268]. The estrogenic traits of SM6Met, namely ERβ 
agonism, ERα antagonism and antagonism of E2-induced breast cancer cell proliferation, are 
valuable traits needed in the development of a possible phytoestrogenic nutraceutical. An estrogenic 




supplement with these traits will serve as a safer alternative to traditional hormone replacement 
therapy by not only activating anti-proliferative ERβ [287], but also by antagonising pro-
proliferative ERα [288] and as such it should decrease the incidence of breast cancer, the primary 
adverse outcome of traditional HRT [289]. 
In a recent study LC-MS analysis of a C. subternata aqueous extract was performed [272], 
indicating the presence of 14 phenolic compounds (Fig. 7). In another study quantitative high 
performance liquid chromatography (qHPLC) analysis of SM6Met indicated the presence of 
protocatechuic acid and luteolin [268], and as HPLC is not as sensitive as LC-MS, some of the 
minor compounds previously detected in C. subternata [272] were not detected in this study. In 
addition, different extraction methods were used, which will affect the phenolic profile. 
It is known that the xanthones, mangiferin and isomangiferin, are major constituents of C. 
subternata extracts. Even though isomangiferin has never been tested for estrogenic activity, 
mangiferin has been shown not to bind ERα or ERβ [24]. Interestingly, however, mangiferin has 
been shown to inhibit breast cancer cell proliferation via an ER independent mechanism [290]. In 
addition, mangiferin has been shown to have antioxidant [291], anti-inflammatory [292], 
enhancement of recall memory [293], anti-diabetic [294] and hypolipidemic activity [294].  
Other polyphenols present in relatively high amounts in C.subternata extracts is the flavone, 
scolymoside (luteolin-7-O-rutinoside), and the flavanones, eriocitrin and hesperidin [268,270,272]. 
Eriocitrin, the glycone of eriodictyol, has been shown to bind ERβ, and as such serves as a 
phytoestrogenic compound [24], however, no research has been performed in elucidation of its 
estrogenic effect. In addition, eriodictyol has been shown to have weak estrogenic activity, and it 
has been shown to preferentially bind ERβ [295-297]. The 7-O rutinoside sugar moiety of eriocitrin 
may be hydrolysed by intestinal β-glucosidases prior to absorption [238,298], yielding eriodictyol. 
Eriocitrin and/or eriodictyol may thus partially contribute to the estrogenic activity of SM6Met, 
however, not as a whole, due to fact that they do not bind ERα, and as such they cannot confer the 




ERα-mediated estrogenic effects of SM6Met [25]. Other properties attributed to eriocitrin include 
antioxidant and lipid-lowering activities [299]. Hesperidin has been shown not to bind the ER [24], 
or to transactivate an ERE-containing promoter reporter construct [300], and as such its presence 
cannot explain the estrogenic activity displayed by SM6Met.  
 
Figure 7 Chemical structures of phenolic compounds present in C. subternata. [272]. * indicates that the 
glycoside position is not yet known. Compounds previously identified in SM6Met as in Visser et al. [268] 
are indicated in text boxes. Compounds previously identified in SM6Met, not shown on the figure include 
the flavone, luteolin, and the hydroxybenzoic acid, protocatechuic acid. 
Scolymoside, previously described as ‗unknown 1‘ by Mfenyana et al. [26] is the product of a 7-O 
rutinoside sugar moiety addition to luteolin. Luteolin has been shown to bind both ER subtypes, 
induce breast cancer cell proliferation, and antagonise E2-induced breast cancer cell proliferation 
[24,25,28,295,300,301]. Even though scolymoside has not previously been tested for estrogenic 




activity [28,302], the 7-O rutinoside sugar moiety may be hydrolysed by intestinal β-glucosidases 
prior to absorption [238,298], yielding luteolin, and as a result increase the phytoestrogenicity of the 
investigated extract. Also, luteolin has exhibited anti-tumour activity [303], and as such luteolin and 
scolymoside may be regarded as chemo-preventative and as contributors, partially or as a whole, to 
the phytoestrogenic effects of interest displayed by SM6Met [268]. In addition, scolymoside has 
been shown to be an aldose reductase inhibitor [304], therefore it has strong radical scavenging 
properties, and its antioxidant activity was shown to be better than that of chlorogenic acid [305] 
and comparable to that of L-ascorbic acid [306]. Furthermore, scolymoside has also displayed 
antimicrobial activity [307].  
Iriflophenone-3-C-glucoside belongs to the benzophenone polyphenolic class. Hydroxylated 
benzophenones such as iriflophenone, has been shown to display estrogenic activity in the human 
breast cancer cell line MCF 7 [308,309]. In addition, benzophenone derivatives can exert numerous 
biological effects including cytotoxic, antibacterial and antiviral effects [310]. Iriflophenone-3-C-
glucoside also exerts in vitro antilipogenic activity [311]. It is thus plausible that this compound 
may exert synergistic effects with other Cyclopia constituents, i.e., mangiferin, hesperidin and (+)-
pinitol, contributing to both cholesterol–lowering and anti-diabetic effects of honeybush observed in 
rat models [312]. 
Phloretin-3',5'-di-C-glucoside belongs to the dihydrochalcone compound class, and was previously 
described as unknown 2 [26]. Even though no research has been performed on its estrogenic 
activity, a previous study correlated estrogenic activity in SM6Met with the presence of phloretin-
3',5'-di-C-glucoside [26]. Phloretin-3',5'-di-C-glucoside is a strong antioxidant and an important 
constituent of some citrus fruits like Citrus microcarpa [313] and Fortunella japonica [314], and as 
such it gives some insight into evaluated antioxidative properties of honeybush extracts [269,315].  
In summary, the C. subternata sequential methanol extract, SM6Met, was identified as 
estrogenically the most potent amongst other Cyclopia extracts, and the potency was shown to be 




comparable to commercially available phytoestrogenic nutraceuticlas [26]. Subsequent specific 
estrogenic activity evaluation of SM6Met indicated that it displayed estrogenic attributes desirable 
for the future development of a phytoestrogenic nutraceutical. These attributes included 
transactivation via ERβ, and antagonism of ERα activity [268]. In addition, SM6Met antagonised 
E2-induced breast cancer cell proliferation [268]. The compounds previously identified in SM6Met, 
however, could not fully explain the estrogenic activity of SM6Met [26], which lead the researchers 
to believe that unidentified compounds, or compounds not previously tested for estrogenic activity 
are responsible for the specific estrogenic attributes of SM6Met. The most commonly used method 
for the identification of active compounds in a compound mixture or extract is activity-guided 
fractionation [33,34,316,317], which will briefly be discussed in the next section.  
2.5 Activity-guided fractionation 
Activity-guided fractionation is a technique that allows identification of active compounds from a 
mixture of compounds or from an extract. The procedure includes an assay or assays to determine 
the presence of the activity of interest. Central to this process are the fractionation steps, performed 
using a suitable fractionation technique. Lastly, activity-guided fractionation includes an 
identification step and possibly a quantification step [318]. In the next section the use of activity-
guided fractionation will be discussed in general, where after the assays that can be implemented to 
track estrogenic activity will be discussed. 
Activity-guided fractionation [317] is a technique that has long been the focus of many studies 
[33,34] for the isolation of compound(s) contributing to a specific activity of an extract. A recent 
example of activity-guided fractionation was done by Picot et al. [33] in 2011, where the compound 
responsible for the anti-proliferative activity in a Dunaliella tertiolecta extract was isolated. Here 
separation of the extract was firstly done by semi-preparative reverse phase high performance liquid 
chromatography (RP-HPLC). Each fraction was then tested in MCF-7 cells for anti-proliferative 
activity, where after the most anti-proliferative fraction was identified. This fraction was then sub-




fractioned using again the semi-preparative RP-HPLC technique and the sub-fractions were 
subsequently tested for anti-proliferative activity. RP-HPLC allowed collection of the most active 
sub-fraction. The absorption spectrum of the sub-fraction was then compared to a reference spectra 
and high resolution mass spectrometry confirmed that the active compound in the extract was 
violaxanthin. 
Another example of a study utilizing activity-guided fractionation is a study performed by 
Hostettman et al. in 1999 [34], where compounds conferring antifungal activity to a whole plant 
Parinari capensis dichloromethane extract were isolated as follows: The extract was fractionated 
using HPLC, and peaks 2-4 where identified as major peaks using LC/ultraviolet (UV)/MS. 
Hereafter fractionation of the extract was performed using medium-pressure LC, silica gel column 
chromatography and Sephadex LH-20 gel filtration to produce constituents 2 to 4. Structure 
elucidation was done by 1D and 2D nuclear magnetic resonance (NMR), and it was revealed that 
compounds 2 and 4 were new compounds, where after the absolute configuration of compound 2 
was determined. Evaluation of their anti-fungal activity revealed that constituents 2 and 3 inhibited 
C. cucumerinum growth. 
In 2007 Cvoro et al. [319] identified the presence of ERβ-selective properties in MF101, an extract 
containing 22 herbs. In 2008, Mersereau et al. [316] identified the specific selective ERβ agonist 
compound, liquiritigenin, from the root of Glycyrrhiza uralensis, which is one of the plants found in 
MF101. The identification was made possible by initially fractionating the G. uralensis root-extract 
using gel chromatography. A promoter reporter assay identified the fractions with activity of 
interest, where after active fractions were purified further using preparative RP-LC. Using MS and 
NMR analysis, the identity of the compound was confirmed as liquiritigenin, a compound first 
isolated from Glycyrrhiza species [320]. 
The fractionation technique most commonly used in activity-guided fractionation is liquid 
chromatography (LC), which includes HPLC, low pressure LC, ultra performance (UP) LC, and 




also CCC (counter-current chromatography). Other techniques also used include gel 
chromatography, thin layer chromatography, gas chromatography, and affinity enrichment. 
Advantages of the use of LC techniques include the ease to incorporate other liquid-based systems 
such as fractionators, autosamplers, and detectors, which simplifies the fractionation process, and 
makes the process more time efficient. Disadvantages include the use of organic solvents, not 
compatible with biological assays, which need to be evaporated and as such can result in the loss of 
volatile compounds. 
CCC is a commonly used LC technique for the separation of compounds from a compound mixture 
or an extract [318]. More recently, two types of CCC have evolved from the original technique, 
namely high speed CCC (HSCCC) and high performance CCC (HPCCC). HSCCC differs from 
normal CCC by offering superior sample loading capacity, resolution, and shorter separation time 
[321]. In addition to the benefits of HSCCC, HPCCC works at a higher g-level and subsequently it 
has the ability to purify products more rapidly with a higher throughput [322]. 
Whereas conventional LC uses a single liquid phase in eluting analytes from the adsorptive or 
liquid phase coated solid support, the CCC technique uses a two-phase liquid solvent system, with 
one phase used as stationary and one as mobile phase [34]. This technique thus has an advantage 
over normal column chromatography through elimination of a solid support, as the danger of 
irreversible adsorption on the solid support is eliminated. 
CCC instruments consist of a multilayer coil separation column conferring a type-J synchronous 
planetary motion, where the column holder rotates about its own axis and revolves around the 
centrifuge axis (Fig. 8) [321]. In an end-closed coil system (Fig 9A), planetary motion produces a 
hydrodynamic motion of the two immiscible solvent phases due to the Archimedean screw effect 
[321]. 





Figure 8 Schematic illustration of the type-J synchronous planetary motion of a multilayer coil 
separation column [321]. ω refers to the angular velocity. 
Introduction of the heavier phase at the head will cause movement to the tail end, whereas 
introduction of the lighter phase at the tail end will cause movement toward the head, meaning that 
the mobile phase thus moves quickly through the coil leaving a large volume of the other phase 
stationary in the coil [321], allowing CCC separation as in Fig. 9B.  
 
Figure 9 Mechanism of high speed counter-current chromatography (HSCCC) [321]. A) Bilateral 
hydrodynamic distribution of the two phases. B) Elution modes of both phases in the rotating coiled column 
Drawbacks of the use of CCC as fractionation technique for activity-guided fractionation include 
the complexity of solvent system optimisation in order to obtain sufficient separation, and also the 
separation power of CCC has been reported as relatively limited [318]. Advantages of the technique 
include its robustness in allowing for a more time-efficient process [318], and it also allows no loss 




of sample due to irreversible absorption as mentioned earlier [321]. In addition, no interfering 
surface chemistry, that can potentially alter analytes [323], is present in the use of CCC.  
Detection methods commonly used in activity-guided fraction, which will not be discussed in detail, 
include the use of instrumental detection methods, such as MS and UV, and biodetector methods, 
such as segmented flow enzyme inhibition [318]. 
For the purpose of activity-guided fractionation of SM6Met the fractions obtained would have to be 
evaluated for their specific estrogenic activities. In the next section we will therefore discuss the 
various estrogenic assays that could possibly serve as estrogenic tests in activity-guided 
fractionation of SM6Met. 
2.5.1 Tests to evaluate estrogenic activity 
Various in vitro and in vivo assays are available to evaluate the estrogenic activity of a test 
substance. In 1998 the American Environmental protection agency proposed a two-tiered approach 
for the screening of endocrine disruptors including those affecting estrogen signalling. Tier I was 
aimed at detecting chemical substances capable of interacting with estrogen, androgen, or thyroid 
hormone systems through the use of a battery of suggested in vitro and in vivo assays. Tier II was 
aimed at determining the effects of compounds identified in Tier I on animals, and as such Tier II 
only consisted of suggested in vivo assays. Upon identification of the effects, Tier II was aimed at 
determining a quantitative relationship between the compound and its induced adverse effect [324]. 
Estrogenic tests for the evaluation of estrogenic attributes displayed by SM6Met and subsequent 
fractions should meet certain criteria. Firstly, the tests to be incorporated should be able to evaluate 
whether the attributes of interest are present or not. Therefore, the incorporation of a test that 
evaluates estrogenic activity via ERα or ERβ would be needed. In addition, a test to evaluate the 
effect of SM6Met and its sub-fractions on the proliferation of breast cancer cells would be needed. 
The second criteria that the tests should meet is that it should be easy to perform, require low 




quantities of the test substance for evaluation, and yield as many results as possible, in a short 
period of time. 
2.5.1.1 In vitro measurements for estrogenicity 
Numerous in vitro assays to evaluate estrogenic activity are currently available. The most frequently 
used methods include binding assays, transactivation assays, and cell proliferation assays, which 
will be discussed in further detail in the next section. Due to variability of sensitivity of the various 
in vitro techniques available one should incorporate more than one of these techniques in evaluation 
of the estrogenic activity of a test substance. Other methods that will also be discussed in the next 
section include the analysis of E2-induced mRNA and protein expression. 
2.5.1.1.1 Receptor ligand binding assays 
Various types of assays are available for measuring receptor-ligand binding interactions. In a review 
by Jong et al. [325] frequently used receptor-ligand binding assays are evaluated. Receptor-ligand 
binding assays can be categorised depending on whether a separation step is needed whereby bound 
ligand is separated from free ligand, or by means of the technique used for detection. Categorising 
assays according to the necessity of a separation step leads to three assay types namely 
heterogeneous, homogeneous and non-separating homogeneous [325] assays. Homogeneous assays 
require no washing or separation steps before measurements are taken, therefore it is known as mix-
and-measure assay. An example of this assay is demonstrated in a study performed by Hu et al. 
[326], where a Time Resolved-Fluorescence Energy Transfer (TR-FRET) assay was used to 
investigate the ligand binding of a human G-protein coupled receptor (GPCR) protein. In non-
separating homogeneous assays, described by Hemmila et al. [327], the signal is gathered from the 
target receptor immobilised on a solid phase, and as indicated by the type of assay, there is also no 
need for a separation. Heterogeneous assays require removal of the free from bound ligand by 
dialysis, filtration or centrifugation, resulting in an inconvenience for the experimenter. An example 
of a heterogeneous non-radioactive receptor assay is described in a study by Mahoney et al. [328] in 




which the receptor-ligand binding is measured based on enzyme activity. Substrate was added to the 
enzyme-receptor-ligand mixture after unbound enzyme was washed away, where after absorbance 
measurements were taken.  
The most frequently used technique for binding experiments is the use of a radioactive ligand for 
binding a receptor. This heterogeneous assay is based on competitive interaction between the non-
labelled and labelled ligand for the receptor of interest. The appropriate radioactive ligand of choice 
must meet certain criteria to declare it fit for a study. These criteria are: the most potent enantiomer 
of the radioligand is ideal, the non-specific binding of the radioligand must be minimal, it must be 
chemically pure and have a high affinity for the receptor with a high specific activity, and it should 
be chemically stable and resistant to enzymatic digestion [329]. In a review written by Klinge et al. 
[330] it was stated that for a hormone binding to be a true receptor binding the following criteria 
must be met: the binding must be saturable (Fig. 10A), it must be stereospecific, tissue specific and 
hormone specific, and the binding must be reversible, and highly specific [330]. 
 
Figure 10 Graphical representation of (A) Saturation ligand binding, where (a) is total, (b) is specific 
and (c) is non-specific binding (b=a-c) [330] and (B) Competetive ligand binding [332]. 
Two common types of ligand binding assays may be conducted, namely saturation ligand binding 
(Fig. 10A) and competetive ligand binding (Fig. 10B). For saturation ligand binding increasing 
amounts of radioligand is added and Bmax and the Kd are useful parameters that may be obtained. 




Bmax represents the total amount of receptors; while Kd is a measure of ligand binding affinity (Fig. 
11). For competitve ligand binding increasing amounts of unlabelled ligand is added in the presence 
of one concentration of radiolabelled ligand. Useful parameters that may be obtained from 
competetive ligand binding assays include Ymax and IC50. If the Kd of the radioligand is known, the 
Bmax may be calculated from Ymax (Ymax=Bmax.[L]/(Kd+[L])) and the Ki (the affinity for the 
unlabelled competing ligand) may be calculated from the IC50 (Ki=IC50/(1+[L]/Kd)). In a study by 
Gutendorf et al. [331], evaluating competitive binding of E2 and genistein to human ERα and ERβ, 
it was found that the IC50 values of genistein for ERα and ERβ was 35 µM and 2 µM, respectively, 
whereas for E2 it was 3.5 nM and 65 nM, respectively.  
 
Figure 11 Graphical representation of bound ligand (Y-axis) plotted against free ligand (X-axis) [332]. 
The Bmax value represents the total amount of binding sites and Kd the amount of ligand needed to occupy 
50% of the total amount of binding sites. 
Advantages of the use of radioactive ligands to investigate receptor-ligand interactions include the 
use of a single labelling step and the assay‘s specificity and sensitivity [325]. Binding techniques 
can also serve as a screening tool, meaning that if extracts or fractions do not bind the ER, further 
investigation in other assays will not be needed as estrogenic attributes will not be present. 
Disadvantages includes the inconvenience caused be the separation step and the use of radioactivity, 
which can be harmful to the experimenter. In addition, for the purpose of evaluating estrogenic 
activity in activity-guided fractionation, binding techniques will only demonstrate binding to the 
ER, and as such it will not give insight into the specific biocharacter of the estrogenic activity of the 




extract or fraction investigated. Examples of commonly used in vitro estrogenic assays that do, 
however, give insight into the specific biocharacter of the estrogenic activity of a compound of 
interest, is the promoter reporter gene assay, the breast cancer cell proliferation assay, and analysis 
of mRNA and protein expression. 
2.5.1.1.2 Promoter reporter gene assays 
In the classical estrogen signalling pathway binding of a ligand to intracellular ERs results in ER-
dimerisation, followed by the binding of these ER-dimers to an ERE present in the promoter region 
of estrogen responsive genes [333]. To study these events, the promoter reporter gene assay 
measures the estrogenic activity in an indirect manner based on the expression of an ERE linked 
reporter gene, which is under promotional control of the ERE (Fig. 12) [334]. In this assay a 
mammalian cell line or a yeast strain can be transfected with the ERE-containing promoter reporter 
construct, together with the ER cDNA if the cell line does not express the ER endogenously. 
Subsequently, upon ER activation the expression of the reporter gene is measured and quantified. 
The promoter reporter assay can thus be used to determine the potency, or EC50 values of 
compounds, which can be compared to the EC50 value of E2 [334]. The potency refers to the 
concentration of a ligand needed to induce a response halfway between the baseline and the 
maximal response. The baseline and maximal response is obtained by constructing ligand dose 
response curves. Similarly, the efficacy values of a compound can be determined, and compared to 
the efficacy value of E2. Efficacy refers to the maximal response induced by a ligand. 





Figure 12 Graphic depiction of cell-based reporter gene assay [335]. Extracellular signals causes binding 
of either transcription factors or intracellular receptors to response elements (RE), resulting in the 
transcription on expression of the reporter protein. 
Commonly used reporter genes include chloramphenicol acetyl transferase (CAT), B-galactosidase, 
luciferase, alkaline phosphatase, and green fluoresescent protein (Table 2). From Table 2 the most 
advantageous reporter gene to include in a promoter reporter assay for activity-guided fractionation 
of an extract would be the firefly luciferase reporter gene due to the numerous advantages of firefly 
luciferase reporter gene usage, such as amongst others, its specificity and broad dynamic range, 
accompanied by no significant disadvantages, as the substrate of this assay is commercially 
available.  
Luciferase originates from a family of enzymes that are responsible for the oxidation of substrates 
such as luciferin, which consequently results in light discharge [335]. Three types of luciferase 
reporter genes currently in common use are the firefly (Photinus pyralis) luciferases, the bacterial 
luciferases, and in more recent times, the Renilla luciferase (Renilla reniformis) [336,337].  
 
 




Table 2. Evaluation of frequently used reporter genes [335]. 




1. No endogenous activity 
2. Automated ELISA available 
 
1.Narrow linear range 




1. Well characterised  
2. Stable 
3. Simple colorimetric readouts 




1. Endogenous activity 
(mammalian cells) 
Luciferase (firefly) 1. High specific activity 
2. No endogenous activity 
3. Broad dynamic range 
4. Convenient assays 
 
2. Requires substrate (luciferin) 
and presence of O2 and ATP 
 
Luciferase (bacterial) 1. Good for measuring/analysing 
prokaryotic gene transcription 
 
1. Less sensitive than firefly; not 
suitable for mammalian cells. 
Alkaline phosphatase 
(human placental) 
1. Secreted protein 
2. Inexpensice colorimetric and 
highly sensitive luminescent 
assays available 
 
1. Mostly endogenous activity  
2. Interference with compounds 
being  screened 
Green fluorescent protein 
(GFP) (jellyfish) 
1. Autofluorescent (no substrate 
needed) 
2. No endogenous activity 
3. Mutants with altered spectral 
qualities available 
1. Requires post-translational 
modification 
2. Low sensitivity (no signal 
amplification) 
ELISA refers to enzyme-linked immunosorbent assay 
Renilla luciferase [26] can catalyse the oxidation of membrane permeable coelenterazine, thus 
allowing quantification of gene expression of intact systems (i.e. a living cell). Bacterial luciferases 
are dimeric, heat-labile proteins, which limit their use, however, a rather sensitive assay has been 
developed using bacterial luciferases [338]. The most commonly used luciferase gene is the firefly 
luciferase, which produces 62 kDa protein requiring no post-translational modification for 
enzymatic activity [339,340]. The firefly luciferase reporter gene is commonly used is due to fact 
that it responsible for a reaction that is highly efficient [336], with a quantum yield of 




bioluminescence < 0.88 [341]. Additionally, the firefly luciferase reporter gene is highly sensitive 
and has an expansive linear range of roughly up to 7 to 8 orders of magnitude [342,343], with little 
to no background noise in host cells. Firefly luciferase is vulnerable to proteolysis and as such it is 
fairly unstable in mammalian cells [344]. Its stability in lysis extract at 4°C is 6 weeks [345,346], 
whereas it is stable -80°C [336].  
Estrogenic test substances are regarded as either agonists or antagonists, depending on their 
behaviour compared to known standard ER agonists such as E2, or ER antagonists such as ICI 
182 780 [347]. Antagonists, in contrast to agonists, are defined by their inability to elicit a response 
in a cell or tissue system on their own, while opposing standard agonist-induced activity. 
In the proper use of any assay, positve and negative controls need to be in place to guard against 
false positive and negative results. Therefore in the evaluation of the estrogenicity of a test 
substance where either ERα/ERβ is co-transfected with the promoter reporter construct, the cells 
that undergo transfection should not express ER endogenously. The amount of the repective DNA 
constructs transfected, and the total amount of DNA transfected should also be constant. In 
addition, to control for the fact that the test substance solvent (vehicle) does not have an effect on 
the estrogenic result, the vehicle has to be evaluated on its own (in quantitative accordance as in a 
normal treatment condition) and compared to cells not treated with the vehicle. Inclusion of a 
standard positive control, such as E2, will prevent false negative results. 
An example of a promoter reporter assay for evaluation of estrogenic activity, was performed by 
Duong et al. [348] in which HeLa cells were transfected with an ERE2-TK-LUC promoter reporter 
constuct and either CMV-ERα or CMV-ERβ. Treatment with increasing concentrations of E2 
revealed an EC50 value of approximately 10
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2.5.1.1.3 Cell proliferation assays 
Various methods to measure cellular proliferation exist. These methods are aimed at either 
quantifying the ability of cells to metabolise dyes, to determine the protein content of cells, 
counting cells with a haemocytometer or cell counter, or measuring radiolabelled thymidine 
incorporation. In the next section  the pros and cons of most of these assays will be discussed, 
however, as the use of metabolising dyes are most common in determining cell proliferation [349] it 
will be discussed in further detail.  
Cell counting as measurement of cell proliferation using the traditional hemocytometer is usually 
very accurate, but this procedure cannot be used in high-throughput screening as the assay is 
laborious and time-consuming [350]. Another very accurate method involves the detection of 
tritiated thymidine fusion into the DNA of the cells [351], however, this method is also laborious, 
cost-ineffective, and requires safety measures due to the use of radioactivity [352]. 
Given these constraints, this resulted in the development of an array of other methods, which allows 
measurement of metabolic activity as an indicator of cell viability, and as such, cell proliferation. 
These assays include measurement of reduction of tetrazolium salts [353,354] and resazurin [355] 
via the action of mitochondrial enzymes, and measurement of cell esterase activity [356], 
glyceraldehyde-3-phosphate activity (G3P) [357], and cytosolic acid phosphatase activity [358]. 
These assays have proven to be very sensitive [359,360], however, as they measure cellular activity, 
which varies substantially over time, numerous measurements need to be made at specific time 
intervals for a substantial period of time, which can make the assays inconvenient [352]. In 
addition, as cellular nucleic acid is a sensible pointer of cell number [361], fluorescent indicators of 
DNA, such as 4'6-diamidino-2-phenylindole-2HCl (DAPI) [362], propidium iodide [363], and 
Hoechst 33258 [364], have made cell quantitation assays faster, but, roughly 10 times less sensitive 
than that of the newly developed methods described above [352]. 




Assays involving the use of tetrazolium salts include the MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyl-tetrazolium bromide) assay, the XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide), and the WST (water soluble tetrazolium) assay. In the MTT assay, the 
most frequently used cell proliferation technique to screen for proliferation of honeybush extract-
induced breast cancer cells [25,28,268], tetrazolium salts are reduced by mitochondrial and extra-
mitochondrial dehydrogenases to form insoluble blue formazan crystals, and as such an extra 
solubilisation step is needed before absorbance values are obtained [365]. Disadvantages of the 
MTT assay is that damaged mitochondria may still be able to reduce MTT to formazan, and that the 
substrate is toxic to cells [366-369]. In addition, the MTT assay has been shown to underestimate 
the anti-proliferative activity of certain polyphenols [370]. Advantages, however, include the fact 
that the colorimetric reaction occurs relatively fast [367], and the assay is non-hazardous, accurate 
and reproducible [371]. In the XTT assay the substrates are analogous to MTT, however, the 
formazan product is soluble, and another advantage of this assay is that the reactions are carried out 
intracellularly in the presence of phenazine methosulfate (PMS), which enhances the assay‘s 
sensitivity. In contrast, a disadvantage of this assay is that fatty acids, serum albumin and phenol 
red in cell culture media have all been shown to impair data collected from XTT and WST assays 
[372]. In WST assays the substrate is cell-impermeable and is reduced extracellularly by plasma 
membrane electron transport to generate soluble formazan [373] in the presence of PMS. 
Disadvantages, as with the other tetrazolium salt based assays, is the fact that cell metabolic 
processes vary under different cell culture conditions, and that these assays measure cell 
proliferation indirectly [374]. Advantages of WST assays, however, include the fact that it is more 
cost efficient than the MTT and XTT assay, and also, the formed product is water soluble, which 
allows for a more time efficient assay.  
Analysis of dose response curves constructed from results obtained from an MTT assay, as in the 
case of the promoter reporter gene assay, allows for the determination of ligand potency and 
efficacy. An example of a study used to measure cell proliferation of breast cancer cells was 




performed by Van Meeuwen et al. [375] in 2007. They incorporated the use of an MTT assay to 
evaluate the proliferation of MCF-7BUS cells after E2 and genistein treatment and consequently an 
EC50 value of 38 nM and 5 pM was obtained for genistein and E2, repectively. 
2.5.1.1.4 Analysis of estrogen-induced mRNA and protein expression 
The effect of a test substance on protein level is mostly evaluated by means of Western Blot 
analysis, whereby quantification of a specific protein that serves as a marker for estrogenicity is 
evaluated. Proteins that have been identified as markers for estrogenicity include the progesterone 
receptor (PR), present in breast tissue and the uterus [376,377], position specific antigen 2 (pS2), 
present in breast cancer cells [378], and cathepsin D, expressed in MCF-7 breast cancer cells [379]. 
In addition to measuring protein levels, quantification of estrogen responsive enzymes is also a 
possibility, which can be done using an alkaline phosphatase assay to measure activity of this 
enzyme [26]. 
The evaluation of the estrogenicity of a test substance can also be determined at the RNA level, 
where the mRNA encoding for the abovementioned marker proteins is investigated. These 
techniques include mRNA quantification using Northern Blot analysis, quantitative polymerase 
chain reaction (QPCR), and DNA microarray techniques [380,381]. The DNA microarray analysis 
of gene expression encompasses one major advantage, which is the fact that it allows the 
investigator to monitor the regulation of a variety of genes of interest. In a study by Coser et al. 
[382] a large number of estrogen regulated genes were investigated after exposure to a range of E2 
concentrations. This allowed investigators to categorise these genes into six categories, namely, 
very high E2 sensitivity, high E2 sensitivity, moderate E2 sensitivity, low E2 sensitivity and E2 
suppressible genes. 
As abovementioned in vitro techniques, compared to in vivo techniques, are usually cost-effective, 
not time-consuming, and allows the investigator to do several assays in a relatively short period of 
time, it is important to note that the use of in vitro techniques to determine for instance 




phytoestrogen estrogenicity, is also coupled to some limitations. These include the fact that in vitro 
assays can be inconsistent due to differences in cell line strains, media compositions, and serum 
sources [383,384]. Most importantly, the ability of in vitro assays to accurately mimic the responses 
of in vivo assays is questionable due to the fact that in vitro assays do not possess the same 
metabolic competencies and as such can produce false positive results due to, for example, its 
incapability to metabolically inactivate an estrogenic substance [385,386]. 
2.5.1.2 In vivo measurements for estrogenicity 
In an attempt to comprehensively evaluate a substance, such as a possible phytoestrogen containing 
extract, for estrogenic activity, it is important to link the results obtained from as many as possible 
in vitro estrogenic assays with those obtained from as many as possible in vivo estrogenic assays. 
Two commonly used in vivo assays for assessing estrogenic activity include the uterotrophic and 
vaginal cell cornification assays [387-391].  
For the uterotrophic assay, increased uterine wet weight relative to rat body weight is the most 
commonly used in vivo marker to establish estrogenicity of a test substance [389,392]. For the 
proper use of this assay standardized operating procedures need to be employed, as variables such 
as different species may result in different study outcomes [383]. It has, for example, been shown 
that the mouse uterus is more responsive to estrogens than the rat uterus [389]. Other variables to be 
considered is the fact that ovariectomised animals display greater sensitivity in the uterotrophic 
assay [393,394], and that the uterus is not only responsive to E2, but also to compounds such as 
testosterone and progesterone related compounds [395-399]. This can influence results when 
investigating extracts for estrogenic activity, as extracts represent complex mixtures, of which many 
constituents are not characterised in terms of biological activity. As the uterotrophic assay only 
measures uterine weight, inclusion of other endpoints, such as the vaginal opening, cardiovascular 
system, liver and bone tissue, the mammary gland, and the brain, can also explain test substance 
organ or tissue specificity [400].  




The vaginal epithelial cell cornification assay is believed to be a conclusive in vivo test regarding 
the estrogenic activity of a test substance [401]. The assay investigates the percentage of cornified 
cells in a vaginal smear sample collected from a treatment group of animals, relative to the 
percentage of cornified cells in a vaginal smear sample collected from animals in a control group. 
As an increased vaginal epithelial cell cornification percentage is indicative of test substance 
estrogenicity [402], the animal group treated with estrogenic compounds will display a higher 
percentage of vaginal epithelial cell cornification. Advantages of this assay include the fact that the 
assay is relatively easy to perform, and the same animal can be used for multiple tests as long as the 
test substance does not bioaccumulate. In contrast, a main disadvantage of this assay is that it is 
rendered time-consuming as the treatment period usually lasts for roughly three weeks, and a large 
number of animals need to be evaluated in order to acquire accurate results [389,391].  
In conclusion, it is thus apparent that the use of single assay type is not sufficient for evaluation of 
the estrogenicity of a test substance, but that the investigator should rather employ a series of both 
in vitro and in vivo assays in an attempt to accurately predict the estrogenic potential of a test 
substance such as a possible phytoestrogenic source. It is important, however, to remember that in 
vivo assays are time-consuming assays, and as such, for the purpose of efficiently and accurately 
performing activity-guided fractionation of an extract, the incorporation of more than one in vitro 
assay would be needed. 
2.6 Absorption and metabolism 
As mentioned earlier SM6Met serves as a candidate source for the future development of possible 
oral phytoestrogenic nutraceutical. There are various factors to consider in the development of such 
a nutraceutical [29-32], however, two main preliminary concerns would be to firstly, identify the 
compound or compounds pertaining to the specific estrogenic activity of the extract and, secondly, 
to determine whether these compounds are absorbed intestinally, as it is required for a therapeutic 
effect [403-405]. In the next section the types of transport that occur during intestinal absorption 




will be discussed. The focus will fall on the intestinal structure and function, phytoestrogen-related 
metabolism, and intestinal absorption of Cyclopia extract-related compounds. Furthermore, models 
for predicting and evaluating intestinal absorption will also be discussed. 
2.6.1 Intestinal structure and function 
The small intestine is known as the primary site of intestinal absorption of orally administered drugs 
[406] (Fig. 13a). The inner absorptive surface of the small intestinal wall is greatly increased by the 
presence of villi, whilst the colonic intestinal wall possesses invaginations, and as such contributes 
to increased absorption of drug molecules [407]. The intestinal epithelial cell membrane serves as 
the primary barrier in drug transport from the lumen to the blood (Fig. 13b). In the intestine, most 
lipophilic compounds permeate the intestine via a passive diffusion process. Diffusion across a 
mucosal layer can either take place via a paracellular (between cells) or transcellular (across cells) 
pathway [408]. Paracellular diffusion commonly occurs via tight junctions between two or three 
cells, whereas transcellular diffusion may occur either via receptor-mediated binding followed by 
vesicular transport (transcytosis), or via passive absorptive transcytosis (fluid phase) [409]. 
Compounds can also be absorbed by means of carrier-mediated transport, involving transporters 
such as H
+
/peptide cotransporter, peptide transporter 1 (PEPT1), for movement into intestinal 
epithelial cells followed by active transport into the bloodstream by a transporter such as multidrug-
resistance-associated protein 3 (MRP3). In contrast, some compounds make use of efflux 
transporters such as P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP), resulting in a 
lowered bioavailability of these compounds as they are frequently pumped back into the lumen 
[410]. In addition, drug molecules may also be metabolised by intestinal enzymes such as 
cytochrome P450-dependent mixed-function oxidase 3A4 (CYP3A4), resulting in inactivation 
[411]. Another means of diffusion process classification also exists whereby permeation processes 
are divided into non-polar (partitioning into the lipid bilayer of the mucosa) and polar (aqueous 
channels in mucosa) pathways, however, literature suggests that the transepithelial permeation of 
most molecules occur as a simple first-order diffusion process [412,413]. 





Figure 13 Small intestine physiological structure and function [403]. a) the oral drug absorption route, b) 
main pathways in the gastrointestinal tract absorption: 1) transcellular transport, 2) paracellular transport, 3) 
transcytosis (enzyme metabolism), 4) carrier-mediated transport and, 5) efflux transport. PEPT1 refers to 
H
+
/peptide cotransporter 1, OATP-B refers to organic anion-transporting polypeptide-B, OCTN2 refers to 
novel organic cation transporter 2, Pgp refers to P-glycoprotein, MRP refers to multidrug resistance-
associated protein, BCRP refers to breast cancer resistance protein and, MRP3 refers to multidrug resistance 
protein 3. 
2.6.2 Intestinal metabolism and absorption of phytoestrogens 
In the next section phytoestrogen metabolism and absorption will be discussed, and as lignans and 
isoflavones are considered to be the main phytoestrogens [414], and thus the most studied, the focus 
will mainly be on the metabolism and absorption of these plant constituents. 
Isoflavones exist in three different forms in nature known as the acetylglycosides, aglycones 
(unconjugated) and malonylglycosides [415]. Daidzein and genistein are present in soybeans and 
soy products, mostly as their glycones, daidzin and genistin [416]. After ingestion, these glycones 
are hydrolyzed by intestinal β-glucosidases releasing the bioactive aglycones, genistein and 
daidzein, which enables intestinal absorption of these compounds [238,417]. Pharmacokinetic 
studies in humans have indicated that absorption of isoflavones occur along the entire length of the 
intestine [418]. The lignans, matairesinol and secoisolariciresinol, are converted into enterolactone 
and enterodiol, respectively, by bacterial metabolism, where after enterodiol may then be converted 




into enterolactone in the gut [419]. Once absorption occurs, isoflavones and lignans undergo hepatic 
sulfation and glucuronidation, where after the conjugates either undergo enterohepatic circulation, 
or they are excreted in the bile and urine [417,420]. The formation of genistein and daidzein can 
also occur through bacterial demethylation of formononetin and biochanin A (found in red clover), 
respectively [421]. Thereafter, daidzein is metabolised to non-estrogenic O-desmethylangolensin 
(O-DMA) and estrogenic equol [422], whereas genistein is metabloised to dihydrogenistein and 
consequently 6´-hydroxy-O-DMA (6´-OH-O-DMA) [213,423]. There is, however, a considerable 
amount of interindividual variation in the metabolism of isoflavones [239]. For instance, 80-90 % of 
humans can convert daidzein to O-DMA, whereas only 30-50 % of humans can convert daidzein to 
equol [424,425]. The metabolites O-DMA and equol occur in an inverse relationship [426], and as 
equol is regarded as estrogenic, such variation may be of toxilogical importance [427]. The 
variation in phytoestrogen metabolism may be attributed to the presence or absence of bacteria 
adept at metabolising these compounds, the intestinal transition time, or the pH. These factors are 
influenced by the host diet, diseases, surgery, immunity and intake of drugs. 
Excretion of isoflavones from the body occurs within 24 h after ingestion, predominantly in urine, 
and to a lesser extent, in feces [428]. It has been shown that genistein and daidzein urinary excretion 
content does not correlate with ingested doses, which might be attributed to the lessened absorption 
of isoflavones with high ingested doses [429]. Equol, genistein and daidzein have been detected in 
human urine [430], plasma [431], saliva, prostatic fluid and breast aspirate [432]. Contrastingly, 
lignan concentration in urine and plasma increases in a dose-dependent manner [433]. In addition, it 
has been shown that the lignans, enterodiol and enterolactone, are detected in human semen [434], 
bile [435], faeces and also serum [436]. It has been shown that various factors play a role in equol 
excretion, including individual genetic factors, diet, and type of intestinal bacteria present 
[124,437,438]. 




An important factor to keep in mind is the effect of the matrix (presence of other compounds) in 
which compounds are administered to the host, on the absorption of compounds of interest. For 
example, phloridzin, a constituent of apples, has been shown to amplify the absorption of the 
isoflavone genistin (genistein glucoside) in rat small intestine [439], furthermore, phytic acid has 
been shown to enhance the absorption of anthocyanins in both humans and rats [440]. In addition, 
milk has been shown to enhance absorption of green tea polyphenols in a Caco-2 cell model [441]. 
In contrast, the flavonoids, quercitin and rutin, attach to the small intestine of the rat in an in vitro 
assay, which greatly limits their absorption [442]. Furthermore, the flavonol quercetin-3-glucoside 
has been shown to inhibit cyanidin-3-glucoside absorption in a mouse in vitro assay [443]. The 
presence of other compounds do not always have an effect on the compound of interest‘s 
absorption, as demonstrated by Zuo et al. [444], where the Caco-2 cell model, rat in situ intestinal 
perfusion model, as well as the in vivo pharmacokinetics studies in rats demonstrated that the co-
occurring components in a hawthorn phenolic extract might not have a significant effect on the 
intestinal absorption of the three major hawthorn flavonoids, hyperoside, isoquercitrin and 
epicatechin. 
2.6.3 Intestinal absorption of Cyclopia extracts 
No absorption studies have been performed on the Cyclopia subternata extract SM6Met, however, 
as the polyphenolic content of SM6Met has been investigated [26], available literature on the 
absorption of the individual compounds or extracts containing the same polyphenols known to be 
present in SM6Met can be investigated. 
Previous qHPLC results have indicated that SM6Met contains numerous polyphenolic compounds 
[26,268]. These compounds include two xanthones, mangiferin and isomangiferin, two flavanones 
eriocitrin and hesperidin, two flavones, luteolin and apigenin-6,8-di-C-glucoside, and two unknown 
compounds, unknown 1 and unknown 2 [26,268]. Unknown 1 was later identified as the flavone, 
scolymoside, and unknown 2 was identified as the dihydrochalcone, phloretin-3',5'-di-C-glucoside 




[268]. Furthermore, another dihydrochalcone, 3-hydroxyphloretin-3',5'-di-C-hexoside, referred to as 
aspalathin by Visser et al. [268], was also identified in SM6Met. In addition, the presence of two 
benzophenones, iriflophenone-3-C-glucoside and iriflophenone-di-O,C-hexoside, and also, the 
hydroxybenzoic acid, protocatechuic acid, was indicated in SM6Met [268]. 
In a study by Bock et al. [445] pigs were fed a mangiferin-enriched C. genistoides extract, whereby 
pigs were fed 1 mg hesperidin per kilogram bodyweight, and 74 mg mangiferin per kilogram 
bodyweight for 11 days, respectively, where after plasma, urine, and faeces samples were collected 
at various time intervals. The plasma samples revealed only the presence of the mangiferin 
aglycone, norathyriol, whereas the urine revealed six metabolites of mangiferin and hesperidin. 
Furthermore, 8.2 % of initial mangiferin intake was detected in the faeces, whereas no hesperidin or 
hesperidin metabolites were detected in the faeces.  
In a study investigating absorption of the dihydrochalcone C-glucoside, aspalathin, an aspalathin-
rich rooibos extract was orally administered to pigs at 157-167 mg aspalathin per kg body weight 
daily for 11 days, whereafter plasma and urine samples were collected at various time intervals 
[446]. Even though no traces of aspalathin was detected in pig plasma, five diydrochalcones were 
detected in the urine samples, indicating that absorption of aspalathin did take place, and that 
cleavage of the compound took place to form the aglycone and sugar moiety. This study also 
concluded that phase II enzyme metabolism was involved as the methylation and glucoronidation of 
metabolites occurred. In addition, a human study [447] also investigated bioavailability of 
aspalathin, nothofagin and also four eriodictyol-C-glycoside isomers. Upon administration of these 
compounds to five male and five female volunteers, where each had to consume 500 ml of 
fermented or unfermented tea, urine and plasma samples were collected at 0-24 h. The unfermented 
tea had 10 times higher aspalathin and nothofagin, and a four times lower eriodictyol-C-glycoside 
content, than fermented tea. Even though no metabolites were detected in the plasma, urine analysis 
revealed eight metabolites, of which the fermented drink yielded mainly eriodictyol-O-sulfate, and 




the unfermented drink, O-methyl-aspalathin-O-glucuronide. Interestingly, this study concluded that 
all aspalathin metabolites were excreted within 5 h, indicating absorption in the small intestine, 
whereas the eriodictyol metabolites were excreted between 5-12 h, indicating absorption in the large 
intestine. 
Furthermore, rat studies investigating the absorption of the dihydrochalcones, phloretin and 
phloridzin, was conducted by Crespy et al. [448]. Rats were fed a single meal containing 0.157 % 
of the dihydrochalcone aglycone, phloretin, and 0.22 % of the glucosidic form of phloretin, 
phloridzin, of which the phloretin and phloridzin were the equivalent of 22 mg phloretin. 
Thereafter, plasma samples were collected as various time intervals, and analysed. Conjugated 
phloretin was mostly detected in the plasma, however, some unconjugated phloretin was also 
detected, whereas no intact phloridzin was detected, suggesting that cleavage of the glucoside 
moiety from phloridzin occurs during absorption. 
In an investigation of flavone absorption by rats, Shimoi et al. [449] administered 50 µmol/kg 
luteolin or luteolin 7-O-β-glucoside by gastric intubation to rats, with blood samples collected at 
various time intervals afterwards. Analysis of plasma revealed that free luteolin, luteolin conjugates 
and methylated luteolin conjugates were present, illustrating that some luteolin can escape the 
intestinal conjugation and hepatic sulfation/methylation. The same study also demonstrated that 
luteolin was transformed to it glucuronide forms during intestinal permeation. 
In a study by Zhang et al. [450] the benzophenone iriflophenone-3-C-glucoside, together with other 
compounds present in a mango leave extract, was orally administered to KK-A
y
 mice for 8 weeks at 
two different concentrations. Iriflophenone-3-C-glucoside was found to be present in both the blood 
samples and the soleus muscle samples, which is indicative of the fact that absorption did occur. 
In conclusion, as detection of ingested compound metabolites in blood or urine is indicative of 
systemic absorption, most of the above mentioned compounds were absorbed. It is, however, 




important to remember that variability occurs in the absorption of orally administered compounds. 
A factor contributing to this variability is the site of absorption, i.e. the small or large intestine. 
Furthermore, deglycosylation of the ingested compounds vary and serves as a prerequisite for 
absorption in a compound-dependent manner. In the next section we will discuss the various types 
of models available for the purpose of predicting intestinal absorption. 
2.6.4 Models for predicting intestinal absorption 
Commonly used test systems for the investigation of intestinal absorption of compounds are listed 
in Table 3, where the type of system, the different models, the species of origin, and also the pros 
and cons of the models are presented. These commonly used test systems may be divided into five 
different system classifications namely, in vitro, in vivo, in situ, ex vivo and in-silico models.  
2.6.4.1 In silico methods  
In silico methodology refers to the use of computational or virtual screening to accurately predict 
intestinal permeation. These models make use of the molecular descriptors of compounds such as 
compound molecular size, lipophilicity, hydrogen bonding capacity, etc. in order to accurately 
predict absorption, and in doing so it serves as a high throughput (HT), and thus time-saving 
alternative to the conventional experimental studies.  
A well-known in silico model for the quantitative prediction of intestinal absorption was proposed 
by Lipinski et al. [478] in 1997, known as Lipinski‘s ―Rule of five‖. In this model poor intestinal 
permeation is predicted for compounds with a molecular weight more than 500, a cLogP (octanol-
water partitioning coefficient) value greater than five, and for compounds with more than 10 
hydrogen bond acceptors (HBA), and more than 5 hydrogen bond donors (HBD) [461]. In addition, 
quantitative structure and property relationship (QSPR) programs, such as the ADMET Predictor 
program, or GastroPlus™, which makes use of the physicochemical, spectroscopic, and 
chromatographic properties of compounds, have been used to predict human intestinal absorption 
[456,457,479,480].  




Table 3 Summary of the pros and cons of commonly used assays for the prediction of intestinal absorption as adapted from Liu et al. [403]. 
System Model Species of origin Pros Cons 
In silico Computational approaches such as 
structure activity relationships 
Computer databases HT 1. Lack of active processes (at present)  
2. Depends heavily on the quality and 
quantity of available data 
In vitro Artificial membrane systems 
(PAMPA, IAM) 
— 1. HT 
2. Easy to utilise and analyse 
Dependent on lipid composition and pH 
 Caco-2 Human colon 
adenocarcinoma 
1. Most well established model 
2. Differentiates and expresses relevant 
transporters 
3. Moderate to HT 
4. For active and passive transport 
1. Expression of influx transporters is 
variable 
2. Long culture period (21 days) 
3. Can measure only transcellular permeation 
accurately 
 MDCK Dog kidney Ideal for transfections Cells express low levels of ABC transporters 
 2/4/A1 Rat foetal intestinal 
epithelial cells 
Ideal for paracellularly absorbed 
compounds 
Temperature sensitive 
Ex vivo Rat everted gut sacs Rats guts 1. Easy and inexpensive 
2. Useful for mechanistic studies 
1.Viability of tissue (<30 min) 
 Flow-through diffusion Porcine intestine 1. HT 
2. Can be used to determine compound 
pharmacokinetic data  
Produces a large amount of variation in 
results 
In situ Rat intestinal perfusion Rat intestines 1.Transporters, enzymes 
2. Relevant tight junctions 
1. Difficult analysis 
In vivo Animal blood or urine Rats, mice, rabbits, 
dogs, pigs 
1. Transporters, enzymes present 
2. Relevant tight junctions 
3. Presystemic metabolism 
4. Closer to human in vivo conditions 
1. Ethical considerations 
2. Expensive 
3. Laborious and time-consuming 
HT refers to high throughput, MDCK refers to Madin-Darby canine kidney, PAMPA refers to parallel artificial membrane permeability assay, IAM refers to immobilized artificial 
membrane 
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Most of the computational models currently in use only predict passive absorption as it does not 
account for influx or efflux transporters. As this technique can be used only for passively 
transported compounds, it may lead to inaccurate results regarding compounds that are also actively 
transported [481]. 
As computational modelling of intestinal absorption is still a relatively new field, researchers 
propose the combinatorial use of in vivo methods and in silico methods to accurately predict human 
intestinal absorption of a compound. This will also allow validation of the sole use of in silico 
methods for use in future experiments [481].  
2.6.4.2 In vitro methods 
The in vitro section will only focus on the most frequently used in vitro assay, the Caco-2 cell 
monolayer assay. 
2.6.4.2.1 Caco-2 cell monolayer 
The most commonly used in vitro approach for prediction of intestinal absorption is the use of the 
Caco-2 cell monolayer (human adenocarcinoma cells derived from the colon) [451-457] (Fig. 17). 
 
Figure 17 Graphical representation of the Caco-2 cell monolayer assay experimental setup. 




As the colonic Caco-2 cells are morphologically and functionally similar to small intestinal cells, 
advantages of using these cells are that these cells differentiate and express relevant transporters, 
and as such, active and passive transport can occur. Also, the technique is known as a moderate to 
HT technique, as it yields a relatively large amount of data per experiment [403]. Factors that 
inhibit the performance of the cells include the lack of cell heterogeneity, and variable expression of 
only some intestinal enzymes and transporters [458,459]. Furthermore, the culture period of 21 days 
make the use of these cells a time-consuming pursuit. In a study by Walter et al. [460] it was shown 
that the permeability of the paracellular marker, mannitol, varied as much 100-fold depending on 
the source of the Caco-2 cells, however, regardless of its source these cells will always separate the 
completely absorbed compounds from the poorly absorbed compounds. Further limitations in the 
use of this cell line include poor predictive absorption of some compounds, for example, some low 
molecular weight compounds have been shown to be adequately absorbed in humans, whilst the 
Caco-2 model have predicted poor absorption for these compounds [461]. Furthermore, the use of 
an adequate amount of organic solvent in the cell model is restricted, as integrity of the cell 
junctions is easily disturbed, even at a low percentage concentration of these solvents [461].  
2.6.4.3 Ex vivo methods 
Ex vivo methods includes the excision of the intestinal area of interest e.g. the jejunum, and 
investigation of the tissue specimen outside the body of the animal of origin. Examples of two well-
known ex vivo absorption methods are the everted intestinal sac assay and the flow-through 
diffusion assay.  
2.6.4.3.1 The rat everted intestinal sac assay 
The rat everted (definition: the position of being turned outward) intestinal sac assay developed by 
Wilson et al. [476], whereby the everted sacs are filled with incubation solution, sealed at both 
ends, and put into a solution containing the investigated drug, in order to determine the presence 
and extent of the intestinal permeation for the drug. Kelber et al. [477] showed that this technique 




can yield results that correlate accurately with the Caco-2 cell monolayer assay and in vivo assays. 
Limitations of this technique include the absence of in vivo conditions such as blood and nerve 
supply, and the absence of intestinal microflora that can play a part in the intestinal absorption of 
some compounds.  
2.6.4.3.2 Flow-through diffusion system 
The flow-through diffusion system (Fig. 18) is useful for predicting permeation of a compound, or 
comparing the permeation of compounds through a mucosal sample, since the structural integrity of 
the tissue specimen is close to that of the in vivo conditions. However, even though the technique 
yields seven replicates per experiment, and the experiment only takes 24 h, a large amount of 
variation exists between replicates, and as such the researcher needs to perform the experiment 
multiple times, resulting in the analysis of many collected fractions, in order to get a viable or 
significant result. The flow-through diffusion assay, however, when used for purposes of predicting 
human intestinal absorption, incorporates the use of either porcine small or large intestine, which is 
useful as porcine intestine resembles the human intestine both functionally and morphologically 
[462]. In addition, the flow-through diffusion assay allows pharmacokinetic evaluation of the 
absorption of compounds.  
The method has been used to investigate various mucosal membranes for the permeability of drugs. 
In a study by van der Bijl et al. [463], the flow-through diffusion system was used to compare 
human buccal and human vaginal mucosa permeability for sumatriptan, a synthetic drug used in the 
treatment of migraine headaches. This study was later extended to compare the permeability of 
various chemical markers through human buccal and vaginal mucosa, as well as porcine mouth 
floor and buccal mucosa [464]. 





Figure 18 The flow-through diffusion assay system set-up. On the bottom left of the figure is the fraction 
collector. Above the fraction collector are seven flow-through chambers, each containing a porcine tissue 
sample with the apical-side facing upwards. The sample is placed on the porcine intestine, and phosphate 
buffered saline (PBS) is pumped through the flow-through chamber containing the intestinal sample by 
means of a pump present on the bottom right of the figure. 
In addition, the flow-through diffusion technique was used to investigate the effects of penetration 
enhancers on the permeation of human corneal permeability for the immunosuppressive agent, 
Cyclopsporin A [465]. It was also used to compare the permeability of human and rabbit cornea for 
Cyclosporin A and tritiated water [466]. More recently, a comparative diffusion study of drugs 
through porcine bronchial tissue was performed by Van Zyl et al. [467].  
Permeability of human intestinal mucosa has also been evaluated using this technique [468], where 
it was concluded that the continuous flow-through perfusion system was sufficient for testing 
intestinal permeation of compounds with a molecular weight smaller than 500 Da, however other 
human mucosa, such as vaginal mucosa, have to be considered as an alternative to intestinal mucosa 
for intestinal permeation evaluation of compounds larger than 500 Da. Furthermore, in 2003 a 
comparative permeation study was performed to investigate permeation of a range of compounds 
through human vaginal, colonic and small intestinal tissue [469]. It was concluded that colonic 




mucosa is more permeable to E2, water, arecoline and arecaidine, however, it was found that drugs 
with a molecular weight of more than 300 Da may necessitate the use of other mucosal membranes, 
such as vaginal mucosa, as an alternative.  
2.6.4.4 In situ methods 
The in situ rat single pass intestinal perfusion model (Fig. 19) includes anesthetising the rat of 
interest, followed by creating two incisions, one at the top and one at the bottom of the still intact 
intestinal area of interest (the jejunum as in the case of Fig. 19). The inlet of the tube is inserted at 
the proximal incision, whereas the outlet of the tube exits by the distal incision. Perfusion solution 
containing the investigated drug is then pumped through the tubing with samples collected at the 
outlet (Fig. 19), where after the perfusate is analysed in order to determine the absorption of 
compounds. The in situ perfusion model is a dependable assay as it devises biliary secretion profiles 
that resemble in vivo conditions, and it incorporates transporters and enzymes present in in vivo 
conditions [403].  
 
Figure 19 Graphical representation of the rat single pass intestinal perfusion model [473]. 
In order to elucidate the absorption mechanism, absorption site and transport route, the in situ 
method can be combined with the Caco-2 method as was done in Zhou et al. [474]. An advantage 




that the in situ technique holds over an in vitro technique is the incorporation of the intact nerve and 
blood supply. Various different types of in situ perfusion has been investigated such as oscillating 
perfusion, the common single pass perfusion, closed loop perfusion, and studies have even been 
extended to humans as in Lennernas et al. [475], where this technique has been dubbed accurate in 
the prediction of passively transported compounds. In contrast, the single pass perfusion method has 
some limitations, namely it is not cost-effective, and the rate of diffusion from the luminal side does 
not always accurately correlate with the rate of actual absorption [461]. 
2.6.4.5 In vivo methods 
In vivo models are frequently used in the prediction of human intestinal absorption of herbal 
medicines, individual compounds, or extracts as mentioned in the section on absorption of 
polyphenols also present in SM6Met. Advantages of the use of an in vivo model to predict intestinal 
absorption includes the incorporation of enzymes, transporters, and relevant tight junctions. 
Furthermore, in vivo test systems also incorporate the use of a presystemic metabolism, and as such, 
in vivo test system conditions are the closest to human in vivo conditions (Table 3). The animal 
model regarded as the most accurate in predicting human intestinal absorption is the pig. However, 
a few disadvantages exist, namely the requirement of a large number of animals, inter-animal 
variability, and also the long period usually needed for a study. Drug absorption has been shown to 
be influenced by the age, sex, chronic therapy, and disease state [470,471] of the animal. In 
addition, the absorption results can be species-dependent [472], and as such caution should be taken 
in explaining and extrapolating results. Species-dependent absorption can be ascribed to 
fluctuations in physiological factors within species, such as differential distribution of enzymes, 
gastrointestinal tract motility, pH, and transporters [426]. Even though in vivo methods are 
resource-intensive, it is commonly used to predict the absolute extent of human intestinal drug 
absorption [426]. 




In summary, numerous test system types and also test system type models are available to predict 
human intestinal absorption. Some models are more useful than others, however, most 
experimenters will use the model that presents the highest throughput, and yields the most reliable 
data. For the purpose of a preliminary investigation of the absorption of compounds present in an 
extract such as SM6Met, ex vivo and in vitro assays, such as the flow-through diffusion assay and 
the Caco-2 assay, would most frequently be used. However, in an attempt to more closely predict 
human intestinal absorption one should incorporate the use of as many as possible other test 
systems as it entails a more holistic approach. 
2.7 Conclusion and aim of thesis 
Conventional HRT used in the treatment of menopausal symptoms and menopause related diseases 
has been shown to be effective in most instances; however, its usage is accompanied by a range of 
side effects [6-18], of which invasive breast cancer is considered the primary adverse outcome 
[9,10]. In the search for a safer, more natural alternative to conventional HRT women have shown 
an interest in phytoestrogens [191,192], perceived to have a better side effects profile [153,156]. 
In 2007 Verhoog et al. [24] identified two Cyclopia species displaying phytoestrogenic properties 
using ER binding assays. It was also concluded that unfermented rather than fermented plant 
material should be used for extracts to display optimal estrogenic activity, and that methanol rather 
than water should be used as extraction solvent to obtain an extract that displays optimal estrogenic 
activity. Verhoog et al. [25] did a follow-up study in 2007 focussing on C. genistoides and showing 
that its extracts displayed phytoestrogenic properties and acted predominantly via ERβ, however, 
none of the investigated polyphenols could explain this activity. In 2008 Mfenyana et al. [26] 
screened various C. genistoides and C. subternata extracts for estrogenic activity in order to 
determine the most potent estrogenic extract, which was identified as the C. subternata extract, 
SM6Met. In 2013 Visser et al. [268] showed that SM6Met has three desirable estrogenic traits, 
namely ERα antagonism, ERβ agonism, and the ability to antagonise E2-induced breast cancer cell 




proliferation. In addition, it was shown that P104, a C. genistoides DME, binds to both ERα and 
ERβ, but transactivates only via ERβ in an ERE-containing promoter reporter assay, and that even 
though it induces breast cancer cell-proliferation, it does so at significantly lower levels than E2. 
These attributes displayed by P104 and SM6Met are desirable as, unlike conventional HRT, they 
should not increase the risk of breast cancer, and as such, should be retained in a future oral 
phytoestrogenic nutraceutical, however, as no more P104 plant material is available for further 
investigation, SM6Met serves as the candidate for the current study. 
The current study, part of a comprehensive study on the phytoestrogenic activity of Cyclopia, 
investigates a specific Cyclopia extract as a candidate source for the possible future development of 
an oral nutraceutical for the treatment of menopausal symptoms. The study will focus on two 
aspects that are important within this context, namely the identification of specific compounds 
conferring the desired estrogenic traits, and also whether these compounds will be absorbed 
intestinally. Thus the aims of this study are firstly, activity-guided fractionation of SM6Met in order 
to identify compounds conferring specific estrogenic traits to SM6Met, and secondly to evaluate 
intestinal absorption of SM6Met compounds. For the first aim SM6Met will be separated and 
fractionated into less complex extracts and fractions. After every fractionation step in vitro 
promoter reporter and breast cancer cell proliferation assays will be employed to monitor the 
estrogenic activity. Also, qHPLC will allow quantitative identification of compounds in extracts or 
fractions to link the presence of compounds with a specific estrogenic activity. For the second aim, 
the permeability of porcine small and large intestinal tissue for SM6Met compounds will be 
investigated using the ex vivo flow-through diffusion assay. Analysis of collected fractions will be 
performed using liquid chromatography–tandem mass spectrometry (LC-MS/MS) in an attempt to 
predict absorption of SM6Met compounds in the human body. Results obtained from the flow-
through diffusion assay will also be accompanied by results obtained from various in silico models 
in an attempt to more accurately predict human intestinal absorption. 
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Menopause is characterised by a decrease in ovarian function and associated estrogen production 
[1], which in some women leads to adverse side effects [2]. Symptoms are known to be more 
pronounced after ablation of the ovaries as per oophorectomy [3,4]. Menopausal symptoms may be 
divided into climacteric symptoms, such as hot flushes and night sweats, and psychosomatic 
symptoms, such as poor concentration, memory loss and loss of confidence [5]. Menopause may 
also cause long-term problems such as osteoporosis, CHD and Alzheimer‘s disease [6-8].  
Menopausal symptoms are traditionally treated with HRT, which supplements the deficit of 
estrogen [6-9]. Specifically, HRT consist of estrogen, for women without an intact uterus, or 
estrogen and progestin, for women with an intact uterus [10]. HRT may reduce the risk of CHD, 
osteoporosis, fatal colon cancer [11] and possibly Alzheimer‘s disease [8,12-15], while preventing a 
decline in cognitive function [16], and improving quality of life [17]. However, HRT usage results 
in several adverse effects such as an increased risk of breast, ovarian and endometrial cancer [18-
24], vaginal bleeding [25], strokes, venous thromboembolism [26], cardiovascular disease 
[3,27,28], and gall bladder disease [29], of which invasive breast cancer is considered the primary 
adverse outcome [27,28].  
The adverse side effects profile of conventional HRT has prompted the search for alternatives with 
a safer side effect profile, specifically, a treatment that would effectively address menopausal 
symptoms, while as a side effect preventing breast cancer [30,31]. Understanding the molecular 
mechanism of action of estrogen could aid in this search. At the molecular level, in most tissue 
types the action of estrogen is mediated via the ER, which forms part of a large superfamily of 
nuclear receptors, and functions as a ligand activated transcription factor [32]. The two mains 
subypes of the ER are ERα and ERβ [33-35]. Estrogen activates both ER-subtypes [36,37], 
however, ER-subtype specific agonist and antagonist ligands have been identified [38-43]. 
Physiologically, ERα is associated with an increase in cellular proliferation, whereas ERβ inhibits 




ERα-mediated cell proliferation [44], thus it has been suggested that compounds, which antagonise 
ERα and/or activate ERβ may be useful in the prevention and treatment of breast cancer [45-47]. 
Phytoestrogens are plant compounds that mimic the action of estrogen as they are structurally and/ 
or functionally similar to mammalian estrogen and its active metabolites [48] and thus may serve as 
a possible alternative to conventional HRT [49,50]. Furthermore, studies have shown that although 
most phytoestrogens bind both ERα and ERβ, they generally show a higher binding affinity for ERβ 
than ERα [35,51-53]. In addition, epidemiological studies have shown that phytoestrogen 
consumption, in Asian populations as part of a soy-based diet, correlates with a low incidence of 
prostate, colon and breast cancers [54,55]. Phytoestrogens are thus seen as a safer alternative to 
conventional HRT [56] and may serve as a source of ER subtype specific ligands [57].  
The genus Cyclopia (family: Fabaceae), which is endemic to the Western and Eastern Cape 
provinces of South Africa [58], contains phytoestrogenic compounds [59]. The aerial parts of the 
bush have been and are still used for the production of honeybush tea, which has a sweetish flavour 
and dark-brown colour [60]. DMEs from C. genistoides and C. subternata have been shown to bind 
the ER and transactivate an ERE-containing promoter reporter construct [61-63]. Whereas initially 
only the DME from C. genistoides (P104) was investigated for ER subtype specific estrogenicity 
and found to activate only via ERβ [61,62], a recent study has established that DMEs from both C. 
genistoides (P104) and C. subternata (SM6Met) are ERβ agonists and ERα antagonists [64]. In 
addition, studies have shown that even though Cyclopia extracts, including SM6Met and P104, 
induce weak proliferation of a human breast cancer cell line (MCF-7BUS), they antagonise 
estrogen-induced proliferation [62-64]. These results suggests that DMEs of Cyclopia may serve as 
a possible source of ER subtype specific ligands for the development of a phytoestrogenic 
nutraceutical that may be suitable for the treatment of menopausal symptoms, while preventing the 
development of breast cancer [64]. 




The current study, part of a larger study investigating the development of a phytoestrogenic 
nutraceutical from Cyclopia, focusses on activity-guided fractionation of the DME from Cyclopia 
subternata, SM6Met. SM6Met was chosen for this study as it is the only extract investigated for 
which the specific source material used in the previous studies was available in bulk. Our activity-
guided fractionation will concentrate on the positive estrogenic attributes previously identified for 
SM6Met, namely ERβ agonism, ERα antagonism and antagonism of estrogen-induced breast cancer 
cell proliferation [62-64]. Activity-guided fractionation is being pursued in an attempt to identify 
the compound or compounds responsible for the above mentioned estrogenic activity. Such a 
marker compound(s) would be useful not only for quality control of a future nutraceutical, but also 
to screen prospective Cyclopia harvestings destined for nutraceutical production. In addition, such a 
marker compound(s) could in future be used to direct plant breeding programs. Thus, qHPLC and 
LC-MS/MS were used to track polyphenols during fractionation for correspondence with above-
mentioned positive estrogenic attributes. 
3.2 Materials and Methods 
3.2.1 Fractionation of SM6Met 
3.2.1.1 Large scale SM6Met production 
The method (Fig. S1), executed at room temperature and adapted from Mfenyana et al. [63], 
entailed defatting of 500 g finely milled, dried plant material, originating from a M6 Cyclopia 
subternata harvesting (harvested 30 March 2004 near Barrydale, South Africa) [63], by stirred 
extraction over a period of 24 hours, using 2 L of dichloromethane (Merck
®
, 99.0% pure). 
Following extraction the plant material was filtered, the filtrate discarded, and the dichloromethane-
extracted M6 air-dried overnight at room temperature. This defatting process was repeated four 
times. Next the air-dried, defatted M6 plant material (400-500 g) was subjected to sequential 
extraction using three solvents (2 L each) in order of increasing polarity (ethyl acetate (99.5% pure), 
ethanol (99.5% pure) and methanol (99.0% pure), supplied by Merck
®
, South Africa). Each 




extraction step in the sequence was performed three times for 3 hours per extraction. The filtrates of 
the methanol extraction step was retained and pooled. Before a solvent change was made, the plant 
material was air-dried overnight in a fume cabinet at room temperature. The methanol was 




Switzerland) at 40°C from the pooled extract, 
whereafter the resultant extract was freeze-dried (Virtis Advantage Plus
®
, USA). The resultant 
DME was ground with a pestle and mortar until a fine powder was obtained, which was then stored 
under vacuum in a desiccator in the dark at room temperature. Four batches of SM6Met (B1-B4) 
were prepared using the protocol above with B1-4Mix being a 1:1:1:1 homogenised mixture of the 
batches B1-B4. 
3.2.1.2 Liquid-liquid fractionation 
SM6Met B1-4Mix (4.3 g), suspended in 300 mL deionised water and decanted into a separating 
funnel, was liquid-liquid extracted using 150 mL of n-butanol (BuOH) (Sigma Aldrich
®
, South 
Africa). The mixture was then shaken lightly and inverting 5 times, and releasing the pressure in the 
separating funnel after every invert. After extraction the mixture was allowed to form two layers, 
and the lower, polar, and the upper, less polar, layers collected separately. For the purpose of this 
study the less polar fraction will be referred to as non-polar. The lower layer was then decanted 
back into the separating funnel, 150 mL of fresh n-butanol added, and the liquid-liquid extraction 
procedure repeated until four n-butanol partitionings were done in total and the respective fractions 
pooled. The resultant fractions, polar fraction (PF) and non-polar fraction (NPF), were rotary 
evaporated under vacuum at 40°C, where after the extracts were frozen at -20°C overnight. 
Following freeze-drying, the dried extracts were stored at room temperature in the dark under 
vacuum in a desiccator.  
3.2.1.3 High performance counter-current chromatography (HPCCC) fractionation 
The instrument used was a multilayer coil planet J-type centrifuge Spectrum model (Dynamic 
Extraction, United Kingdom). The machine is equipped with two preparative (1.6 mm i.d.) and two 




analytical (0.8 mm i.d.) coils of polytetrafluoroethylene (PTFE) tubing, connected in series for a 
total volume of 172 mL. The inner βr-value for the preparative coil was measured as 0.52 at the 
internal end of the coil and the outer βr-value was 0.86 (equation βr = r/R, in this case r is defined as 
the distance from the coil (planetary) axis to the nearest and farthest layer of the PTFE tubes wound 
around the coil system), while the inner and outer βr-values for the analytical coil was 0.64 and 
0.81, respectively. Fractionation was performed at 30°C, a rotation speed of 1600 revolutions per 
min (RPM) and a flow rate of 3 mL/min.  
The two-phase solvent system used consisted of tert-butyl methyl ether (Sigma Aldrich
®
) – butanol 
(Sigma Aldrich
®
) – water (2:1:5, v/v). The solvents were mixed in a separating funnel, allowed to 
equilibrate at room temperature and separated into the organic and aqueous phases shortly before 
use. The separated phases were degassed using sonication. The upper organic phase served as the 
stationary phase, whereas the lower aqueous phase served as the mobile phase. 
The coiled column was filled with the stationary (organic) phase using a Gilson
®
 305 HPLC pump 
(Gilson
®
, USA), equipped with a Gilson
®
 806 manometric module. The sample (30 mg NPF) was 
dissolved in 2.5 mL organic phase and 2.5 mL aqueous phase and then injected into the coil using a 
manual sample injection valve and a 10 mL loop. The mobile (aqueous) phase was pumped in the 
head-to-tail direction at a flow rate of 3 mL/min. The effluent of the column, monitored between 
210 nm and 400 nm, using a Waters
®
 2996 diode-array detector (Waters
®
, USA) equipped with a 
semi-preparative flow cell (3 mm path length), was collected into test tubes at 1 min intervals, using 
a Gilson
®
 FC203B fraction collector. The mobile phase flow was stopped at 52 min and the 
stationary phase pumped at 10 ml/min until 75 min. The procedure was repeated 15 times 
processing 450 mg NPF in total. The fractions collected were pooled into 3 main fractions, F1-F3, 
based on clustering of maximum absorbance peaks seen at 210 nm to 400 nm in separation of the 
NPF (Fig. S2). F1-F3 were rotary evaporated under vacuum and freeze-dried. The fractions were 
then stored at room temperature in the dark under vacuum in a desiccator. 




3.2.2 Evaluation of estrogenic activity 
3.2.2.1 Cell culture 
HEK293 human embryonic kidney cells [65] (a kind gift from R. Louw, Stellenbosch University) 
and MCF-7BUS cells [66] (a kind gift from A. Soto, Tufts University, USA) were maintained in 
Dulbecco‘s Modified Eagles‘s Medium (DMEM) [Sigma Aldrich
®
] supplemented with 5% fetal 
calf serum (FCS) [Highveld Biologicals, South Africa], 100 IU/ml penicillin and 100 µg/ml 
streptomycin (Sigma Aldrich
®
, South Africa). All cells were maintained at 37°C, 95% CO2 and 5% 
relative humidity. 
3.2.2.2 Compounds 





, France), mangiferin (Sigma-Aldrich
®
), isomangiferin (Chemos 
GmbH
®





Pure scolymoside and iriflophenone-3-C-glucoside could not be obtained at the time and thus 
enriched HPCCC fractions were used. The scolymoside (Fig. S3, Table S1) and iriflophenone-3-C-
glucoside (Fig. S4, Table S2) enriched fractions were kind gifts from Dr. E. Willenburg, ARC 
Infruitec-Nietvoorbij, Stellenbosch, South Africa. As the concentration of the compounds present in 
these enriched fractions were not known at the time of experimental procedures, we presumed that 
the fractions represented a high percentage of scolymoside and iriflophenone-3-C-glucoside, 
respectively, thus, we treated the fractions as pure compounds. However, HPLC results later 
revealed that, even though the extracts displayed relatively high purity, scolymoside and 
iriflophenone-3-C-glucoside only represented ca. 21% and 31%, respectively, of the enriched 
fractions (Figs. S3&4, Tables S1&2). 




3.2.2.3 Characterisation of cell lines used to evaluate estrogenic activity 
3.2.2.3.1 Western blots 
To investigate the presence of GR (glucocorticoid receptor), ERα, ERβ, PRA (progesterone receptor 
isoform A), PRB (progesterone receptor isoform B), MR (mineralocorticoid receptor) and AR 
(androgen receptor), HEK293 cells were seeded into 10 cm cell-binding sterile tissue culture plates 
(Corning
®
, USA) at a density of 4 x 10
6
 cells per plate using 1:1 DMEM:HamF12 medium (Gibco
®
 
by Life Technologies, USA) containing 5% FCS and 100 IU/ml penicillin and 100 µg/ml 
streptomycin, where after the cells were incubated (95% relative humidity and 5% CO2 at 37°C) for 
24 h. The next day the medium was changed to DMEM containing 10% FCS,100 IU/ml penicillin 
and 100 µg/ml streptomycin and the cells washed once using phosphate buffered saline (PBS) 
preheated to 37°C. Twenty-four hours later the plates were placed on ice and washed once using 10 
mL ice cold PBS. Cells were then lysed using 1225 µL lysis buffer A [10 mM KCl (Saarchem
®
, 
South Africa) 0.1% NP-40 (Roche
®
, South Africa), 10 mM Hepes (Sigma Aldrich
®
) pH 7.5, 1.5 
mM MgCl2 (Merck
®
) and Complete Mini protease inhibitor cocktail (Roche
®
)], kept on ice while 
placed on an orbital shaker for 10-20 mins and then frozen overnight at -20°C. The next day the 
lysate was thawed on ice, where after it was centrifuged at 12000 x g for 10 min at 4°C. The cleared 
lysate (supernatant) was then transferred to a 2.0 mL microfuge tube and stored at -20°C. 
Lysates were electrophoresed at 200 V for 50 min using a 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel and proteins were transferred to a Hybond-
ECL (AEC Amersham Biosciences
®
, South Africa) nitrocellulose membrane at 0.18 A for 90 min 
using a Bio-Rad
®
 (USA) cell in transfer buffer (0.37 % SDS, 200 mM glycine, 240 mM Tris-HCL, 
20 % (v/v) methanol). The membranes were then blocked for 120 min in either 5% (w/v) casein or 
10% (w/v) milk powder dissolved into Tris-buffered saline (TBS) containing 0.1 % (v/v) Tween 
(TBST) at 25°C. Membranes were then washed once using TBST, where after the primary antibody 
was added to the membrane and incubated overnight at 4°C. Mouse anti-AR (sc-7305), mouse anti-




GAPDH (sc-47724) and rabbit anti-MR (H-300), anti-GR (H-300), anti-ERα (MC-20) and anti-ERβ 
(H-150) were all obtained from Santa Cruz Biotechnology
®
, USA. Mouse anti-PR (ab2764) was 
obtained from Abcam
®
, USA.  
The next day the membranes were washed for 20 min, and then twice for 5 min on an orbital shaker 
at 25°C using TBST. Incubation of the secondary antibody (Horse Radish Peroxidase (HRP) – 
conjugated) followed for 2 h, whilst shaking at 25°C. Thereafter washing was performed as above, 
with an additional TBS rinse step, followed by a TBS wash for 5 min at 25°C. Secondary antibodies 
(HRP-conjugated goat anti-mouse (sc-2005) and HRP-conjugated goat anti-rabbit (sc-2030)) were 
obtained from Santa Cruz Biotechnology
®
. Visualisation was performed using above mentioned 





Africa) and medical x-ray film (Axim) in conjunction with a molecular weight marker (PageRuler 
Prestained Protein Ladder, Thermo Scientific
®
) to determine if the bands present on the x-ray film 
correlate with the expected molecular weight of a specific nuclear receptor. For all experiments, 
except for probing of MR, untransfected COS-1 cell lysates were used as a negative control. For 
investigation in the presence of MR, untransfected Ect1/E6E7 cell lysates were used as a negative 
control. COS-1 cells transfected with a plasmid expressing the nuclear receptor of interest served as 
a positive control throughout.  
To investigate the presence of ERα and ERβ in MCF-7BUS cells, the cells were seeded at a density 
of 2 x 10
6
 cells per 10 cm tissue culture plate in the same temperature, humidity and CO2 
concentration as above mentioned for HEK293 cells. In the determination of the presence or the 
abscence of ERα and ERβ in MCF-7BUS cells the concurrent steps were then followed as for 
HEK293 cells using the same ERα and ERβ antibodies, and, untransfected COS-1 cell lysate served 
as a negative control. 




3.2.2.3.2 Whole cell binding 
HEK293 cells were seeded into 24-well cell-binding tissue culture plates (Corning
®
) at a density of 
5 x 10
4
 cells per well in 1:1 DMEM:HamF12 medium containing 5% FCS, 100 IU/ml penicillin and 
100 µg/ml streptomycin where after the cells were incubated for 24 h. The following day the 
medium was aspirated and changed to DMEM with 10% FCS, 100 IU/ml penicillin and 100 µg/ml 
streptomycin. The next day the cells were washed 3 times using pre-heated PBS and then whole cell 
binding of the ER was performed using 20 nM radio-labelled estrogen (2,4,6,7-[
3
H]17-β-oestradiol, 
specific activity 100 Ci/mmol, obtained from Amersham Biosciences
®
). The total binding mixture 
contained 
3




 M unlabelled estrogen. Cells were then incubated for 4 h, where after the cells were 
washed 3 times (15 min per wash) using ice cold 0.2% PBS-BSA (bovine serum albumin obtained 
from Sigma Aldrich
®
). After the washing steps were completed, the cells were washed 3 times with 
pre-heated PBS in order to remove albumin and 100 µL passive lysis buffer (10% (v/v) glycerol 
(BDH Chemicals Ltd
®
, England), 0.2% (v/v) Triton (BDH Chemicals Ltd
®
), 2.8% (v/v) Tris-
phosphate EDTA and 1.44 mM EDTA (Saarchem
®
, South Africa)) was added per well, the plates 
shaken at room temperature for 10-20 min and frozen overnight at -20°C. The next day, samples 
were thawed and 5 µL of lysate was used for protein determination according to the Bradford 
method [67]. The lysate that remained was transferred to scintillation vials containing 1 mL of 
scintillation fluid (Quickszint FLOW 2, Zinsser Analytic
®
, South Africa). Counting efficiency was 
43% and all binding experiments showed a ligand depletion index of less than 10%. Radioactivity 
was measured using the Beckman
®
 LS 3801 Beta-scintillation counter (Beckman
®
, South Africa) 
and results were normalised to protein content. Specific binding values were obtained by 
subtracting the non-specific binding values from the total binding values. 
3.2.2.4 Promoter reporter studies 
HEK293 cells were seeded at 4 x 10
6
 cells per plate in sterile cell-binding 10 cm plates with 1:1 
DMEM:HamF12 containing 10% FCS, 100 IU/ml penicillin and 100 µg/ml streptomycin, where 




after the cells were allowed to settle for 24 h. The cells were then rinsed with PBS, pre-heated to 
37°C, to remove the phenol red. The medium was then changed to phenol red-free DMEM 
supplemented with 10% FCS, 100 IU/ml penicillin and 100 µg/ml streptomycin. After the medium 
was changed the HEK293 cells were transfected with a total amount of 6150 ng of plasmid DNA. 
Transfections of cells were performed using FugeneXtreme transfection reagent (Roche
®
) according 
to manufacturer instructions. DMEM without phenol red (pre-heated to 37°C) was used in the initial 
DNA-FugeneXtreme-mixture. The complex was then added to the 10 cm plates containing the 
HEK293 cells (post–initial medium change), where after the cells were incubated for 24 h. 
Transfection optimisation was performed (Fig. S5) where after 150 ng pSG5-hERα [68] (a gift from 
F. Gannon, European Molecular Biology Laboratory, Heidelberg, Germany), 3750 ng ERE.vit2.luc 
[69] (a gift from K. Korach, National Institute of Environmental Health Science, USA) and 2250 ng 
empty vector (pGL2-Basic, Promega
®
, USA) were used for cells transfected with hERα. For the 
cells transfected with hERβ, 150 ng pSG5-hERβ [69] (a gift from F. Gannon), 3000 ng 
ERE.vit2.luc [69] and 3000 ng empty vector (pGL2-Basic) were used.  
The next day the cells were replated into sterile 24-well cell-binding tissue culture plates at 5 x 10
4
 
cells per well using phenol red-free DMEM supplemented with 10% charcoal stripped FCS, 100 
IU/ml penicillin and 100 µg/ml streptomycin. The following day the cells were induced with the 
respective test compounds or test samples, all dissolved in DMSO to yield a final DMSO 
concentration of 0.1% (v/v) in the medium. All extracts and fractions were tested at a concentration 
of 9.8 µg/mL as a previous experiment performed in the laboratory (data not shown) showed that 
this is the highest concentration of SM6Met readily soluble in DMSO. It would have been helpful to 
include dose response curves for all of the obtained extracts and fractions in order to obtain efficacy 
and potency values, which would have been useful in selecting specific treatment concentrations, 
however, we did not have sufficient amounts of sample available to perform these experiments. In 
addition, sufficient time to make more of the samples was not available as it is a time-consuming 
task. Efficacy and potency data regarding previously produced SM6Met, however, is available [63]. 




For investigation in agonist mode the extracts or test compounds were administered alone, whereas 
for investigation in antagonist mode, extracts or test compounds were administered in the presence 
of E2 (10
-11
M). DMSO served as the negative control as it was used to dissolve the compounds, 
whereas E2, the endogenous ligand of the ER, served as the positive control. After 24 h the cells 
were rinsed using 500 μL ice cold PBS and lysed overnight at -20°C using 50 μL passive lysis 
buffer (as used for whole cell binding). Luciferase assays were performed using the Luciferase 
assay reagent from Promega
®
, USA according to manufacturer‘s instruction, where 50 μL of 
luciferase reagent was added to 10 μL of cell lysate. The luciferase activity, given in relative light 
units (RLUs), was obtained using a Veritas
®
 luminometer (Turner Biosystems
®
, USA). Protein 
determination was done using the Bradford method [67], where 250 μL of the Bradford reagent was 
added to 5 μL of the cell lysate in a 96-well plate. Luciferase RLUs were normalised to protein 
concentration and the results were expressed as fold-induction compared to DMSO set as 1.  
3.2.2.5 Proliferation studies 
MCF-7 BUS cells, which had been withdrawn from the penicillin-streptomycin mixture for at least 
7 days, were plated at a density of 10000 cells per well in a 96-well plate (Greiner Bio-One
®
, 
Germany) in DMEM containing 5% FCS. The next day the cells were washed with PBS (200 
µL/well), pre-heated to 37°C, and the medium was changed to unsupplemented phenol red-free 
DMEM (200 µL/well) for 24 h (steroid and growth factor starvation) in the absence of the 
penicillin-streptomycin mixture. The treatment time schedule was optimised (Fig. S6), and thus, on 
day three the medium was aspirated and cells incubated for 24 h with test compounds or extracts (in 
DMSO) in phenol red-free DMEM containing 10% stripped FCS, in the absence of the penicillin-
streptomycin mixture. The medium was then aspirated and cells re-induced at 24 and 48 h after 
initial treatment. All assays included a negative control consisting of 0.1% (v/v) DMSO and a 
positive control (10
-9
M E2). On day seven (24 h after the last treatment) the MTT (Sigma Aldrich
®
) 
assay was performed, where medium was aspirated and cells incubated with phenol red-free 
medium (200µL/well) in the absence of the penicillin-streptomycin mixture and stripped FCS, plus 




MTT solution (5 mg/mL; 50 µL/well) for 4 h at 37°C. After incubation, the wells were aspirated 
and DMSO (solubilisation solution; 200 µL/well) was added. The DMSO was then pipetted up and 
down twice per well in order to obtain a uniform purple colour in each well. The absorbance value 
of each well was measured at 550 nm using a BioTek® PowerWave 340 spectrophotometer 
(Biotek
®
 instruments, USA). Results were expressed as fold induction relative to the negative 
control (0.1% (v/v) DMSO) for agonism or relative to 10
-9
M E2 for antagonism, which was set as 
one. For investigation in agonist mode test samples were administered alone, whereas for 
investigation in antagonist mode, test samples were administered in the presence of 10
-9
M E2. 
3.2.3 Characterisation of phenolic content 
3.2.3.1 Determination of total polyphenol content 
The method was adapted from Singleton and Rossi [70] to accommodate 96-well tissue culture 
plates (Greiner Bio-One
®
). Initially, 100 μl 10% (v/v) Folin-Ciocalteau reagent (Merck
®
) was added 
to 20 μl of sample (0.5 mg/ml DME) and gallic acid (Sigma Aldrich
®
) standards (0.01-0.1mg/ml), 
followed by the addition of 80 μl (7.5%) Na2CO3 (Sigma Aldrich
®
). The 96-well plates were then 
incubated at 37°C for 2 h, where after absorbance was measured at 765 nm using a BioTek
®
 
PowerWave 340 spectrophotometer. Extract gallic acid equivalents (GAE) were obtained from the 
standard curve and the total polyphenol content, determined in triplicate, expressed as g GAE/100 g 
of extract.  
3.2.3.2 Determination of total flavanoid content 
The method, described by Zishen et al. [71], was adapted to 96-well tissue culture plate format. 




was added to 100 μl of standard (rutin hydrate 
(0.01-0.1 mg/ml) from Sigma Aldrich
®
) and DME (0.05 mg/ml). The reaction was allowed to 
proceed for 5 min before 60 μl 10% (w/v) AlCl3 (Merck
®
) was added. The reaction was allowed to 
proceed for a further 6 min before adding 34 μl NaOH (1M) (Saarchem
®
) followed by incubation at 
room temperature for 20 min. The 96-well plates were then incubated at 37°C for 2 h, where after 




absorbance was measured at 450 nm using a BioTek
®
 PowerWave 340 spectrophotometer. Extract 
rutin hydrate equivalents (RE) were obtained from the standard curve. The total flavonoid content, 
determined in triplicate, was expressed as g RE/100 g of extract. 
3.2.3.3 Quantification of phenolic compounds using HPLC-DAD 
Stock solutions of standards and SM6Met, as well as liquid-liquid and HPCCC fractions, were 
prepared in DMSO and frozen at -20°C until needed for analysis. For experimental analysis, the 
defrosted extracts, fractions and standards were appropriately diluted with water and ascorbic acid 
(Sigma Aldrich
®
) was added to a final concentration of 9 mg/mL. The mixtures were then filtered 
using Millex-HV
®
 syringe filters (Millipore
®
, USA) with a 0.22 µm pore size. Separation was 
achieved on a Gemini-NX C18
®
 column (150 × 4.6 mm; 3 μm; 110 Å; Phenomenex
®
, Santa Clara, 
U.S.A.), protected by a guard column (4 x 3.0 mm; Phenomenex
®
) of the same stationary phase , 
with 2% acetic acid (A) and HPLC-grade acetonitrile (B) as mobile phases. Injection volumes 
ranged from 10-20 µL for standards and 15 µL for the extracts and fractions. Separation was 
performed using the HPLC method described by De Beer et al. [72]. A flow rate of 1 mL/min was 
used with the following mobile phase gradient: 0-2 min (8% B), 2-27 min (8-38% B), 27-28 min 
(38-50% B), 28-29 min (50% B), 29-30 min (50-8% B), 30-40 min (8% B). 
The dihydrochalcones (phloretin-3',5'-di-C-β-glucoside and 3-hydroxyphloretin-3',5'-di-C-
hexoside), flavanones (eriocitrin and hesperidin), benzophenone (iriflophenone-3-C-glucoside) and 
protocatechuic acid were quantified at 288 nm, whereas the xanthones (mangiferin and 
isomangiferin), flavones (luteolin and scolymoside) and p-coumaric acid were quantified at 320 nm. 
A 7-point calibration curve was set up for all the available standards, including standards needed to 












), aspalathin (kind gift from Prof. W. 
Gelderblom, PROMEC unit, Medical Research Council, Tygerberg, South Africa), protocatechuic 











), and nothofagin (kind gift from Prof. W. Gelderblom). Iriflophenone-3-C-
glucoside and iriflophenone-di-O,C-hexoside were quantified using iriflophenone-3-C-glucoside 
isolated from C. genistoides (kind gift from Dr. E. Willenburg, ARC Infruitec-Nietvoorbij, 
Stellenbosch, South Africa). Scolymoside and vicenin-2 were expressed as luteolin and apigenin 
equivalents, respectively, as no authentic reference standards were available for these compounds. 
Phloretin-3',5'-di-C-β-glucoside and 3-hydroxyphloretin-3',5'-di-C-hexoside where expressed in 
terms of nothofagin (phloretin-3'-C-β-glucoside) and aspalathin (3-hydroxyphloretin-3'-C-β-
glucoside) equivalents, respectively. 
3.2.3.4 Identification of phenolic compounds using LC-MS/MS analysis 
Analyses were performed on a WatersAcquity
®
 ultra-performance liquid chromatography (UPLC) 
system comprising an in-line degasser, diode array detector (DAD), column oven and binary pump. 
This system was coupled to a Synapt G2
®
 quadrupole time of flight (QTOF) mass spectrometer 
(Waters
®
) containing an electrospray ionization (ESI) source. The method used was the same as 
described in De Beer et al. [72] for LC-MS/MS analysis. An injection volume of 10 µL was used 
for samples with the eluent being split 1:1 before introduction to the ionization source. MS results 
were acquired in the negative ionization mode with MS and MS
E
 for each sample. For MS
E 
a 
collision energy ramp from 25 to 60 V was used, whereas for MS/MS data a collision energy of 30 
V was used. The parameters used for MS as in De Beer et al. [72] were as follows: capillary 
voltage, 2.5 kV, cone voltage 15 V, desolvation temperature 275°C, source temperature 120°C and 
nitrogen flow rate 650 L/h. Peaks were identified by comparing LC-MS spectra, UV-Vis spectra 
and retention times to authentic standards or as in De Beer et al. [72]. Data were acquired and 









3.2.4 Data manipulation and statistical analysis 
GraphPad Prism
®
 version 5 (GraphPad Software
®
, USA) was used for graphical representation and 
statistical analysis of experimental data. One-way analysis of variance (ANOVA) was performed 
with Dunnett‘s multiple comparisons test as post-test. For all experiments, unless otherwise 
indicated, the error bars represent the SEM (standard error of means) of three independent 
experiments done in triplicate. 
3.3 Results  
We used the positive estrogenic attributes previously identified [62-64] as a guide during activity-
guided fractionation of SM6Met. Specifically, ERα antagonism and ERβ agonism were evaluated 
using an ERE-containing promoter reporter in the HEK293 cell line. The HEK293 cell line is 
ideally suited for this purpose as steroid receptor characterisation using Western blotting (Fig. S7) 
indicated that this cell line contains only GR and MR, AR, or either of the PR isoforms, PRA or 
PRB. More importantly, the HEK293 cells do not contain endogenous ERα or ERβ (Fig. S7), which 
was confirmed by performing a whole cell binding assay using tritiated E2 (Fig. S8). Thus, HEK293 
cells could be transfected with expression vectors for ERα or ERβ, which allowed for investigation 
of ER-subtype specific responses. Furthermore, the HEK293 cell line responds well to E2-treatment, 
which served as a positive control throughout the promoter reporter studies [65]. In addition, 
antagonism of E2-induced breast cancer cell proliferation was investigated in MCF-7BUS cells. The 
use of this model is merited by the endogenous presence of both ERα and ERβ, as demonstrated by 
Western blotting (Fig. S9). Furthermore, it is a more complex model representing both activation 
and repression of genes, and it provides a physiologically relevant system, as breast cancer is a topic 
of interest in the development of a phytoestrogenic nutraceutical from Cyclopia. In addition, LC-
MS and qHPLC were used to track major polyphenols during fractionation to allow for correlation 
with estrogenic activity in an attempt to identify possible marker compounds. 




3.3.1 Activity-guided fractionation of SM6Met 
To assist the reader we provide an overview of the fractionation process and yields obtained (Fig 1). 
Initially, SM6Met was ―mass-produced‖ by several repeats (n = 4) of the process described by 
Mfenyana et al. [63]. SM6Met was subsequently fractionated into polar (PF) and NPF using liquid-
liquid fractionation and the NPF was sub-fractionated via HPCCC yielding F1-F3.  
 
Figure 1. Overview of extract yield during liquid-liquid and HPCCC fractionation. Yields are expressed 
as if 100 g SM6Met was used in fractionation. Values in brackets represent the actual mass used during this 
study as 4.3 g SM6Met was subjected to liquid-liquid fractionation. However, only 450 mg NPF was used to 
produce 180 mg F1, 43 mg F2, and 147 mg F3, thus in the diagram these values were recalculated as if 1.21g 
NPF was used.  
3.3.1.1 Large scale production and evaluation of SM6Met 
SM6Met was prepared (Fig. S1) as in Mfenyana et.al [63] in 4 separate batches (B1-B4), mainly to 
check for inter batch variability in the production of the extract. A small quantity of each individual 
batch was retained for assays and the remainder pooled to form the B1-4Mix. Both individual 
batches and the B1-4Mix were compared to a reference SM6Met sample produced by Mfenyana et 
al. [63].  




Comparison of extract yields (g extract/100 g dried plant material) indicated a yield ranging from 
13.0% for B1 to between 16.1 and 16.6% for B2 to B4 (Table 1). In terms of comparison with the 
reference sample (Mfenyana) the yields of the individual batches were quite similar to that of the 
reference batch. 
Although Mfenyana et al. [63] indicated that no correlation existed between estrogenic activity of 
extracts and their total polyphenol content (TPC) or total flavonoid content (TFC), we decided to 
use these two parameters as an additional measure of comparison between the reference (Mfenyana) 
and newly prepared batches. The TPC and TFC of the newly produced SM6Met batches (B1 to B4) 
ranged from 40.72-44.34 g GAE/100 g extract and 47.62-73.99 g RE/100g extract, respectively 
(Table 1). There was no significant difference between the TPC and TFC values of the newly 
produced batches. Comparison of the B1-4Mix to the Mfenyana reference sample also showed no 
significant difference for TPC and TFC. 
Table 1: Inter batch variability of SM6Met batches. Extracts were produced in four batches B1-B4 and 
were then pooled to form B1-4Mix. Inter batch variability is shown by means of yield, total polyphenol 
content (TPC) and total flavonoid content (TFC). B1-B4 were prepared as in Mfenyana et al. [63] and 
compared to the original SM6Met produced by Mfenyana et al. [63]. The table shows results of two 
independent experiments for TPC and TFC. For statistical analysis One-way ANOVA was used with 
Dunnett‘s Multiple Comparison Test as post-test. No symbol indicates no significant differences compared 








Mfenyana  15.4 43.09 ± 11.11 69.27 ± 6.820 
 B1 13.0 41.00 ± 11.52 48.26 ± 11.18  
 B2 16.1 42.45 ± 12.02 73.99 ± 2.807 
 B3 16.5 40.72 ± 9.56  60.62 ± 9.147 
 B4 16.6 44.34 ± 12.94 47.62 ± 4.491 
 B1-4Mix - 43.01 ± 12.31 62.46 ± 12.26 
a
g/100 g plant material 
b
g gallic acid equivalents (GAE)/100 g extract 
c
g rutin hydrate equivalents (RE)/100 g extract 




Although SM6Met has been shown to display ERα antagonism and ERβ agonism in COS-1 cells 
[64], we for the first time investigated estrogenic activity of a Cyclopia extract in HEK293 cells. In 
our model we transfected HEK293 cells with either ERα or ERβ and an ERE-containing promoter 
reporter construct (ERE.vit2.luc) and investigated transactivation in both agonist and antagonist 
mode (Fig. 2). We found that 1 nM of E2 induced a 3.1 fold and 6.3 fold induction via ERα and 
ERβ, respectively. Although, this induction level is lower than previously found in HEK293 cells 
[65], it is a significant improvement of induction levels found in COS-1 cells [64]. 
All our newly prepared SM6Met batches, with the exception of B1, showed significant (p < 0.01) 
ERα antagonism (Fig. 2C), one of the positive estrogenic attributes of interest. Despite the fact that 
B1 did not display ERα antagonism, the mix of batches, SM6Met B1-4Mix, retained the desired 
ERα antagonist activity. Furthermore, the ERα antagonist activity of this mix was not significantly 
different from the reference sample from Mfenyana. Despite the fact that our newly prepared 
extracts displayed ERα antagonism, as previously demonstrated in COS-1 cells [64], we now, in 
contrast to previous results, also showed significant agonism via ERα, not only for the reference 
sample from Mfenyana, but also for the newly produced B1 and SM6Met B1-4Mix (Fig. 2A). This 
conflict with previous results may be explained by the fact that the HEK293 cells displayed a greater 
estrogenic sensitivity than the COS-1 cells, as demonstrated by the differences in response to E2. 
Extract-induced ERα agonism was, however, significantly lower (p < 0.001) than that of 10
-11
M E2 
for all batches except B1 (Fig. 2A). 
The second desired positive estrogenic attribute we investigated was ERβ agonism. Of the newly 
prepared batches B1, B4 and SM6Met B1-4Mix all showed significant (p < 0.05) ERβ agonism (Fig. 
2B), which in the case of B1 and SM6Met B1-4Mix was significantly (p < 0.05) higher than 10
-11
M 
E2. These results suggest that SM6Met B1-4Mix is a stronger ERβ agonist than an ERα agonist. 
Furthermore, SM6Met B1-4Mix displayed ERβ agonism that was not significantly (p > 0.05) 
different from that of the reference Mfenyana sample. Neither of the newly prepared SM6Met 








































































































































































































































































































































































































Figure 2. Transactivation studies investigating 17β-estradiol (E2) and SM6Met produced: Mfenyana et 
al. [63], batches B1-4 and B1-4Mix. A-B agonist mode; C-D antagonist mode (A) HEK293 cells 




 M E2, 9.8 μg/mL 
SM6Met from Mfenyana et al. [63], B1-B4, or B1-4Mix. (B) HEK293 cells transfected with pSG5-hERβ, 
ERE.vit2.luc and pGL2-Basic were induced as in A. (C) HEK293 cells were transfected as in A and induced 
with 10
-11
 M E2, 9.8 μg/mL SM6Met from Mfenyana et al. [63], B1-B4, or B1-4 Mix, with the extract 
treatments co-administered with10
-11
M E2. (D) HEK293 cells were transfected as in B and induced with 10
-11
 
M E2, 9.8 μg/mL SM6Met from Mfenyana et al. [63], B1-B4, or B1-4 Mix, with the extract treatments co-
administered with10
-11
 M E2. For statistical analysis one-way ANOVA was used with Dunnett‘s Multiple 
Comparisons Test as post-test. For all bars compared to DMSO *** denotes p < 0.001, ** denotes p < 0.01 
and * denotes p < 0.05. For all bars compared to 1nM E2 ### denotes p < 0.001, ## denotes p < 0.01 and # 
denotes p < 0.05. For all bars compared to B1-4Mix $$$ denotes p < 0.001, $$ denotes p < 0.01 and $ 
denotes p < 0.05. For all bars compared to 10 
-11
M E2 &&& denotes p < 0.001, && denotes p < 0.01 and & 
denotes p < 0.05. No symbol above bars indicates no significant differences compared to the above 
mentioned compared conditions.  
The third and final positive estrogenic attribute investigated was antagonism of E2-induced breast 
cancer cell proliferation in MCF-7BUS cells. The MTT assay was used to evaluate the number of 
viable cells, however, as it has been shown that some polyphenols may influence the MTT assay 




without affecting cell viability [73], we conducted an experiment in which we compared 
proliferation results obtained from an MTT assay with results obtained from cell counting (data not 
shown). As the results obtained were similar we decided to use the MTT assay for further analyses. 
Although only one of the newly prepared SM6Met batches, B4, displayed significant antagonism, 
the SM6Met B1-4Mix showed significant (p < 0.01) antagonism (Fig. 3B). Furthermore, this 
antagonism of SM6Met B1-4Mix was not significantly different from the reference Mfenyana 
sample. Despite displaying antagonism of E2-induced breast cancer cell proliferation, the reference 
Mfenyana sample also induced proliferation in the agonist mode (Fig. 3A), however, to a 
significantly (p < 0.05) lesser extent than 1nM E2. None of the newly prepared SM6Met batches, 















































































































Figure 3. Proliferation studies investigating E2 and SM6Met produced: Mfenyana et al. [63], batches 
B1-4 and B1-4Mix. A-B agonist mode; C-D antagonist mode. MCF-7 BUS cells were serum starved for 
24 h, where after cells were induced at 24 h, and re-induced at 48 h and 72 h. The assay was performed at 96 
h. In (A) cells were induced with 10
-9
 M E2, 9.8 μg/mL SM6Met from Mfenyana et al. [63], B1-B4, or B1-4 
Mix. In (B) MCF-7 BUS cells were treated as in (A) with 9.8 μg/mL SM6Met from Mfenyana et al. [63], 
B1-B4, or B1-4Mix, with the extract treatments co-administered with10
-9
 M E2. For statistical analysis one-
way ANOVA was used with Dunnett‘s Multiple Comparison Test as post-test. For all bars compared to 
DMSO *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p < 0.05. For all bars compared to 1 nM E2 
### denotes p < 0.001, ## denotes p < 0.01 and # denotes p < 0.05. For all bars compared to B1-4Mix $$$ 
denotes p < 0.001, $$ denotes p < 0.01 and $ denotes p < 0.05. No symbol above bars indicates no significant 
differences compared to the above mentioned compared conditions.  
Having investigated the positive estrogenic attributes of the newly prepared batches (B1-B4) as well 
as SM6Met B1-4Mix, we were interested in whether the polyphenolic compounds correlated with 
the reference Mfenyana sample and wanted to establish a baseline polyphenol profile of SM6Met 




B1-4Mix to which subsequent fractions, which would be prepared from this mix, could be 
compared. LC-MS/MS analysis was used to identify compounds present in SM6Met B1-4Mix 
(Table S3, Fig. S10A). Most of the identified compounds had previously been identified in aqueous 
Cyclopia subternata extracts prepared from a large number of seedling plants [72]. Some new 
compounds were, however, tentatively identified namely, luteolin-O-hexoside, apigenin-O-
rutinoside /neohesperidoside (flavone), chrysoeriol-O-rutinoside/neohesperidoside (flavone), and 
quercetin-O-rutinoside/neohesperidoside (flavonol). These newly identified compounds were, 
however, present at low concentrations, and may be considered minor compounds. qHPLC was 
used to quantify the major phenolic compounds, i.e. iriflophenone-3-C-glucoside, mangiferin, 
isomangiferin, scolymoside, hesperidin, eriocitrin, phloretin-3',5'-di-C-glucoside and 3-
hydroxyphloretin-3',5'-di-C-hexoside, as well as the phenolic acids, p-coumaric acid and 
protocatechuic acid (Table 2, Fig. S11A). In addition, luteolin was also quantified as previous 
studies had shown that the presence of luteolin may correlate with estrogenic activity of extracts 
[62,63,74]. When we calculated the percentage of major quantified compounds, the flavanones, 
hesperidin and eriocitrin, and the xanthones, mangiferin and isomangiferin, were present at the 
highest percentage. Specifically, the flavanones constituted 30.4%, and the xanthones 26.7% of the 
quantified major phenolic compounds (Table 2). The dihydrochalcones, 3-hydroxyphloretin-3',5'-di-
C-hexoside and phloretin-3',5'-di-C-glucoside, were present at 20.7%, while the benzophenone, 
iriflophenone-3-C-glucoside, comprised 7% of the quantified major phenolic compounds. The 
flavones, luteolin and its rutinoside, scolymoside, were present at 13.9%, while the phenolic acids, 
p-coumaric acid and protocatechuic acid, were only present in trace amounts. Comparison of 
SM6Met B1-4Mix with literature values previously obtained for the reference sample from 
Mfenyana [63] indicated that SM6Met B1-4Mix contained similar amounts of phloretin-3',5'-di-C-
glucoside and the xanthones, flavones and flavanones (Table 2). p-Coumaric acid, protocatechuic 
acid, iriflophenone-3-C-glucoside and 3-hydroxyphloretin-3',5'-di-C-hexoside, were not previously 




determined and thus we cannot compare their concentrations in the current B1-4Mix to the 
reference sample from Mfenyana.  
In terms of identifying polyphenol marker compounds contributing to the estrogenic activity of the 
SM6Met B1-4Mix, luteolin, iriflophenone-3-C-glucoside and eriocitrin may contribute as they have 
previously been shown to have estrogenic activity [61,62,74-78], although in the case of 
iriflophenone-3-C-glucoside, only the aglycone, iriflophenone, was investigated. Mangiferin, 
hesperidin and p-coumaric acid would be unlikely to contribute to the estrogenic activity of the 
extract as previous studies have indicated that they lack estrogenic activity [61,62,78-80]. The other 
compounds have not been tested for estrogenic activity and thus we cannot yet predict a correlation 
with activity. 
Table 2: Polyphenol content of SM6Met B1-4Mix as determined by qHPLC and compared to Mfenyana et 
al. [63] 
Polyphenol  B1-4Mix 





Mfenyana et al. 
(g/100 g extract) 
Mangiferin 1.899 19.9 1.85 
Isomangiferin 0.645 6.8 0.75 
Scolymoside (luteolin-7-O-rutinoside)
a
 1.289 13.5 1.82 
Luteolin 0.040 0.4 0.04 
Iriflophenone-3-C-glucoside




 1.278 13.4 1.27 
3-Hydroxyphloretin-3',5'-di-C-hexoside 0.700 7.3 na 
Eriocitin  0.845 8.9 1.25 
Hesperidin (hesperetin-7-O-rutinoside)  2.049 21.5 1.87 





previously described as unknown 1 
b 
previously described as unknown 2 
c 
Co-elution = p-coumaric acid co-elutes with 3-hydroxyphloretin-3',5'-di-C-hexoside where present; this 
means that the concentration could not be determined accurately if 3-hydroxyphloretin-3',5'-di-C-hexoside 
was present. 
d
% of polyphenol present calculated relative to total concentration of major polyphenols in extract  
e
na = not assayed 
Thus in summary, the newly prepared SM6Met B1-4Mix retained the positive estrogenic attributes 
previously described [63,64], namely, ERα antagonism, ERβ agonism and antagonism of E2-
induced breast cancer cell proliferation. However, in addition some weak ERα agonism was 
observed. SM6Met B1-4Mix, like the reference Mfenyana sample, contained mostly xanthones and 




flavanones, and also significant amounts of dihydrochalcones, flavones and benzophenones, of 
which mostly the flavanones and flavones had previously been shown to display estrogenic activity. 
There was some heterogeneity in the estrogenic activity of the individual B1-B4 batches and in 
hindsight we should have tested these batches before mixing, specifically, batch B1 could have been 
excluded. 
3.3.1.2 Liquid-liquid fractionation of SM6Met B1-4Mix to obtain a polar fraction and a non-
polar fraction 
SM6Met B1-4Mix was fractionated into the two fractions, PF and NPF, according to relative 
polarity by means of liquid-liquid fractionation using water to dissolve/suspend the extract and n-
BuOH as less polar solvent. Liquid-liquid fractionation of 4.3 g SM6Met resulted in 1.21 g NPF 
and 2.92 g PF (Fig.1), giving a total recovery of 96%. qHPLC analysis was performed to 
characterise their individual phenolic compound content. The resultant PF and NPF were then 
evaluated for estrogenic potential using the promoter reporter and cell proliferation assays.  
Both PF and NPF retained significant (p < 0.05) ERα antagonist activity, one of the positive 
estrogenic attributes of interest. In addition, in contrast to the batch of origin, SM6Met B1-4 Mix, 
which displayed significant (p < 0.01) ERα activation (Fig. 4A), neither PF nor NPF showed 
activation via ERα. (Fig. 4A). The absence of ERα agonism, seen for PF and NPF, positions them 
more favourably in terms of positive estrogenic attributes compared to the original SM6Met B1-
4Mix as ERα agonism is known to be pro-proliferative [44]. 
ERβ agonism, another positive estrogenic attribute of interest, was retained by NPF, which showed 
significant (p > 0.05) ERβ agonism, as seen for the extract of origin, SM6Met B1-4Mix (Fig. 3B).  
PF, however, displayed no significant ERβ agonism. In addition, no ERβ antagonism was seen for 
either fraction (Fig. 4D). The additive effect seen for NPF in antagonist mode supports the evidence 
that this fraction is an ERβ agonist. Furthermore, the fact that for NPF a significantly (p < 0.01) 




higher ERβ activation response in antagonist mode was observed when compared to SM6Met B1-






























































































































































































































































































































































Figure 4. Transactivation studies investigating E2, SM6Met B1-4Mix and liquid-liquid fractionation 
produced NPF and PF: A-B agonist mode; C-D antagonist mode (A) HEK293 cells transfected with 




M E2, 9.8 μg/mL SM6Met B1-4Mix, 
PF or NPF. (B) HEK293 cells transfected with pSG5-hERβ, ERE.vit2.luc and pGL2-Basic were induced as 
in A. (C) HEK293 cells were transfected as in A induced with 10
-11
 M E2, 9.8 μg / mL SM6Met B1-4Mix, PF 
or NPF, with the sample treatments co-administered with10
-11
 M E2. (D) HEK293 cells were transfected as in 
B and induced with 10
-11
 M E2, 9.8 μg/mL SM6Met B1-4Mix, PF or NPF, with the sample treatments co-
administered with 10
-11
 M E2. For statistical analysis one-way ANOVA was used with Dunnett‘s Multiple 
Comparisons Test as post-test. For all bars compared to DMSO *** denotes p < 0.001, ** denotes p < 0.01 
and * denotes p < 0.05. For all bars compared to 1 nM E2 ### denotes p < 0.001, ## denotes p < 0.01 and # 
denotes p < 0.05. For all bars compared to NPF $$$ denotes p < 0.001, $$ denotes p < 0.01 and $ denotes p < 
0.05. For all bars compared to 10
-11
 M E2 &&& denotes p < 0.001, && denotes p < 0.01 and & denotes p < 
0.05. No symbol above bars indicates no significant differences compared to the above mentioned compared 
conditions. 
In accordance with SM6Met B1-4Mix activity, significant (p < 0.01) antagonism of E2-induced 
breast cancer cell proliferation, the final positive estrogenic attribute investigated, was seen for both 
PF and NPF (Fig. 5B). In addition, like SM6Met B1-4Mix, PF and NPF did not induce significant 
(p > 0.05) breast cancer cell proliferation (Fig. 5A). 































































































Figure 5. Proliferation studies investigating E2, SM6Met B1-4Mix and liquid-liquid fractionation 
produced NPF and PF: A agonist mode; B antagonist mode. MCF-7 BUS cells were serum starved for 24 
h, where after cells were induced at 24 h, and re-induced at 48 h and 72 h. The assay was performed at 96 h. 
In (A) cells were induced with 10
-9
 M E2, 9.8 μg/mL SM6Met B1-4Mix, PF or NPF. In (B) MCF-7 BUS 
cells were treated as in (A) with 10
-9
 M E2, 9.8 μg/mL SM6Met B1-4 Mix, PF or NPF, with the test sample 
treatments co-administered with10
-9
 M E2. For statistical analysis one-way ANOVA was used with Dunnett‘s 
Multiple Comparisons Test as post-test. For all bars compared to DMSO *** denotes p < 0.001, ** denotes p 
< 0.01 and * denotes p < 0.05. For all bars compared to 1 nM E2 ### denotes p < 0.001, ## denotes p < 0.01 
and # denotes p < 0.05. For all bars compared to NPF $$$ denotes p < 0.001, $$ denotes p < 0.01 and $ 
denotes p < 0.05. No symbol above bars indicates no significant differences compared to the above 
mentioned compared conditions. 
In an attempt to link positive estrogenic effects of PF and NPF to polyphenolic constituents in the 
fractions, LC-MS/MS analysis (Table S3, Figs. S10B&C) was performed to track major and minor 
compounds during the liquid-liquid fractionation procedure. Results (Table S3, Figs. S10B&C) 
showed that all of the major compounds in SM6Met B1-4Mix were retained as major compounds in 
NPF, whereas for PF most of these major compounds, with the exception of 3-hydroxyphloretin-
3',5'-di-C-hexoside, eriocitrin, scolymoside and phloretin-3',5'-di-C-glucoside, were now present as 
minor compounds. In addition, qHPLC analysis of the major compounds in NPF and PF showed an 
overall 2 to 3-fold increase for NPF (Table 3, Figs. S11B&C), and a 3 to 20 fold decrease for PF 
compared to the SM6Met B1-4Mix. Analysis of NPF showed that the xanthones, flavones, 
flavanones and dihydrochalcones each contributed 14.8-29.01% towards the quantified phenolic 
compounds, whereas the benzophenone, iriflophenone-3-C-glucoside, and the phenolic acid, 
protocatechuic acid, contributed 6.07 and 1.35%, respectively, towards the quantified phenolic 
compounds. Thus, as a percentage of the major phenolic compounds the xanthones, flavones, and 




protocatechuic acid increased, while iriflophenone-3-C-glucoside, flavanones, and 
dihydrochalcones decreased in NPF relative to the source SM6Met B1-4Mix. In contrast, although 
in much lower quantities, PF consisted mostly of  flavanones (36.64%), followed by the 
dihydrochalcones, 3-hydroxyphloretin-3',5'-di-C-hexoside, and phloretin-3',5'-di-C-glucoside 
(31.61%), the benzophenone, iriflophenone-3-C-glucoside (15.21%), and low amounts of xanthones 
(9.4%), and the flavone, scolymoside (7.14%). 
Table 3: Individual polyphenol content as determined by qHPLC, concentration change relative to 
SM6Met B1-4Mix, and % polyphenol present as per total quantified polyphenols present in NPF and 
PF. 











Polyphenol  PF NPF PF NPF PF NPF 
Mangiferin 0.094 5.559 0.05 2.93 6.22 21.55 
Isomangiferin 0.048 1.879 0.08 2.91 3.18 7.29 
Scolymoside (luteolin-7-O-rutinoside) 0.111 3.710 0.08 2.88 7.14 14.38 
Luteolin Nd
c
 0.105 Nd 2.64 Nd 0.41 
Iriflophenone-3-C-glucoside 0.230 1.565 0.34 2.34 15.21 6.07 
Phloretin-3',5'-di-C-glucoside 0.251 3.456 0.20 2.70 16.60 13.4 
3-Hydroxyphloretin-3',5'-di-C-hexoside 0.227 1.686 0.32 2.41 15.01 6.54 
Eriocitrin (eriodictyol-7-O-rutinoside) 0.187 2.129 0.22 2.52 12.37 8.25 
Hesperidin (hesperetin-7-O-rutinoside) 0.367 5.356 0.18 2.61 24.27 20.76 
Protocatechuic acid Nd 0.347 Nd 3.07 Nd 1.35 
p-Coumaric acid Nd NA
d
 Nd NA Nd NA 
a
 Polyphenol concentration (g/100g extract) present in fraction relative to polyphenols in SM6Met B1-4Mix 
(Table 2), set as 1 
b
 % of polyphenol present calculated relative to total content of major polyphenols in fraction 
c 
Nd  -  not detected due to absence or very low amounts 
d
 NA  -  value not available as p-coumaric acid co-eluted with 3-hydroxyphloretin-3',5'-di-C-hexoside where 
present 
In terms of identifying polyphenol marker compounds contributing to the estrogenic activity of  
NPF and PF it is clear that, amongst the major polyphenolic compounds (Table 3), the compounds 
identified as possibly contributing to the positive estrogenic attributes, luteolin, iriflophenone-3-C-
glucoside and eriocitrin are all retained and concentrated in NPF, in contrast to PF where only 
iriflophenone-3-C-glucoside and eriocitrin were retained, but not luteolin. These two compounds 
were present, however, at much lower concentrations in PF than in SM6Met B1-4Mix (Table 3). 




Thus in summary, NPF retained all of the positive estrogenic attributes previously described for 
SM6Met B1-4Mix, namely, ERα antagonism, ERβ agonism and antagonism of E2-induced breast 
cancer cell proliferation, whereas PF retained only ERα antagonism, and antagonism of E2-induced 
breast cancer cell proliferation, but not ERβ agonism. Furthermore, the weak ERα agonism 
observed for SM6Met B1-4Mix was lost during fractionation into PF and NPF. Interestingly, 
despite the fact that all of the quantified major phenolic compounds in the batch of origin, SM6Met 
B1-4Mix, increased in concentration in NPF we did not see a significant increase in either ERα 
antagonism nor ERβ agonism, while antagonism of E2-induced breast cancer cell proliferation also 
remained constant. As ERβ agonism is considered an important positive estrogenic attribute for the 
development of a possible phytoestrogenic nutraceutical, due to its anti-proliferative function [44], 
we decided to focus on NPF, rather than PF, for subsequent fractionation. 
3.3.1.3 Fractionation of the non-polar fraction by high performance counter-current 
chromatography to obtain F1-F3 
As NPF retained the positive estrogenic attributes of interest, namely, ERα antagonism, ERβ 
agonism and antagonism of E2-induced breast cancer cell proliferation, we decided to fractionate it 
further using HPCCC. Consequently, HPCCC fractionation of NPF yielded three major fractions 
(F1, F2 and F3) (Fig. 1), with 0.45 g NPF resulting in 0.180 g F1, 0.043 g F2 and 0.147 g F3. The 
overall yield of these three HPCCC fractions was 82.2%. For evaluation of the fractions for desired 
estrogenic attributes and to track polyphenolic compounds for correlation with activity, F1-F3 were 
subjected to the same two estrogenicity assays previously used and analysed by qHPLC and LC-
MS/MS. 
In accordance with the activity of NPF, F1 and F2 displayed significant (p <0.001) ERα 
antagonism, a desirable estrogenic trait. F3 displayed no ERα antagonism in the presence of E2 as it 
induced activity not significantly (p > 0.05) different from that of E2 alone (Fig. 6C). In addition, 
none of the fractions, with the exception of F3, displayed significant ERα agonism (Fig. 6A). 




However, the ERα agonism of F3 was weak and significantly (p < 0.001) lower than that of 10
-11
 M 
E2, reflecting an ―activity profile‖ quite similar to that of the original SM6Met B1-4Mix (Fig. 2A). 
This change in activity may be linked to the increased presence of polyphenolic compounds 
inducing ERα agonism, or it may be due to the decrease or loss of polyphenolic compounds linked 

























































































































































































































































Figure 6. Transactivation studies investigating E2, NPF from liquid-liquid fractionation and HPCCC 
fractions, F1-F3: A-B agonist mode; C-D antagonist mode (A) HEK293 cells transfected with pSG5-




 M E2, 9.8 μg/mL NPF, F1, F2 and F3 (B) 
HEK293 cells transfected with pSG5-hERβ, ERE.vit2.luc and pGL2-Basic were induced as in A. (C) 
HEK293 cells were transfected as in A induced with 10
-11
 M E2, 9.8 μg/mL NPF, F1, F2 and F3, with the 
sample treatments co-administered with10
-11
M E2. (D) HEK293 cells were transfected as in B induced with 
10
-11
 M E2, 9.8 μg/mL NPF, F1, F2 and F3, with the fraction treatments co-administered with10
-9
 M E2. For 
statistical analysis one-way ANOVA was used with Dunnett‘s Multiple Comparisons Test as post-test. For 
all bars compared to DMSO *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p < 0.05. For all bars 
compared to 1 nM E2 ### denotes p < 0.001, ## denotes p < 0.01 and # denotes p < 0.05. For all bars 
compared to F3 $$$ denotes p < 0.001, $$ denotes p < 0.01 and $ denotes p < 0.05. For all bars compared to 
10 
-11
M E2 &&& denotes p < 0.001, && denotes p < 0.01 and & denotes p < 0.05. No symbol above bars 
indicates no significant differences compared to the above mentioned compared conditions.  
Investigation of HPCCC fractions for ERβ agonism, an important estrogenic attribute, revealed that 
F3 acted as a potent ERβ agonist inducing a 4.5 fold induction (Fig. 6B). The induced activity was 




significantly (p < 0.001) higher than that obtained with 10
-11
 M E2, but not significantly different (p 
> 0.05) from 1 nM E2 (Fig. 6B). Furthermore, it was also higher although not significantly so, than 
that obtained with NPF. In contrast, F1 and F2 showed no significant ERβ activation. In addition, 
none of the HPCCC fractions, with the exception of F1, displayed ERβ antagonism (Fig. 6D). 
Evaluation of the effect HPCCC-obtained fractions on breast cancer cell proliferation revealed that 
similar to NPF, none of its fractions, with the exception of F3, induced significant breast cancer cell 
proliferation in the absence of E2 (Fig. 7A). Furthermore, investigation of the final estrogenic 
attribute, antagonism of E2-induced breast cancer cell proliferation, revealed that only F2, like NPF, 


























































































Figure 7. Proliferation studies investigating E2, NPF and HPCCC fractions, F1-F3: A agonist mode; B 
antagonist mode MCF-7 BUS cells were serum starved for 24 h, where after cells were induced at 24 h, and 
re-induced at 48 h and 72 h. The assay was performed at 96 h. In (A) cells were induced with 10
-9
 M E2, 9.8 
μg/mL NPF, F1, F2 or F3. In (B) MCF-7 BUS cells were treated as in (A) with 10
-9
 M E2, 9.8 μg/mL NPF, 
F1, F2 or F3, with the fraction treatments co-administered with10
-9
 M E2. For statistical analysis one-way 
ANOVA was used with Dunnett‘s Multiple Comparisons Test as post-tests. For all bars compared to DMSO 
*** denotes p < 0.001, ** denotes p < 0.01 and * denotes p < 0.05. For all bars compared to 1 nM E2 ### 
denotes p < 0.001, ## denotes p < 0.01 and # denotes p < 0.05. For all bars compared to F3 $$$ denotes p < 
0.001, $$ denotes p < 0.01 and $ denotes p < 0.05. No symbol above bars indicates no significant differences 
compared to the above mentioned compared conditions.  
LC-MS/MS analysis of the three HPCCC fractions (Table S3, Fig. S10D-F) revealed that each 
HPCCC fraction had a different polyphenolic profile, which was also different from NPF, due 
relative distribution of the major and minor polyphenolic compounds introduced by the HPCCC 
two-phase solvent system. Furthermore, in the quest for correspondance of major polyphenolic 




compounds and compounds of interest with the positive estrogenic attributes of the fractions, we 
performed qHPLC analysis on these HPCCC fractions (Table 4, Fig S11D-F). F1 consisted mainly 
of dihydrochalcones (86.0% of major polyphenols in F1) and retained most (97%) of the 
dihydrochalcones recovered during HPCCC (Table 4). Of the dihydrochalcones in F1, phloretin-
3',5'-di-C-glucoside was concentrated roughly 2-fold relative to NPF, while 3-hydroxyphloretin-
3',5'-di-C-hexoside was present at the same concentration (Table 4). F1 also contained hesperidin, a 
minor flavanone component and eriocitrin, respectively, 0.19% and 13.3% of the quantified 
polyphenols in F1. In contrast to F1, 91% of all flavanones and 97% of iriflophenone-3-C-glucoside 
recovered during HPCCC eluted in F2. All the xanthones, flavones and phenolic acids eluted in F3 
so that this fraction consisted of 62.9% xanthones, 31.8% flavones and 4.9% phenolic acids. Only 
trace amounts of the benzophenone, iriflophenone-3-C-glucoside, was present in F3.  
Table 4: Individual polyphenol content as determined by qHPLC, concentration change relative to 
NPF, and % polyphenol present as per total quantified major polyphenols present in F1, F2 and F3. 
 g/100 g test sample 








Polyphenol  F1 F2 F3 F1 F2 F3 F1 F2 F3 
Mangiferin Nd
c
 Nd 11.568 Nd Nd 2.08 Nd Nd 46.70 
Isomangiferin Nd Nd 4.016 Nd Nd 2.14 Nd Nd 16.22 
Scolymoside (luteolin-7-O-
rutinoside) 
Nd Nd 7.669 Nd Nd 2.07 Nd Nd 30.97 
Luteolin Nd Nd 0.205 Nd Nd 1.95 Nd Nd 0.83 
Iriflophenone-3-C-glucoside Nd 11.827 0.092 Nd 7.56 0.06 Nd 18.67 0.37 
Phloretin-3', 5'-di-C-glucoside  6.075 0.691 Nd 1.76 0.20 Nd 67.31 1.09 Nd 
3-Hydroxyphloretin-3',5'-di-C-
hexoside 
1.683 0.245 Nd 1.00 0.15 Nd 18.65 0.39 Nd 
Eriocitin (eriodictyol-7-O-
rutinoside) 
1.185 11.148 Nd 0.56 5.24 Nd 13.13 17.60 Nd 
Hesperidin (hesperetin-7-O-
rutinoside) 
0.082 39.446 Nd 0.02 7.36 Nd 0.19 62.26 Nd 
Protocatechuic acid Nd Nd 0.647 Nd Nd 1.86 Nd Nd 2.6 
p-Coumaric acid Nd Nd 0.570 Nd Nd NA
d
 Nd Nd 2.3 
a
 Polyphenol concentration (g/100 g test sample) present in HPCCC fraction relative to polyphenol in NPF 
(Table 3), set as 1 
b
 % of polyphenol present calculated relative to total concentration of major polyphenols in fraction 
c 
Nd - not detected due to absence or very low amounts 
d
 NA - value not available as p-coumaric acid co-elutes with 3-hydroxyphloretin-3',5'-di-C-hexoside where 
present 




Thus in summary, analysis of the HPCCC fractions revealed separation of the previously 
demonstrated positive estrogenic attributes of NPF into separate fractions, with F1 and F2 acting as 
ERα antagonists, only F2 inducing antagonism of E2 induced breast cancer cell proliferation and 
only F3 retaining ERβ agonist activity. Although the ERβ agonism displayed by F3 was robust and 
significantly higher than that of 10
-11
 M E2, it also displayed weak ERα agonism. Also interestingly, 
for the first time in this study, ERβ antagonism was observed, as induced by F1. F1 was the 
dihydrochalcone-rich fraction, and also contained ca. 31% of the eriocitrin in the HPCCC fractions. 
This compound has been shown to have estrogenic activity [61]. F2 was the flavanone and 
benzophenone-rich fraction, of which only the benzophenone, iriflophenone-3-C-glucoside, and 
eriocitrin may possibly display phytoestrogenic activity [61,75,76]. Amongst the F3 polyphenolic 
constituents, only luteolin, present in low quantities, is a known phytoestrogen [81]. Scolymoside, a 
luteolin rutinoside, may be phytoestrogenic, although it has not previously been tested. If not 
phytoestrogenic, it could potentially have activity in vivo when the sugar moiety is removed to form 
luteolin [82].  
3.3.1.4 Purification schedule of SM6Met B1-4Mix fractionation 
Having discussed each of the fractionation steps separately, we now proceed to a discussion of the 
overall purification schedule of the fractionation outcomes. As results for both estrogenic activity 
and polyphenol content are available, we constructed purification tables of polyphenols present in 
fractions (Table 5) and estrogenic activity of fractions (Table 6). For the construction of the 
estrogenic activity purification table it would have been preferable to have quantitative data on 
efficacy and potency, however, as we did not construct dose response curves, we have to rely on the 
individual values obtained in our assays. Despite this drawback we assayed all fractions at the same 
concentration (9.8 µg/mL) and thus the results may be considered as a type of specific activity 
value. 
Table 5 Purification table of polyphenolic compounds (constructed from results presented in Figure 1 
and Tables 2-4)

































n Yield (%) 
SA (g/100 g 
test sample) 
PuF 
Mangiferin 1.899 100.0 1.899 1.00 0.063 3.3 0.094 0.05 1.564 82.3 5.559 2.93 
Isomangiferin 0.645 100.0 0.645 1.00 0.033 5.1 0.048 0.08 0.528 81.9 1.879 2.91 
Scolymoside 1.289 100.0 1.289 1.00 0.073 5.7 0.108 0.08 1.044 81.0 3.710 2.88 
Luteolin 0.040 100.0 0.04 1.00 0.000 0.0 Nd
f 
nd 0.030 74.2 0.105 2.63 
Iriflophenone-3-C-
glucoside 
0.669 100.0 0.669 1.00 0.155 23.2 0.230 0.34 0.440 65.9 1.565 2.34 
3-Hydroxyphloretin-
3',5'-di-C-hexoside 
0.700 100.0 0.7 1.00 0.154 21.9 0.227 0.32 0.474 67.7 1.686 2.41 
Phloretin-3',5'-di-C-
glucoside- 
1.278 100.0 1.278 1.00 0.170 13.3 0.251 0.20 0.972 76.0 3.456 2.70 
Eriocitrin (eriodictyol-
7-O-rutinoside) 
0.846 100.0 0.846 1.00 0.127 15.0 0.187 0.22 0.599 70.8 2.129 2.52 
Hesperidin (hesperitin-
7-O-rutinoside) 






 co-elution 1.00 0.000 0.0 nd nd co-elution co-elution co-elution co-elution 
Protocatechuic acid 0.113 100.0 0.113 1.00 0.000 0.0 nd nd 0.098 86.2 0.347 3.07 


























Mangiferin 0.000 0.0 Nd Nd 0.000 0.0 nd nd 1.063 55.9 11.565 6.09 
Isomangiferin 0.000 0.0 Nd Nd 0.000 0.0 nd nd 0.369 57.2 4.016 6.23 
Scolymoside (luteolin-
7-O-rutinoside) 
0.000 0.0 Nd Nd 0.000 0.0 nd nd 0.705 54.7 7.669 5.95 
Luteolin 0.000 0.0 Nd Nd 0.000 0.0 nd nd 0.019 47.4 0.205 5.14 
Iriflophenone-3-C-
glucoside 
0.000 0.0 Nd Nd 0.318 47.5 11.827 17.68 0.008 1.3 0.092 0.14 
3-Hydroxyphloretin-
3',5'-di-C-hexoside 
0.189 27.0 1.683 2.40 0.007 0.9 0.245 0.35 0.000 0.0 nd nd 
Phloretin-3',5'-di-C-
glucoside- 
0.684 53.5 6.075 4.75 0.019 1.5 0.691 0.54 0.000 0.0 nd nd 
Eriocitrin (eriodictyol-
7-O-rutinoside) 
0.133 15.8 1.185 1.40 0.299 35.4 11.148 13.18 0.000 0.0 nd nd 
Hesperidin (hesperitin-
7-O-rutinoside) 
0.009 0.5 0.082 0.04 1.060 51.7 39.446 19.25 0.000 0.0 nd nd 
p-Coumaric acid 0.000 0.0 Nd Nd 0.000 0.0 nd nd 0.052 NA
g 
0.570 NA 
Protocatechuic acid 0.000 0.0 Nd Nd 0.000 0.0 nd nd 0.059 52.4 0.647 5.722 
a
 Fractionation yield was calculated relative to initial concentration of polyphenol in SM6Met B1-4Mix, which was set to 100%; for example for mangiferin in PF 
(0.063/1.899) x 100 = 3.3% 
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 SA refers to specific activity, which is the concentration of polyphenol per 100 g test sample 
c
 PuF refers to purification factor (SA of compound in fraction/ SA of compound in SM6Met B1-4Mix)  
d
 g polyphenol in fraction if 100 g SM6Met B1-4Mix was used for fractionation (Fig. 1) for example mangiferin in NPF: (5.559/100) x 28.14 g (as in Fig. 1)=1.564 g 
e
Co-elution refers to the fact that the polyphenol co-elutes with 3-hydroxyphloretin-3',5'-di-C-hexoside 
f 
Nd - polyphenols were not detected due to absence or very low amounts 
g
 NA - not available as p-coumaric acid co-elutes with 3-hydroxyphloretin-3',5'-di-C-hexoside where present 
Table 6: Purification table of estrogenic activity 
 
ERα ERβ MTT 
Agonist activity Antagonist activity Agonist activity Antagonist activity Agonist activity Antagonist activity 
 Folda PuFb % decreasec PuF Fold PuF % decrease Fold % decrease PuF 
B1-4Mix 1.8 
###  1.0 33% ### 1.0 
2.2 
### 
1.0 — — 18% ## 1.0 
           
PF —  26% 
# 0.8 — — — — 17% ## 0.94 
NPF —  30% 
## 0.9 2.3 ## 1.1 — — 17% ## 0.94 
           
F1 —  52% ### 1.6 — — 43% ### — — — 
F2 —  53% ### 1.6 — — — — 16% ### 0.90 
F3 1.7 
### 0.9 —  4.5 ns 2.1 — 1.4 ns — — 
a
 Fold-induction relative to solvent (Figs. 2- 7) 
b 
PuF refers to purification factor (SA of compound in fraction/ SA of compound in SM6Met B1-4Mix) 
c
 Percentage decrease in induction relative to 10
-11
 M E2 set as 100% for promoter reporter studies and 10
-9
 M E2 set as 100% for proliferation studies (Figs. 2-7) 
#
 indicates statistical difference compared to E2, where 
ns
 displays activity not statistically different from E2  
— refers to no activity: for agonist mode this implies no statistical difference from solvent, while for antagonist mode it implies no statistical difference from 10
-11
 M 
E2for promoter reporter studies and 10
-9
 M E2 for proliferation studies. 
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The initial liquid-liquid fractionation of SM6Met B1-4Mix produced two fractions, PF and NPF, 
which was produced with an overall (g/g) yield of 96%, split into 68% for PF and 28% for NPF. 
Fractionation resulted in an increase in the purification of major polyphenols in NPF as reflected by 
purification factor (PuF) values ranging from 2.34 – 3.07 (Table 5). In terms of estrogenic activity, 
all the positive estrogenic attributes of the initial SM6Met B1-4Mix were retained in NPF (Table 6), 
whereas PF retained only ERα antagonism and antagonism of E2-induced breast cancer cell 
proliferation. Despite the concentration of major polyphenolic compounds in NPF we did not 
observe a significant increase in estrogenic activity as compared to that observed for SM6Met B1-
4Mix. 
Subsequent HPCCC fractionation of NPF produced three fractions, F1, F2 and F3, comprising an 
overall yield of 82%, split into 40% for fraction F1, 9.6% for fraction F2, and 32.7% for fraction F3. 
Considering fractionation of the polyphenols, the dihydrochalcones predominantly eluted in F1, 
while the benzophenone and flavanones eluted in F2, and the xanthones, flavones and  polyphenolic 
acids eluted in F3 (Table 5). Specifically, phloretin-3',5'-di-C-glucoside and 3-hydroxyphloretin-
3',5'-di-C-hexoside were concentrated 4.8 fold and 2.4 fold, respectively, in fraction F1, while 
iriflophenone-3-C-glucoside and the flavanones, eriocitrin and hesperidin, were concentrated 17.7, 
13.2, and 19.3 fold, respectively in fraction F2. The xanthones, mangiferin and isomangiferin, were 
concentrated 6.0 and 6.2 fold in fraction F3, while the flavones, scolymoside and luteolin, were 
concentrated 6.0 and 5.1 fold, respectively. Although, the phenolic acids, p-coumaric acid and 
protocatechuic acid, displayed similar specific activity values in fraction F3, the purification factor 
could only be determined for protocatechuic acid (5.7 fold), as the concentration of p-coumaric 
could not be determined in the initial SM6Met B1-4Mix, due to co-elution with 3-
hydroxyphloretin-3',5'-di-C-hexoside. In terms of estrogenic activity, HPCCC resulted in the 
divergence, and in some cases amplification, of the positive estrogenic attributes of the initial 
SM6Met B1-4Mix and NPF. Specifically, ERα antagonism was amplified (1.6 fold) in fractions F1 
and F2, whereas it was absent from fraction F3, while ERβ agonism was only observed in fraction 




F3, where it was amplified 2 fold. The third positive estrogenic attribute, antagonism of E2-induced 
breast cancer cell proliferation, was only retained in fraction F2, the only fraction that displayed 
pure ERα antagonism, an attribute previously shown to be anti-proliferative in breast cancer cells 
[44]. Although, fraction F1 also displayed ERα antagonism, the fact that, in addition, it also 
displayed ERβ antagonism, possibly explains the loss of antagonism of E2-induced breast cancer 
cell proliferation when the roles of the ER-subtypes in breast cancer cell proliferation are 
considered [44]. 
In summary, the liquid-liquid fractionation concentrated all known major quantified polyphenolic 
compounds thereby retaining the positive estrogenic attributes in NPF, while the subsequent 
HPCCC of NPF separated not only the major classes of quantified polyphenolic compounds, but 
also the desired positive estrogenic attributes into three fractions. 
F3 was chosen for further evaluation as ERβ agonism is considered important in the development of 
a phytoestrogenic nutraceutical for women in menopause due to the known fact that ERβ agonism is 
anti-proliferative in breast cancer [44], while recent studies have indicated that ERβ agonists may 
alleviate several menopausal symptoms [83,84]. 
3.3.2 Evaluation of the estrogenic activity of individual polyphenols in F3 and reconstituted F3 
Having quantified the major polyphenolic compounds in HPCCC fraction F3 (Table 4), we wanted 
to investigate whether reconstitution of the HPCCC fraction F3 using only the major phenolic 
compounds quantified would display the same activity as the isolated HPCCC fraction. We 
reconstituted the F3 fraction using the concentrations of major phenolic compounds that would be 
present in 9.8 µg/mL of extract (Table 7). 
The HPCCC fraction F3 previously showed potent ERβ agonist activity (Fig. 6B), which was also 
displayed upon re-investigation (Fig. 8B), with the HPCCC fraction F3 inducing a 3.5 fold 
induction of an ERE-containing promoter reporter via ERβ. 
 




Table 7: Individual polyphenol content as per 9.8 µg HPCCC fraction F3 
HPCCC fraction F3 polyphenol content 
Polyphenol  µg/9.8 µg extract % polyphenol present
b
 
Mangiferin 1.113 46.7 
Isomangiferin 0.394 16.2 
Luteolin 0.020 0.8 
Scolymoside (luteolin-7-O-rutinoside) 0.752 31.0 
Iriflophenone-3-C-glucoside 0.009 0.4 
Phloretin-3', 5'-di-C-glucoside  Nd
a
 Nd 
3-Hydroxyphloretin-3',5'-di-C-hexoside Nd Nd 
Eriocitin  Nd Nd 
Hesperidin (hesperitin-7-O-rutinoside) Nd Nd 
Protocatechuic acid 0.063 2.6 
p-Coumaric acid 0.056 2.3 
a
 Nd - polyphenol not detected  
b
 % of polyphenol present calculated relative to total concentration of major polyphenols in extract 
The reconstituted F3 major compound mixture (F3M) induced a 2.6 fold induction via ERβ, which 
was unfortunately significantly (p < 0.01) lower than HPCCC fraction F3. Despite this, the ERβ 
antagonism experiment (Fig. 8D) confirmed that both HPCCC fraction F3 and F3M are ERβ 
agonists displaying, in the presence of 10
-11
 M E2, an agonism significantly (p < 0.05) higher than 
10
-11
 M E2. Previously, HPCCC fraction F3 displayed weak ERα agonism (Fig. 6A), which was 
also displayed upon re-investigation (Fig. 8A), with HPCCC fraction F3 inducing a 1.8 fold 
induction of an ERE-containing promoter reporter via ERα. F3M, however, induced a significantly 
(p < 0.001) higher induction (2.7 fold) via ERα. The ERα agonism of HPCCC fraction F3, but not 
F3M, was significantly lower than 10
-11
 M E2.  
Together these results indicate that neither the desired ERβ agonist activity, nor the weak ERα 
agonism, present in the HPCCC fraction F3, could be fully recapitulated by reconstituting only the 
major polyphenolic compounds present in HPCCC fraction F3. We should, however, keep in mind 
that neither scolymoside nor iriflophenone 3-C-glucoside used to reconstitute F3M were pure 
compounds, but rather enriched HPCCC fractions, thus, the concentration of these compounds in 
F3M were underestimated, which may have contributed to the discrepancy between the HPCCC 
fraction F3 and F3M results. Specifically, the HPCCC enriched fraction of scolymoside contained 
only 20.5 g (Fig. S3) scolymoside per 100 g extract, while the HPCCC enriched iriflophenone-3-C-
glucoside fraction contained only 32 g iriflophenone-3-C-glucoside per 100 g extract (Fig. S4). 




































































































































































































































































































































































































































































































































































































































































































Figure 8. Transactivation studies investigating E2, HPCCC fraction F3, reconstituted fraction F3 
(F3M) and compounds as in HPCCC fraction F3: A-B Agonist Mode; C-D Antagonist Mode. (A) 





M E2, 9.8 μg/mL F3 (HPCCC F3 and F3M); and 1.133 μg mangiferin, 0.394 μg isomangiferin, 0.056 μg p-
coumaric acid, 0.063 μg protocatechuic acid, 0.752 μg scolymoside enriched HPCCC fraction (Fig. S3), 
0.0201 μg luteolin or 0.0090 μg iriflophenone-3-C-glucoside enriched HPCCC fraction (Fig. S4), as in 9.8 
μg F3 (Table 7). (B) HEK293 cells transfected with pSG5-hERβ, ERE.vit2.luc and pGL2-Basic were 
induced as in A. (C) HEK293 cells were transfected and induced as in A with HPCCC F3, F3M, HPCCC-
rich fractions and compounds, administered in the presence of 10
-11
 M E2. (D) HEK293 cells were 
transfected as in B induced with HPCCC F3, F3M, HPCCC-rich fractions and compounds, administered in 
the presence of 10
-11
 M E2. For statistical analysis one-way ANOVA was used with Dunnett‘s Multiple 
Comparisons Test as post-test. For all bars compared to DMSO *** denotes p < 0.001, ** denotes p < 0.01 
and * denotes p < 0.05. For all bars compared to 1nM E2 ### denotes p < 0.001, ## denotes p < 0.01 and # 
denotes p < 0.05. For all bars compared to F3M $$$ denotes p < 0.001, $$ denotes p < 0.01 and $ denotes p 
< 0.05. For all bars compared to 10 
-11
M E2 &&& denotes p < 0.001, && denotes p < 0.01 and & denotes p < 
0.05. No symbol above bars indicates no significant differences compared to control. 
@
 refers to the luteolin-
7-O-rutinoside enriched fraction. 
!
 refers to the iriflophenone-3-C-glucoside enriched fraction. 
Alternatively, other minor compounds present in HPCCC fraction F3 may be involved in 
modulating towards greater ERβ agonism and lesser ERα agonism as evaluated via the ERE-




containing promoter reporter assay. Despite the differences observed between the HPCCC fraction 
F3 and F3M in the subtype specific promoter reporter assays, no significant difference was 
observed in the breast cancer cell proliferation assay, with both fractions displaying weak and 






































































































































































































































































Figure 9. Proliferation studies investigating investigating E2, HPCCC fraction F3, reconstituted 
fraction F3 (F3M) and compounds as in HPCCC F3 (F3M): A agonist mode; B antagonist mode. MCF-
7 BUS cells were serum starved for 24 h, where after cells were induced at 24 h, and re-induced at 48 h and 
72 h, where after the assay was performed at 96 h. In (A) cells were induced with 10
-9
 M E2, 9.8 μg/mL F3 
(HPCCC F3 and F3M) and 1.133 μg mangiferin, 0.394 μg isomangiferin, 0.056 μg p-coumaric acid, 0.063 
μg protocatechuic acid, 0.752 μg scolymoside enriched HPCCC fraction, 0.0201 μg luteolin and 0.0090 μg 
iriflophenone-3-C-glucoside HPCCC enriched fraction, as in 9.8 μg HPCCC F3 (Table 7). In (B) MCF-7 
BUS cells were treated as in (A) with the fractions and compounds, administered in the presence of 10
-9
 M 
E2. For statistical analysis one-way ANOVA was used with Dunnett‘s Multiple Comparison Test as post-test. 
For all bars compared to DMSO *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p < 0.05. For all 
bars compared to 1 nM E2 ### denotes p < 0.001, ## denotes p < 0.01 and # denotes p < 0.05. For all bars 
compared to F3M $$$ denotes p < 0.001, $$ denotes p < 0.01 and $ denotes p < 0.05. No symbol above bars 
indicates no significant differences compared to control. 
@ 
refers to the luteolin-7-O-rutinoside enriched 
fraction. 
!
 refers to the iriflophenone-3-C-glucoside enriched fraction. 
Despite the differences between HPCCC fraction F3 and F3M, it is interesting to note the 
contribution of the individual major polyphenolic compounds to ER-subtype specific activity (Fig. 
8) compared to F3M. The desired ERβ agonism appears to be mostly explained by the presence of 
the scolymoside enriched fraction (Fig. 8B), which displayed similar (p > 0.05) ERβ agonism as 
F3M. Interestingly enough, mangiferin, isomangiferin, luteolin, p-coumaric acid, and 




protocatechuic acid, at the concentrations of the pure compounds present in F3M, as well as the 
iriflophenone-3-C-glucoside HPCCC enriched fraction, displayed ERβ antagonism (Fig. 8D), which 
is not reflected as ERβ antagonism of F3M, nor in reduced ERβ agonism of F3M relative to 
scolymoside (Fig. 8B). Scolymoside or other compounds present in the scolymoside enriched 
fraction, is not only an ERβ agonist, but also displayed ERα agonism (Fig. 8A), which in contrast to 
that found via ERβ, is significantly higher (p < 0.01) than observed for F3M. Here we find that ERα 
antagonism (Fig. 8C) of other major compounds (mangiferin, iriflophenone-3-C-glucoside (or other 
minor compounds in the enriched fraction), luteolin, and protocatechuic acid), at the concentrations 
present in F3M, appeared to be responsible for tempering the strong ERα agonism of scolymoside 
to result in the lower ERα agonism seen for F3M (Fig. 8A). Weak induction of breast cancer cell 
proliferation was observed for the scolymoside enriched fraction (Fig. 9A), which although not 
significantly different from F3M, is slightly higher. The downward modulation of the proliferative 
effect of the scolymoside enriched HPCCC fraction observed in the final F3M mixture could be 
ascribed to the significant (p < 0.001) antagonism of protocatechuic acid (Fig. 9B). 
In summary, reconstitution of the major polyphenolic compounds of the HPCCC fraction F3 in 
F3M did not result in similar activities in the ER-subtype specific ERE-containing promoter 
reporter assays. The discrepancy in the results (Figs. 8A&B) suggested that minor compounds in 
the HPCCC fraction F3 would have to act as ERα antagonists and ERβ agonists. Amongst the 
individual major compounds, scolymoside or minor compounds in the scolymoside enriched 
fraction, appears to be the most likely candidates to elicit the observed ER agonism of F3M. 
Interestingly, scolymoside, a rutinoside of luteolin, has not previously been investigated for ER-
subtype specific activity, and thus this study is the first to show that it may behave as both an ERα 
and ERβ agonist. However, we should keep in mind that pure scolymoside was not tested, but rather 
an enriched HPCCC fraction, and thus any conclusions drawn concerning this fraction should await 
validation with pure scolymoside. 





Menopausal women have shown great interest in commercial phytoestrogenic nutraceuticals, as it is 
seen as a safer alternative to traditional HRT [85-91]. Cyclopia shows potential for the development 
of a phytoestrogenic nutraceutical [61,62]. More recently SM6Met, a sequential methanol extract 
from a Cyclopia subternata harvesting, M6, showed the highest potency of tested Cyclopia extracts 
with regards to phytoestrogenic properties and displayed positive estrogenic attributes, such as ERα 
antagonism, ERβ agonsim and antagonism of E2-induced breast cancer cell proliferation [63,64]. In 
the current study, these positive estrogenic attributes were used in activity-guided fractionation of 
SM6Met with the hope of identifying marker compound(s) responsible for these attributes to be 
used for quality control, screening, and in future plant breeding programs. 
Activity-guided fractionation is commonly used to identify compounds within mixtures responsible 
for specific activity profiles [92-94]. In the field of estrogenic nutraceuticals, activity-guided 
fractionation was most successfully employed to isolate the ERβ-subtype specific agonist, 
liquiritigenin, from MF101, a plant extract containing 22 herbs, which has ERβ selective properties 
[94]. In the case of SM6Met the desired positive estrogenic attributes are more complex in that both 
ERβ agonism, as well as ERα antagonism was targeted. The existence of a compound displaying 
these desired estrogenic attributes seemed possible as the R,R enantiomer of 5, 11-cis-diethyl-
5,6,11,12-tetrahydrochrysene-2,8-diol (R,R-THC) has been shown to be both an ERα agonist and an 
ERβ antagonist [42,43,95]. Our results, however, suggest that it is unlikely that the ERβ agonism as 
well as the ERα antagonism of SM6Met may be attributed to a single compound as we showed that 
ERα antagonism was only observed for HPCCC fractions F1 and F2, but not F3, while ERβ 
agonism was only observed for HPCCC fraction F3. The difference in activity was as a result of the 
differential fractionation of the major polyphenolic compounds in NPF into the individual HPCCC 
fractions. Specifically, the HPCCC fraction F1 consisted mainly of dihydrochalcones, the HPCCC 
fraction F2 of mainly flavanones and the benzophenone, and the HPCCC fraction F3 of mainly 
xanthones, flavones, and phenolic acids.  




The two dihydrochalcones, phloretin-3',5'-di-C-glucoside and 3-hydroxyphloretin-3',5'-di-C-
hexoside, present in HPCCC fraction F1 have not been tested for estrogenic activity, although a 
previous study did correlate estrogenic activity with the presence of phloretin-3',5'-di-C-glucoside 
in SM6Met, which was previously unidentified, and designated as unknown 2 [63]. Although 
present at lower levels than the dihydrochalcones, one of the other major polyphenolic compounds 
found in HPCCC fraction F1, eriocitrin, has been shown to bind both ERα and ERβ [61], however, 
no information concerning agonism or antagonism is available. Thus, although no definitive 
conclusions regarding the specific polyphenolic compounds responsible for the observed ERα and 
ERβ antagonism of HPCCC fraction F1 may be drawn, the fact that eriocitrin was also present in 
HPCCC fraction F2, which also displayed ERα antagonism, is intriguing. Evidence supporting the 
possible ERα antagonism of eriocitrin is that it binds to ERα [61], and is present in HPCCC 
fractions F1 and F2, but not in HPCCC fraction F3. However, the fact that there is no quantitative 
difference in the level of ERα antagonism between HPCCC fraction F1 and F2, despite F2 
containing ten times more eriocitrin than F1, argues against eriocitrin being solely responsible for 
the observed ERα antagonism. No other compounds that could possibly explain the ERα 
antagonism and antagonism of E2-induced breast cancer cell proliferation of HPCCC fraction F2 
appeared to be present, as hesperidin, the most abundant polyphenol present in F2, does not bind 
ERα or ERβ while iriflophenone, the aglycone of iriflophenone-3-C-glucoside, the second most 
abundant polyphenol in F2, has previously been shown to be proliferative in breast cancer cells 
[75,76], a finding we could not reproduce with the iriflophenone-3-C-glucoside enriched fraction 
(Fig. 6A). Our own results with the iriflophenone-3-C-glucoside enriched fraction, however, 
suggested that iriflophenone-3-C-glucoside, or the suite of minor compounds accompanying 
iriflophenone-3-C-glucoside in the enriched fraction (Fig. S4), could act as ERα and ERβ 
antagonists (Figs 8C&D). Studies have indicated that iriflophenone-3-C-β-glucoside may exert 
synergistic effects with other compounds in SM6Met such as mangiferin and hesperidin [96,97] 
which has been linked to anti-diabetic and cholesterol-lowering effects seen in rat models [98]. It 




could be interesting to investigate synergistic estrogenic effects of iriflophenone-3-C-glucoside and 
hesperidin as both are present in the iriflophenone-3-C-glucoside enriched fraction (Fig. S4) and in 
F2. Our own results (Fig. 8) implicated the scolymoside enriched HPCCC fraction as the primary 
candidate responsible for the robust ERβ agonism of HPCCC fraction F3. Scolymoside has not 
previously been tested for estrogenicity. Our study showed that the scolymoside-enriched HPCCC 
fraction displayed not only ERβ agonism, but also ERα agonism, which is likely due to the presence 
of scolymoside, but, may also be due to the presence of the other minor compounds in the 
scolymoside enriched HPCCC fraction (Fig. S3). Luteolin, the other flavone and an aglycone of 
scolymoside, present in HPCCC fraction F3, has been much more extensively studied. Although 
luteolin is a known phytoestrogen [81] showing preferential binding to ERβ over ERα, 
transactivating an ERE-containing promoter reporter via both ER-subtypes, though more potently 
via ERα, and antagonising E2-induced breast cancer cell proliferation [62,77,81], our results 
suggested that at the concentration present in HPCCC fraction F3, luteolin displayed none of the 
above mentioned estrogenic properties. We did, however, observe ERα and ERβ antagonism, which 
we postulated could be responsible for tempering the ERα agonism of the scolymoside enriched 
HPCCC fraction towards the lowered agonism observed for F3M. The most abundant class of 
polyphenols in HPCCC fraction F3 were the xanthones, mangiferin and isomangiferin. Mangiferin 
does not bind to the ER-subtypes [59], nor does it transactivate an ERE-containing promoter 
reporter via either ER-subtype [62], which corresponds with our findings (Figs. 8A&B). 
Antagonism via the ER-subtypes has not previously been investigated; our results indicated that 
mangiferin acts as an ERα, but not ERβ antagonist (Fig. 8C). Furthermore, although mangiferin has 
been shown to have anti-tumour properties against MCF-7 breast cancer cells by regulating matrix 
metalloproteinases, the epithelial to mesenchymal transition, and the β-catenin signalling pathway 
[99], our results indicted no antagonism of E2-induced breast cancer cell proliferation at the 
concentration of mangiferin present in HPCCC fraction F3 (Fig. 9B). Our studies indicated that the 
other xanthone, isomangiferin, a regio-isomer of mangiferin, acted as an ERβ antagonist at the 




concentration present in HPCCC fraction F3. To our knowledge no other studies investigating the 
phytoestrogenic properties of isomangiferin have been done. The phenolic acids, p-coumaric acid 
and protocatechuic acid, present in lower amounts in HPCCC fraction F3, are unlikely to contribute 
to ERβ agonism displayed by this fraction, as in our study they did not transactivate via either of the 
ER-subtypes (Figs. 8A&B), and previous studies have shown that p-coumaric acid was not 
estrogenic in a rat uterotrophic model [80]. Interestingly, both phenolic acids displayed ERβ 
antagonism, while in addition, the protocatechuic acid displayed ERα antagonism (Fig 8C) and 
antagonism of E2-induced breast cancer cell proliferation (Fig. 9B). 
It should be noted that all discussions regarding scolymoside and iriflophenone-3-C-glucoside 
should, however, be viewed in the light of the fact that these compounds were not tested as pure 
compounds, but rather as enriched fractions. The scolymoside enriched fraction also contained trace 
amounts of mangiferin and isomangiferin and low amounts of hesperidin , while the iriflophenone-
3-C-glucoside enriched fraction also contained trace amounts of mangiferin, isomangiferin, 
eriocitrin and narirutin, and low amounts of maclurin-3-C-glucoside and hesperidin (Figs. S3&4). It 
is thus possible that the effects observed for these enriched fractions are actually due to the 
combination of compounds in the enriched fractions. 
Future work should focus on fine-tuning the polyphenol composition of F3M to bring activity more 
in line with HPCCC fraction F3. This may be accomplished by, for example, including minor 
compounds identified in HPCCC fraction F3 (Table S3). Fine-tuning of F3M may allow for 
identification of the suite of compounds that together display robust and specific ERβ agonism, 
without ERα agonism. In addition, reconstitution of HPCCC fractions F1 and F2 should also be 
considered to identify the marker compounds or suite of compounds responsible for ERα and ERβ 
antagonism. Furthermore, consideration should be given to expanding the array of estrogenic 
assays, to include in vitro assays such as, whole cell binding, determination of ERα and ERβ levels, 
ERα and ERβ hetero- and homo-dimerization, and microarray analyses to evaluate effects on 




endogenous genes and in vivo assays such as an immature rat uterine model or a rat breast cancer 
model. Furthermore, estrogenic activity assays to be conducted in the future should also include 
investigation of test samples in the presence and absence of the ER antagonist, ICI 182780, in order 
to determine whether the response induced by a test sample is indeed via the ER only. In addition, 
future research should include dose response curves for all extracts and fractions as this will allow 
one to acquire the relevant efficacy and potency data, which will allow for a more accurate activity 
analysis. 
In conclusion, the fact that the positive estrogenic attributes of interest, ERα antagonism, ERβ 
agonism, and antagonsim of E2-induced breast cancer cell proliferation, separated into different 
fractions following HPCCC fractionation of NPF, indicates that correlating one compound with all 
the positive estrogenic attributes is highly unlikely. This supports the idea that several of the 
polyphenols present in SM6Met or the NPF may have synergistic, additive or antagonistic effects in 
conferring these desired estrogenic traits. The concept of formulations consisting of intelligent 
mixtures of natural products to treat diseases has become a popular thrust of recent studies [100-
105], and thus, future studies will include focussing on the isolation or production of a mixture of 
compounds, an ―intelligent‖ mixture, where compounds show additive, synergistic or antagonistic 
effects to design a nutraceutical product to user demand of estrogenic activity. 
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3.6 Supplementary Data 
 
Figure S1. Production of SM6Met. SM6Met was produced as adapted from Mfenyana et al. [63]. 





Figure S2. Representative high performance counter-current chromatogram (HPCCC) illustrating the 
fractionation of the non-polar fraction (NPF), whereby specific fractions were pooled to form F1 (24-40 
min), F2 (41-52 min) and F3 (52-75 min). 
 
  






Figure S3. HPLC-DAD chromatogram of a high performance counter-current chromatography (HPCCC) fraction enriched in scolymoside. * indicates ascorbic acid 
added to prevent oxidation during analysis. Numbers correspond with Table S1. Consider all other peaks as unidentified.  
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Figure S4. HPLC-DAD chromatogram of high performance counter-current chromatography (HPCCC) fraction enriched in iriflophenone-3-C-glucoside. * indicates 
ascorbic acid added to prevent oxidation during analysis. Numbers correspond with Table S2. Consider all other peaks as unidentified. 
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Figure S5. Optimisation of HEK 293 transfection. HEK 293 cells were transfected with varying ratios of 
150 ng pSG5-hERα or 150 ng pSG5-hERβ to ERE.vit2.luc (1:10, 1:20, 1:30 and 1:40) with the addition of 
pGL-2-Basic in each instance to reach a total DNA amount of 6150 ng. In A) ERα:ERE DNA ratios, whereas 
in B) ERβ:ERE ratios were tested using normal sterile 10 cm and 24-well tissue culture plates. In C) and 
subsequently for all following transfections a ratio of 1:25 ERα:ERE was chosen coupled with the usage of 
sterile cell-bind 10 cm and 24-well tissue culture plates, whereas in D) and subsequently for all following 
transfections a ratio of 1:20 ERβ:ERE was chosen coupled with the usage of sterile cell-bind 10 cm and 24-
well tissue culture plates. For statistical analysis one-way ANOVA was used with an unpaired t-test. For all 
bars compared to DMSO *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p < 0.05 












































































































































































Figure S6. Optimisation of the treatment schedule for optimal E2-induced breast cancer cell 
proliferation responsiveness. A) Induction of breast cancer cell (MCF-7 BUS)proliferation 48 h after the 
first treatment with E2, B) 72 h after treatment, C) 48 h after the first treatment, with re-treatment at 24 h, D) 
72 h after the first treatment with re-treatment at 24 h, E) 72 h with re-treatment at 24 h and 48 h. The 
treatment schedule for all following proliferation studies was chosen as 72 h with re-treatment at 24 h and 48 
h as it produced the most optimal responsiveness of E2-induced breast cancer cell proliferation. Proliferation 
was measured by means of the MTT assay. For statistical analysis one-way ANOVA was used with an 
unpaired t-test. For all bars compared to DMSO *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p 
< 0.05 






Figure S7. Steroid receptor characterisation of the HEK293 cell line. Western Blot analysis reveals the 
absence of ERα (A), ERβ (B), AR (C), PRA (E), PRB (F) and the presence of hGRα (D) and MR (G) in the 
HEK293 cell line. + indicates positive control for the steroid receptor which is the lysate obtained from 
COS-1 cells transfected with the cognate receptor, - indicates the negative control for the steroid receptor 
consisting of lysate from untransfected COS-1 cells, except for MR where it refers to an Ect1/E6E7 cell 
lysate. HEK293 refers to the HEK293 lysate used for HEK293 steroid receptor characterisation. 



















































Figure S8. Estrogen receptor characterisation of HEK293 cells using a whole cell binding assay. For 
estrogen receptor characterisation HEK293 cells were incubated with 20 nM radio-labelled E2 (2,4,6,7-
[
3
H]17-β-oestradiol, specific activity 100 Ci/mmol), and DMSO, which served as the total binding condition. 
In addition, the cells were incubated with 20 nM radio-labelled E2 and 10
-5
 M unlabelled E2, which served as 
the non-specific binding condition. Specific binding was calculated by subtracting the non-specific binding 
from the total binding. The graph shows results of three independent experiments. For statistical analysis, 
Student‘s t-test was used, which indicated no significant differences between total binding and non-specific 
binding. 
 
Figure S9. Estrogen receptor characterisation of the MCF-7 BUS cell line. Western Blot analysis reveals 
the presence of ERα and ERβ in the MCF-7 BUS breast cancer cell line. - indicates the negative control for 
the steroid receptor (untransfected COS-1 cells). MCF-7 BUS refers to the MCF-7 BUS lysate used for 
MCF-7 BUS estrogen receptor characterisation.
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(D) HPCCC F1 
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(E) HPCCC F2 
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(F) HPCCC F3 
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Figure S10A-F. LC-MS/MS analysis (graphs in base peak intensity, BPI) of SM6Met B1-4Mix (A) and fractions (NPF (B), PF (C), HPCCC F1 (D), HPCCC F2 
(E), and HPCCC F3 (F)) obtained during activity-guided fractionation. Numbers correspond with Table S3. The initial peak in all samples was due to ascorbic acid 
added to prevent oxidation and not taken into account when numbering peaks. Peaks above the dotted lines are considered to be major peaks, whilst peaks below the 
dotted lines are considered to be minor peaks as indicated in Table S3. 
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 indicates the polyphenol retention time 
b
 MS data from literature used to tentatively identify compounds 
c
* indicates the deprotonated molecular ion species in the case of [M-H]
-
 and in the case of the fragment ions it indicates the major daughter ion 
d
Minor polyphenols in extract are represented by ―x‖ 
e
Major polyphenols in extract are represented by ―X‘‘ 
ID refers to the fact that the compound was identified by means of an authentic reference standard 
NC refers to the presence of a compound not identified before and further structure elucidation is required 
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(D) HPCCC F1 
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(E) HPCCC F2 
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Figure S11A-F. HPLC-DAD chromatograms of SM6Met B1-4Mix (A) and fractions obtained during fractionation (PF (B), NPF (C), HPCCCF1 (D), HPCCCF2 
(E), HPCCC F3 (F)). Numbers correspond with Table S3. The first peak in all samples was due to ascorbic acid added to prevent oxidation and was not included in 
the numbering of peak. 
  
(F) HPCCC F3 
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Intestinal absorption of Cyclopia subternata 
extract, SM6Met 
  





Development of an oral nutraceutical would require screening for absorption into the human body. 
Intestinal absorption of bioactive polyphenols in plant extracts would be crucial for systemic 
availability and exertion of desired therapeutic effects [1-3]. Even though the process of intestinal 
absorption can be transcellular, via passive or active transport or paracellular, due to movement 
through tight junctions, the most common route for drugs is via a passive transcellular process [4]. 
Furthermore, pharmacokinetic studies have shown that this process may occur along the entire 
length of the intestine [5], and that the transport and distribution of most drugs are via passive 
diffusion, which depends on compound lipophilicity [6]. Also, literature suggests that for a 
compound to permeate the intestinal barrier, it needs to comply with a set of rules known as the 
Lipinski ―Rule-of-5‖, in addition, unless actively transported, the compound needs to possess a 
polar surface area (PSA) less than 140Å
2
, and less than 10 rotatable bonds (RB) [7,8]. Although 
several in vivo and in vitro models for prediction of human intestinal absorption have been used in 
recent years, these methods are labour intensive and give variable results [2]. The use HT methods 
such as QSPR determination methods [2], has become increasingly popular in modern science, of 
which physicochemical profiling is most commonly used [9].  
The Cyclopia subternata extract, SM6Met, displays desirable attributes for the development of a 
phytoestrogenic nutraceutical to treat menopausal symptoms [10-13]. Thus investigation of the 
intestinal absorption of SM6Met is vital, as intestinal absorption serves as a preliminary 
qualification for the polyphenols within the extract to become part of the general systemic 
circulation and thus to exert a therapeutic effect [1]. No absorption studies have been performed on 
the SM6Met extract; however, research has been performed on other plant extracts and on some of 
the major polyphenols present in the SM6Met extract. For example, a study investigating the oral 
ingestion of a C. genistoides extract, with known mangiferin and hesperidin content, by pigs 
indicated that the xanthones, mangiferin and isomangiferin were not detected in plasma, but that 
their corresponding aglycone, norathyriol, was detected [14]. Furthermore, neither the flavanone, 




hesperidin, nor any of its metabolites, were detected in the plasma, although several biotransformed 
metabolites of both mangiferin and hesperidin were detected in the urine [14]. In a separate study, 
absorption of an aspalathin-rich rooibos extract revealed no detection of aspalathin, a 
dihydrochalcone C-glucoside, in pig plasma, however, aspalathin and five dihydrochalcone 
metabolites were identified in urine, indicating the involvement of phase II enzyme metabolism 
[15]. Also, in a human study, aspalathin was detected in trace amounts in urine, however, no 
aspalathin was detected in the plasma [16]. In contrast, in an absorption study in rats, the 
dihydrochalcone aglycone, phloretin, was detected in rat plasma, mainly in conjugated form, 
although some unconjugated phloretin was also detected [17]. Furthermore, luteolin or luteolin-7-
O-β-glucoside administered to rats via gastric intubation resulted in free luteolin and conjugates of 
luteolin in the plasma, but no luteolin-7-O-β-glucoside, suggesting hydrolysis and absorption of free 
luteolin [18]. Literature suggests that the hydrolysis of these glycoside residues arises to ensure 
permeability of the aglycone for optimal absorption [19]. C-glycosides are less likely to be 
hydrolysed than O-glycosides as the C-C bond confers acid stability [20]. They are, however, in 
some cases, still hydrolysed in the colon by bacterial C-glycosyl cleavage enzymes released 
intestinal flora, as in the case of mangiferin hydrolysis [21]. 
Whereas previous studies [14,15,17,18] showing absorption of some of the polyphenols present in 
SM6Met, accounted not only for intestinal absorption, degradation and/or modification by intestinal 
microflora and further hepatic metabolism, the current study focused only on intestinal absorption. 
Specifically, the movement of SM6Met polyphenols across the porcine small and large intestine 
was investigated using a flow-through diffusion system with collected fractions analysed using LC-
MS/MS. In addition, physicochemical profiling as method for prediction of absorption of the 
individual polyphenols in SM6Met, was also performed using three open source programs. 




4.2 Materials and methods  
4.2.1 Tissue specimens 
Tissue specimens were obtained from a local abattoir (Winelands Pork (PTY) LTD, Western Cape, 
South Africa). Small intestine (duodenum), ca. 10 cm after the stomach, and large intestine (colon), 
ca. 60 cm before the anus, were excised at a size of 30 cm each, from one pig. The specimens were 
then carefully rinsed with PBS (pH 7.4) at 20°C where after excess fat was carefully removed using 
a scalpel, without disturbing the integrity of the epithelial surface. Tissue disks were made from the 
top half of each tissue type, and were then snap frozen and stored at -80°C until used.  
4.2.2 Sample preparation 
SM6Met was made up to a final concentration of 244 mg/mL using PBS (pH 7.4) with ascorbic 
acid at a final concentration 9.1 mg/mL. The sample was then centrifuged at 5000 RPM (2991 x g) 
for 1 min to remove any insoluble material and the supernatant used in the permeability 
experiments. In addition, the supernatant used in each permeability experiment served as a positive 
control in LC-MS/MS analysis of fractions obtained. 
4.2.3 Permeability experiments 
The in vitro technique used for the analysis of diffusion of SM6Met polyphenols through the small 
and large intestine was the flow-through diffusion system (ISCO Retriever IV, ISCO
®
. USA), as 
adapted from Van Zyl et al. [22]. Tissue specimens were thawed at room temperature in PBS (pH 
7.4) and then equilibrated for 10 min in the aforementioned PBS, where after they were investigated 
under the microscope for any potential tissue integrity disturbances before experiments were 
conducted. Specimens were then mounted (mucosal side facing the donor chamber) in flow-through 
diffusion cells (exposed area of 0.196 cm
2
) as described by Van der Bijl and van Eyk [23]. Each 
experiment was performed concurrently on 7 tissue replicates. Before the experiment was started 
the mounted tissue specimens were allowed to equilibrate for a further 10 min in PBS (21°C or 
37°C, pH 7.4, containing 9.1 mg/mL ascorbic acid) in the acceptor and donor compartments of each 




diffusion cell. Thereafter the PBS was removed from the cells and replaced with 500 uL of SM6Met 
at a concentration of 244 mg/mL. PBS, containing 9.1 mg/mL (21°C or 37°C) was pumped through 
the acceptor compartments at a rate of 1.5 mL/h and fractions collected by means of a fraction 
collector (IPC High Precision Multichanger Dispenser ISMATEC, IDEX Health & Science
®
, 
Germany) at 2 h intervals for 24 h. The study was performed under sink conditions, i.e. at the end of 
each run the concentration of SM6Met in the acceptor chamber never exceeded 10 % of that in the 
donor chamber. 
4.2.4 LC-MS/MS analyses 
Analyses of collected fractions and ‗untreated‘ SM6Met were performed on a Waters Acquity 
UPLC system containing an in-line degasser, binary pump, column oven and PDA detector (Waters, 
Milford, MA, USA). This system was coupled to a Synapt G2 QTOF mass spectrometer (Waters) 
containing an ESI source. Ascorbic acid was added at a concentration of 9.1 mg/mL. The samples 
were then filtered using Millex-GV syringe filters (Millipore) with a 0.22 µm pore size. The HPLC 
method of De Beer et al. [24] was adapted for UPLC use. Separation was achieved on a Gemini-NX 
C18 (150 × 2 mm; 3 μm; 110 Å) column with 2 % acetic acid (A) and acetonitrile (B) as mobile 
phases. A flow rate of 0.320 mL/min for 0-20.1 min and 0.300 mL/min for 20.1-21.1 min was used 
with the following mobile phase gradient: 0-0.5 min (8.5 % B), 0.5-20 min (8.5-34.5 % B), 20-
20.10 min (34.5-90 % B), 20.1-21 min (90 % B), and 21-21.1 (90-8.5 % B). An injection volume of 
5 µL was used for all samples with the eluant being split 1:1 before introduction into the ionization 
source. MS results were acquired using negative ionization in MS
E
 mode. A collision energy ramp 
from 25 to 60 V was used, whereas for MS/MS data a collision energy of 30 V was used. The other 
MS parameters were the same as in De Beer et al. [24]: capillary voltage, 2.5 kV, cone voltage 15 
V, desolvation temp 275°C, source temp 120°C and nitrogen flow rate 650 L/h. Peaks were 
identified by means of comparing LC-MS spectra and relative retention times with data in De Beer 
et al. [24]. Peak areas of targeted compounds were acquired by means of MassLynx v4.1 software 




(Waters, USA) (manual integration) and TargetLynx (automated integration). Compounds were 
quantified in terms of peak area as no calibration standards were employed. 
4.2.5 Computational tools 
Three open source software programs were used to calculate the physicochemical properties of the 
individual polyphenols in SM6Met as a prediction tool for absorption of polyphenols. These 
programs were Osiris Property Explorer [25], ACD/Labs and ChemAxon [26]. 
4.2.6 Data analysis 
Absolute peak areas were obtained for SM6Met (A0) and fractions (A2, A4, A6, etc) collected every 
2 h for 24 h (Fig. S1-3, Table S1). The cumulative quantity of a compound that diffused at a 
specific time point (tn) was calculated as the sum of the individual peak areas of the compound at 
the time points leading up to the specific time point of interest: cumulative peak area (ACn) 
ACn = A2 + A4 + A6 + … An     
For example the cumulative peak area of a specific compound at 24 h (AC24), divided by the 
absolute peak of the same compound (A0), was used to calculate the percentage diffusion, i.e. the 
percentage of the parent compound that crossed the intestinal mucosa at t = 24: 
% diffusion = AC24 / A0 x 100 
Flux values (J) were calculated for each compound, taking into account the quantity (ng) of the 
compound (Q) that crossed the intestinal mucosa during the time (t) of exposure (min), and the 
intestinal area exposed (A) (cm
2




   J = (dQ/dt x 1/A) 
Q of each compound at t = n was calculated taking into account the composition of SM6Met (as 
determined in Chapter 3), the volume of SM6Met solution (500 uL of 244 mg/mL solution) added 
to the chamber, and the percentage diffusion of the compound at t = n.  




The apparent permeability coefficients were calculated as follows [22]:  
  Papp=J/Co  
Co is the initial concentration of the compound of interest (mg/mL), i.e. concentration in the starting 
mixture of SM6Met (244 mg/mL).  
4.2.7 Data manipulation and statistical analysis 
GraphPad Prism
®
 version 5 (GraphPad Software, San Diego, CA) was used for graphical 
representation and statistical analysis of experimental data.  
4.3 Results  
Identification of a possible marker compound or compounds for correlation with estrogenic activity 
forms an integral part of the development of an oral phytoestrogenic nutraceutical (Chapter 3). 
Investigation into whether the compounds of interest will be absorbed and to what extent absorption 
will take place, is also crucial, due to the fact that for any nutraceutical to have an anticipated 
therapeutic effect, its active constituents need to enter the host bloodstream and reach target organs 
in adequate concentrations [27]. For this to take place compounds need to cross the lining of the gut 
after ingestion. Studies have shown that absorption of polyphenols, whether via passive or active 
transport [28], may take place in either the small intestine or large intestine depending on the 
compound investigated [14,18,29-32]. As mentioned earlier, absorption of compounds depend on 
the physicochemical properties of compounds such as, amongst others, molecular weight (MW), 
lipophilicity, PSA and the RB number [33], but further research shows that it also depends on 
physiological factors such as regional permeability differences, pH and luminal and mucosal 
enzymes [34]. We thus decided to perform a preliminary study focussing on only the absorption of 
polyphenols present in a Cyclopia subternata extract, SM6Met [12]. The flow-through diffusion 
apparatus used in the current ex vivo study has been previously used for absorption studies 
investigating absorption of drugs across bronchial tissue [22]. As absorption may take place in 
either the small or large intestine we investigated both tissues. Fractions obtained from the flow-




through diffusion assay was analysed using LC-MS/MS for detection of polyphenols originating 
from SM6Met. 
4.3.1 Optimisation of the flow-through diffusion assay for use as an accurate model for 
intestinal absorption of polyphenolic compounds  
A preliminary assay investigating diffusion through the small intestine was performed at room 
temperature (21°C). Although not physiologically relevant, low temperature was considered to 
minimise phenolic degradation as these type of compounds are instable at a high pH, such as pH 7.4 
[35-37]. At this temperature the polyphenolic compounds where detected only after 20 h (Fig. 1A, 
Fig. S1). Thereafter the assay temperature was increased to the physiologically relevant 37°C (Fig. 
1B, Fig. S2), resulting in the detection of compounds within 6-10 h, which is in agreement with 
previous findings of studies in rats [17,18,38-40]. Also, isomangiferin and 3-hydroxyphloretin-3',5'-
di-C-hexoside were detected when the assay was performed at 37°C, but not at 21°C. These 
findings suggested that 37°C, rather than 21°C, should be used for further investigation.  
The temperature-‗optimised‘ assay procedure was then duplicated for investigation of absorption by 
the large intestine, however, no polyphenols were detected within the 24 h experimental period 
(Fig. 2B, Fig.S3). 





























































Figure 1 Optimisation of the flow-through diffusion assay for diffusion analysis of polyhenolic 
compounds in SM6Met across porcine small and large intestine. The permeability assay evaluating the 
diffusion of SM6Met polyphenols across porcine small intestine using the flow-through diffusion system 
[22] was performed at 21°C (A) and at 37°C (B) over 24 h. In (C) the temperature-‗optimised‘ assay (37°) 
was used for evaluation of diffusion of SM6Met polyphenols across porcine large intestine. Fractions 
obtained from the flow-through diffusion assay were analysed using LC-MS/MS to determine the presence 
of polyphenols originating from SM6Met. Values obtained were expressed as peak areas. Graphs displayed 
were obtained from one replicate per assay performed, and thus served as a representative graph for all other 
replicates in the assay. 
As the time of diffusion of the polyphenols through the small intestinal mucosa obtained with the 
flow-through diffusion model correlated to some extent with previous studies in rats [17,18,38-40], 
and no permeation was observed through the large intestinal mucosa, differing from previous 




studies [41-43], we decided to focus solely on the results obtained for the optimised procedure 
investigating the small intestine in the following section. 
4.3.2 Detailed analysis of diffusion across small intestine at 37°C 
4.3.2.1 Inter replicate variability 
A single flow-through diffusion experiment was performed, which consisted of 7 replicates. Since 
one of the replicates leaked, LC-MS/MS analysis of the fractions collected from cells 2-7 was 
performed. An averaged peak area, calculated from the peak areas of the individual compounds, 
was used to plot diffusion over time in order to assess the replicates. A large degree of variation in 
absorption time and peak area was observed between replicates (Fig 2A-F). Replicates 2, 3, 4 and 7 
(Fig. 2A-C&F) presented fairly similar plots, whereas replicates 5 and 6 (Fig. 2D&E) displayed 
substantially lower peak areas at corresponding time points for the 24 h period. Consequently, as 
replicates 5 and 6 were considered outliers, and their data were excluded from our more detailed 
analysis of polyphenol diffusion across the small intestine. Comparing the average peak area-time 
plots of the replicates, pre- and post-exclusion, showed similar trends, with slightly higher values 
post-exclusion of replicates 5 and 6 (Fig. 2G&H). 























































































































































































































































Figure 2 Evaluation of inter-replicate variability on the diffusion of all SM6Met polyphenols across 
porcine small intestine. The permeability assay was performed at 37°C over 24 h, using a flow-through 
diffusion system [22] with fractions collected at 2 h intervals. Fractions were analysed using LC-MS/MS to 
determine the presence and quantity of polyphenols originating from SM6Met. Graphs A-F represent the 
individual replicates obtained from the assay, with the average peak area for all compounds plotted over 
time: A) Replicate two; B) replicate three; C) replicate four; D) replicate five; E) replicate six; F) replicate 
seven. Graphs G and H represent the average of data shown in graphs A-F and graphs A-C; F (data of 
replicates five and six excluded), respectively. 




4.3.2.2 Analysis of diffusion of individual polyphenols originating from SM6Met across 
porcine small intestine 
As the peak area of a compound at a specific time takes into account only the amount of a 
polyphenol that has crossed over the mucosa during the preceding 2 h interval (Fig 1B), it does not 
reflect the total amount of polyphenol that has diffused through the mucosa up to that time point. 
Consequently, we decided to display our data in a manner that would reflect the cumulative 
diffusion of a specific polyphenol over time (Fig. S4-8). However, as previous studies have shown 
that absorption or diffusion of compounds are concentration driven [44-46], the initial concentration 
of each polyphenol in the SM6Met extract was taken into account by calculating the % of 
polyphenol that diffused across the intestinal lining (Fig. 3-7) 
The cumulative peak area for the xanthones, mangiferin and isomangiferin, that diffused over 24 h 
(Fig. 3A, Fig. S4) in relation to their peak areas for the SM6Met solution in the donor chamber at t 
= 0, indicates a concentration dependent diffusion for the xanthones in this model. Slightly better 
diffusion was observed for mangiferin that isomangiferin with 7.6 ± 2.5 % of the initial amount of 
mangiferin (Fig. 3B&C) moving across the porcine intestine, compared to 6.5 ± 2.2 % for 
isomangiferin (Fig. 3D&E).  
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Figure 3 Diffusion analysis of the xanthones originating from SM6Met via porcine small intestine. The 
permeability assay was performed at 37°C, over 24 h, using a flow-through diffusion system [22] with 
fractions collected at 2 h intervals. Fractions were analysed using LC-MS/MS to determine the presence of 
polyphenols originating from SM6Met. A) Peak area values displayed in red for the individual polyphenols 
as present in SM6Met, and cumulative peak areas displayed in blue, portraying the amount of the 
polyphenols that permeated the small intestine over 24 h. Graphs B-E represent the cumulative peak area as a 
percentage of the polyphenol peak area in SM6Met at t = 0; B) individual replicate percentage diffusion of 
mangiferin; C) average replicate percentage diffusion of mangiferin; D) individual replicate percentage 
diffusion of isomangiferin; E) average replicate percentage diffusion of isomangiferin.  
For the flavanones, the only two polyphenols crossing the small intestine in relatively high amounts 
were eriocitrin and hesperidin (Fig 4A, Fig. S5), however, this might again be due to a 
concentration dependent diffusion effect as the flavanones present at lower concentrations in the 
starting mixture diffused across the small intestine in lowered amounts. Thus, only 3.4 ± 1.8 %-4.1 




±1.0 % of the initial (S) and (R)-eriodictyol-di-C-hexoside and naringenin-O-dihexoside in SM6Met 
diffused across the porcine small intestine (Fig 4B-G). In contrast, 6.9 ± 2.3 %-11.7 ± 3.9 % of the 
initial amount of hesperidin and eriocitrin diffused across the small intestine by 24 h (Fig. 4H-K), 
while 1.5 ± 0.9 %-2.0 ± 1.0 % of the initial eriodictyol-O-glucoside and naringenin-di-C-hexoside 
diffused (Fig. 4L-O). These results suggest that when considering starting concentrations, the 
flavanones present in SM6Met diffuse across the porcine small intestine in the following order of 
increasing preferential diffusion: eriodictyol-O-glucoside, naringenin-di-C-hexoside, naringenin-O-
dihexoside, (S) and (R)-eriodictyol-di-C-hexoside, eriocitrin, and hesperidin. 
When considering the individual diffusion profiles of the compounds for each replicate, some trends 
were evident. The two major flavanones, hesperidin and eriocitrin, displaying the highest 
percentage diffusion, had similar diffusion profiles (Fig. 4H&J). A similar trend was also observed 
for the two polyphenols with the lowest percentage diffusion (Fig. 4L&N). In addition naringenin-
di-C-hexoside showed similar replicate profiles to that of naringenin-O-dihexoside (Fig. 4F&N), 
whereas (S)- and (R)-eriodictyol-di-C-hexosides displayed similar profiles (Fig. 4B&D). 
Furthermore, the replicate profiles of the latter compounds were also similar to that of hesperidin 
and eriocitrin (Fig. 4B, D, H&J). These results suggest that the primary polyphenol structure rather 
than the sugar moiety or the position of the sugar moiety determined the absorption profile. 
Hesperetin, the aglycone of hesperidin, is similar in structure to eriodictyol, except for the 
methylated C3'-OH. 
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Figure 4 Diffusion analysis of the flavanones originating from SM6Met via porcine small intestine by 
means of comparing accumulated polyphenol small intestinal cross-over relative to its starting 
concentration. The permeability assay was performed at 37°C, over 24 h, using the flow-through diffusion 
system [22], with fractions collected at 2 h intervals. Fractions were analysed using LC-MS/MS to determine 
the presence of polyphenols originating from SM6Met. A) Peak area values displayed in red for the 
individual polyphenols as present in SM6Met, and cumulative peak areas displayed in blue, portraying the 
amount of the polyphenols that permeated the small intestine over 24 h.; Graphs B-O represent the 
cumulative peak area as a percentage of the polyphenol peak area in SM6Met at t = 0; B) individual replicate 
contribution of (S)-eriodictyol-di-C-hexoside; C) average replicate contribution of (S)-eriodictyol-di-C-
hexoside; D) individual replicate contribution of (R)-eriodictyol-di-C-hexoside; E) average replicate 
contribution of (R)-eriodictyol-di-C-hexoside; F) individual replicate contribution of naringenin-O-
dihexoside; G) average replicate contribution of naringenin-O-dihexoside; H) individual replicate 
contribution of hesperidin; I) average replicate contribution of hesperidin; J) individual replicate contribution 
of eriocitrin; K) average replicate contribution of eriocitrin; L) individual replicate contribution of 
eriodictyol-O-glucoside; M) average replicate contribution of eriodictyol-O-glucoside; N) individual 
replicate contribution of naringenin-di-C-hexoside; O) average replicate contribution of naringenin-di-C-
hexoside  




Considering the flavones, scolymoside and apigenin-6,8-di-C-glucoside were present in the highest 
amount in the starting mixture, SM6Met (Fig. 5A, Fig. S6), and they also showed also the highest 
diffusion levels across the small intestine after 24 h. Taking into account the initial concentration in 
the donor chamber, most of the flavones displayed a relatively low diffusion after 24 h, with 
percentages ranging from 1.6 ± 0.9% to 2.4 ± 0.8% for apigenin-O-rutinoside/neohesperidoside, 
chrysoeriol-O-rutinoside/neohesperidoside, luteolin-O-hexoside and apigenin-6,8-di-C-glucoside 
(Fig. 5C, G, I&K). In contrast, 11.5 ± 3.9% of the initial concentration of scolymoside diffused 
across the porcine small intestine within 24 h (Fig. 5E). 
Analysis of variability introduced by each replicate revealed that scolymoside and apigenin-6,8-di-
C-glucoside shared a similar replicate diffusion profile (Fig. 5D&J), whereas apigenin-O-
rutinoside/neohesperidoside and chrysoeriol-O-rutinoside/neohesperidoside shared a similar profile 
(Fig. 5B&F). Luteolin-O-hexoside was the only flavone where only 2 out of the 4 replicates 
displayed diffusion across the porcine small intestinal mucosa (Fig. 5H). 
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Figure 5 Diffusion analysis of the flavones originating from SM6Met via porcine small intestine by 
means of comparing accumulated polyphenol small intestinal cross-over relative to its starting 
concentration. The permeability assay was performed at 37°C, over 24 h, using the flow-through diffusion 
system [22], with fractions collected at 2 h intervals. Fractions were analysed using LC-MS/MS to determine 
the presence of polyphenols originating from SM6Met. A) Peak area values displayed in red for the 
individual polyphenols as present in SM6Met, and cumulative peak areas displayed in blue, portraying the 
amount of the polyphenols that permeated the small intestine over 24 h.; Graphs B-K represent the 
cumulative peak area as a percentage of the polyphenol peak area in SM6Met at t = 0; B) individual replicate 
contribution of apigenin-O-rutinoside; C) average replicate contribution of apigenin-O-rutinoside; D) 
individual replicate contribution of scolymoside; E) average replicate contribution of scolymoside; F) 
individual replicate contribution of chrysoeriol-O-rutinoside; G) average replicate contribution of 
chrysoeriol-O-rutinoside; H) individual replicate contribution of luteolin-O-hexoside; I) average replicate 
contribution of luteolin-O-hexoside; J) individual replicate contribution of apigenin-6,8-di-C-glucoside; K) 
average replicate contribution of apigenin-6,8-di-C-glucoside. 
 
Investigation of the dihydrochalcones and benzophenones also revealed concentration dependent 
diffusion over the porcine small intestine (Fig. 6A & 7A, Fig. S7&8). The percentage of diffusion 
ranged between 7.1 ± 3.0% for iriflophenone-di-O,C-hexoside and 12.7 % ± 4.1% for phloretin-
3',5'-di-C-β-glucoside (Fig 6C,E & Fig.7C&E). 
A similar replicate diffusion profile was evident for the benzophenones and dihydrochalcones (Fig. 
6B, D & Fig. 7B), with the exception of iriflophenone-di-O,C-hexoside (Fig. 7D). In the latter case 
replicate two displayed substantially higher percentage diffusion than replicates 3, 4 and 7. 
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Figure 6 Diffusion analysis of the dihydrochalcones originating from SM6Met via porcine small 
intestine by means of comparing accumulated polyphenol small intestinal cross-over relative to its 
starting concentration. The permeability assay was performed at 37°C, over 24 h, using the flow-through 
diffusion system [16], with fractions collected at 2 h intervals. Fractions were analysed using LC-MS/MS to 
determine the presence of polyphenols originating from SM6Met. A) Peak area values displayed in red for 
the individual polyphenols as present in SM6Met, and cumulative peak areas displayed in blue, portraying 
the amount of the polyphenols that permeated the small intestine over 24 h.; Graphs B-E represent the 
cumulative peak area as a percentage of the polyphenol peak area in SM6Met at t = 0; B) individual replicate 
contribution to phloretin-3',5'-di-C-glucoside; C) average replicate contribution of phloretin-3',5'-di-C-
glucoside; D) replicate contribution of 3-hydroxyphloretin-3',5'-di-C-hexoside; E) average replicate 
contribution of 3-hydroxyphloretin-3',5'-di-C-hexoside. 
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Figure 7 Diffusion analysis of the benzophenones originating from SM6Met via porcine small intestine 
by means of comparing accumulated polyphenol small intestinal cross-over relative to its starting 
concentration. The permeability assay was performed at 37°C, over 24 h, using the flow-through diffusion 
system [16], with fractions collected at 2 h intervals. Fractions were analysed using LC-MS/MS to determine 
the presence of polyphenols originating from SM6Met. A) Peak area values displayed in red for the 
individual polyphenols as present in SM6Met, and cumulative peak areas displayed in blue, portraying the 
amount of the polyphenols that permeated the small intestine over 24 h.; Graphs B-E represent the 
cumulative peak area as a percentage of the polyphenol peak area in SM6Met at t = 0; B) individual replicate 
contribution of iriflophenone-di-O,C-hexoside; C) average replicate contribution of iriflophenone-di-O,C-
hexoside; D) individual replicate contribution of iriflophenone-3-C-glucoside; E) average replicate 
contribution of iriflophenone-3-C-glucoside.  
In conclusion, even though large variability was observed between the individual replicates within 
the single experiment, it was possible to categorize the polyphenol compound classes present in 




SM6Met in terms of their degree of diffusion across the porcine small intestinal mucosa. The 
dihydrochalcones displayed the highest average percentage of intestinal cross-over with 10.1 ± 3.2 
%, followed by the benzophenones with 8.0 ± 2.9 %, the xanthones with 7.1 ± 2.4 % and the 
flavanones with 4.8 ± 1.7 %. The lowest percentage of diffusion was displayed by the flavones with 
3.9 ± 1.6 %. The only polyphenols that were outliers within their respective groups were the 
flavanone, hesperidin (11.7 ± 3.9 %) and the flavone, scolymoside (11.5 ± 3.9 %).  
4.3.3 Calculating select SM6Met polyphenol Papp values 
The apparent permeability coefficients (Papp), which considers both the flux (J) and the initial 
concentration values (Co in mg/mL), were calculated using the formula Papp=J/Co [22]. As we had 
previously (Chapter 3) determined the concentration of the polyphenols present in SM6Met using 
qHPLC (Table 1), we could quantify the intestinal cross-over concentration of these polyphenols. 
The concentrations of only some of the polyphenols in the positive control could be determined, and 
as such, the J and Papp values could only be calculated for these polyphenols.  
Calculated Papp values, post-exclusion of replicates five and six, for the xanthones, mangiferin and 
isomangiferin, were 2.23 x 10
-6
 and 1.91 x10
-6
 cm/s, respectively; for the flavanones, eriocitrin and 
hesperidin, the values were 2.03 x 10
-6
 and 3.46 x 10
-6
 cm/s, respectively, whereas for the flavone, 
scolymoside, and the dihydrochalcones, phloretin-3',5'-di-C-glucoside and 3-hydroxyphloretin-3',5'-
di-C-hexoside, the values were 3.39 x 10
-6
, 3.7 x 10
-6
 and 2.2 x 10
-6
 cm/s, respectively (Table 1). 
The benzophenone, iriflophenone-3-C-glucoside displayed a Papp value of 2.64 (Table 1). Even 
though the trend of polyphenol Papp values stayed similar prior to (Table S2) and after exclusion 
(Table 1 & Table S2) of replicates five and six, an overall increase in values (Table 1) ranging from 
38.22-44.26 % was observed when replicates five and six were excluded. 
 




Table 1. Calculated flux and Papp values from quantified SM6Met polyphenols  













Xanthone Mangiferin 1.899 4.634 2.317 7.56 6.21 2.23 
 Isomangiferin 0.645 1.574 0.787 6.47 1.80 1.91 
        
Flavanone Eriocitrin (eriodictyol-
7-O-rutinoside) 
0.846 2.064 1.032 6.86 2.51 2.03 
 Hesperidin (hesperetin-
7-O-rutinoside) 
2.049 5.000 2.500 11.73 10.38 3.46 
        
Flavone Scolymoside (luteolin-
7-O-rutinoside) 
1.289 3.150 1.573 11.48 6.40 3.39 
        
Dihydrochalcone Phloretin-3',5'-di-C-
glucoside 
1.278 3.118 1.560 12.68 7.01 3.74 
 3-Hydroxyphloretin-
3',5'-di-C-hexoside 
0.700 1.708 0.854 7.48 2.26 2.21 
        
Benzophenone Iriflophenone-3-C-
glucoside 
0.669 1.632 0.817 8.93 2.58 2.64 
a
 refers to cumulated polyphenol peak area at 24 h relative to its peak area in the positive control  
b





















1.899g/100g was the concentration of mangiferin present in SM6Met 
7.56 % was the cumulated peak area of mangiferin at 24 h relative to its peak area in the positive control  
0.122 g was the amount of SM6Met loaded onto each replicate 
1440 min = 24 h x 60 min  
A = 0.196 cm
2 











Calculation of Q and Co was performed as described in section 4.2.6 
Co is represented in mg/mL 
Q is represented as x 10
6
 ng 
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There is currently no literature data available on the Papp values of these polyphenols regarding 
movement across intestinal mucosa. A general rule of thumb states that compounds with a Papp 
value larger than 2 x 10
-6
 cm/s are generally considered as being well absorbed in the human body 
[47]. In addition, other studies have indicated that compounds with Papp values higher than 1 x 10
-6
 
cm/s display 100% absorption in the human body [48]. Interestingly, all of the polyphenols 
investigated, with the exception of isomangiferin (1.91 x 10
-6
 cm/s), displayed Papp values larger 
than 2 x 10
-6
 cm/s (Table 1), indicative of the fact that all of these polyphenols may be well 
absorbed in the human body. 
4.3.4 Physicochemical properties of select SM6Met polyphenols 
Comparing the physicochemical properties of SM6Met polyphenols (Table 2) with available 
literature allowed us to determine whether the investigated polyphenols would be fit for drug 
development as a possible phytoestrogenic nutraceutical. Specifically, we were interested in 
properties that would predict the extent of absorption in the human body. We were unable to obtain 
data for several of the polyphenols ((S)-eriodictyol-di-C-hexoside, (R)-eriodictyol-di-C-hexoside, 
naringenin-di-C-hexoside, luteolin-O-hexoside and iriflophenone-di-O,C-hexoside) investigated in 
the present absorption study. The OSIRIS program [25] was used to calculate polyphenol octanol-
water partitioning coefficients (cLogP), solubility coefficients, ‗drug-likeness‘ and overall drug-
score, whereas the ACD/Labs software program [26] was used to calculate the molecular weight 
(MW), HBA, HBD, number of Lipinski‘s ―Rule-of-5‖ violations (VI), rotating bonds (RB) and 
PSA. In addition to using the OSIRIS program, cLogP values were also calculated with the 
ACD/Labs and ChemAxon software programs [26] for comparison as values could differ between 
programs. 
The cLogP value is accepted in drug design as a reliable measure of the hydrophilicity of a 
compound, where low hydrophilicity [49] corresponds to a high cLogP value. It is well known that 
compounds with a cLogP value greater than five are poorly absorbed in the human body [50]. Even 




though large variation was observed between programs for the calculation of cLogP values, all 
SM6Met polyphenols displayed cLogP values lower than five, irrespective of software program 
used (Table 2). Values calculated with OSIRIS ranged from -3.12 for 3-hydroxyphloretin-3',5'-di-C-
hexoside to 2.4 for luteolin. ACD/Labs values ranged from –2.57 for apigenin-6,8-di-C-glucoside to 
2.4 for luteolin, and the ChemAxon values ranged from -2.81 for apigenin-6,8-di-C-glucoside to 2.4 
for luteolin, thus indicating that all will be absorbed with relative ease in the human body when 
considering cLogP [50]. 
Solubility was another factor of concern as we know that higher solubility is correlated with 
increased Papp [9] and thus absorption. In addition, as indicated by the OSIRIS program, over 80 % 
of commercially available drugs have a calculated log S (solubility coefficient) value greater than -
4. Again, this was evident for all of the compounds investigated (Table 2), with values ranging from 
-3.97 for isomangiferin to -1.04 for protocatechuic acid, again predicting good absorbance of all 
SM6Met polyphenols in the human body. 
Compound drug-likeness is an indication of whether a compound has physical properties frequently 
present in commercial drugs, however this is irrespective of its lipophilicity [25]. About 80 % of 
commercially available drugs have a positive drug-likeness value, and it is thus suggested that a 
positive drug-likeness value is ideal [25]. The only polyphenols from SM6Met that exhibited 
negative drug-likeness values were the xanthones, mangiferin and isomangiferin, the flavanones 
eriodictyol-O-glucoside, the flavone, apigenin-6,8-di-C-glucoside, the dihydrochalcones, 3-
hydroxyphloretin-3',5'-di-C-hexoside) and phloretin-3',5'-di-C-β-glucoside, the benzophenone, 
iriflophenone-3-C-glucoside and the phenolic acid, protocatechuic acid (Table 2). The majority of 
the polyphenols in SM6Met therefore exhibited the desired degree of druglikeness. 
 The overall drug-likeness score considers cLogP, logS, molecular weight and toxicity risks in one 
value that may be used to judge the overall potential of a compound to qualify for a drug [25]. 
Overall drug-likeness score values obtained for the SM6Met polyphenols were relatively low to 




moderate with values ranging from 22 to 42 % for the xanthones, 44-59 % for the flavanones, 13-34 
% for the flavones, 38-43 % for the phenolic acids, 32-34 % for the dihydrochalcones, and 21-22 % 
for the flavanols (Table 2). These low to moderate values may be attributed to the fact that some 
polyphenols did not exhibit drug-likeness characteristics as evidenced by a negative drug-likeness 
score. In addition, some polyphenols display moderate to severe toxicity risks which comprises of 
tumorigenic (luteolin, quercetin-O-rutinoside, and quercetin-O-neohesperidoside (moderate)), 
irritant (isomangiferin (severe)), mutagenic (protocatechuic acid (severe), p-coumaric acid 
(moderate), scolymoside (severe), luteolin (severe), quercetin-O-rutinoside (severe), chrysoeriol-O-
rutinoside (severe), apigenin-6,8-di-C-glucoside (severe), quercetin-O-neohesperidoside (severe), 
chrysoeriol-O- neohesperidoside (severe), apigenin-O- neohesperidoside (severe)) and reproductive 
affecting risks (p-coumaric acid (severe), luteolin (moderate), quercetin-O-rutinoside (moderate), 
apigenin-6,8-di-C-glucoside (severe), quercetin-O-neohesperidoside (moderate), apigenin-O-
rutinoside (severe), apigenin-O-neohesperidoside (severe)) (Table 3) [25]. 
The ACD/Labs program uses the number of Lipinski‘s ―Rule-of-5‖ violations [50] as a measure of 
the absorption potential and drug-likeness of the compound of interest. Literature suggests that if a 
compound violates more than 1 of the rules it will display poor absorption in the human body [50]. 
For any of the ―Rule-of-5‖ to be violated, the compound must display either a molecular weight 
greater than 500 g/mol, a cLogP value more than five, number of HBD more than 5, and number of 
HBA more than 10. In addition, if the PSA is greater than 140 Å
2
 and the number of RB is more 
than ten, the compound is likely to display poor absorption, unless these compounds are actively 
transported [7,8]. In the case of the xanthones, mangiferin and isomangiferin, two of the ―Rule-of-
5‖ parameters are violated (Table 2), namely the number of HBA and HBD, indicating poor 
absorption. In addition, the PSA for both compounds is above 140Å
2
. For the investigated 
flavanones, the number of parameter violations ranged from 2 for eriodictyol-O-glucoside to 3 for 
eriocitrin and hesperidin. The cut-off for the number of HBD and acceptors are exceeded in all 
cases, and in addition, the molecular weight cut-off is exceeded by eriocitrin and hesperidin. 




Furthermore, poor absorption for all three compounds is indicated, based on their PSA exceeding 
140 Å
2
, and the number of RB exceeding 10 (Table 2). All of the flavones, with the exception of 
luteolin, display three parameter violations of the ―Rule-of-5‖, i.e. molecular weight, and number of 
HBD and HBA. Their PSA and number of RB also exceed the recommended value for good 
absorption. Luteolin is the only flavone that passes the ―Rule-of-5‖ and stays within the limits for 
PSA and number of RB.  
Data available for the flavonol quercetin-O-rutinoside/neohesperidoside and the phenolic acid, 
protocatechuic acid, indicate poor absorption as both violated 3 Lipinski ―Rule-of-5‖ parameters. 
Additionally the flavonol, but not the phenolic acid, exceeds the limits for PSA and number of RB 
(Table 2). 
Table 3. Toxicity risks of polyphenols as indicated by the OSIRIS program [25] 
Polyphenol description Toxicity Risks 
 Irritant Mutagenic Tumorigenic Reproductive affecting 
Luteolin  S M M 
Quercetin-O-rutinoside  S M M 
Queretin-O-neohesperidoside  S M M 
Isomangiferin S    
Protocatechuic acid  S   
p-Coumaric acid  M  S 
Scolymoside (luteolin-7-O-rutinoside)  S   
Chrysoeriol-O-rutinoside  S   
Chrysoeriol-O-neohesperidoside  S   
Apigenin-6,8 di-C-glucoside  S  S 
Apigenin-O-neohesperidoside  S  S 
Apigenin-O-rutinoside    S 
M refers to moderate  
S refers to severe 
Compounds not allocated a toxicity risk rating as for certain compounds above did not display toxicity risks. 
As there is uncertainty about whether the sugar moeity for apigenin-O-rutinoside/neohesperidoside and 
chrysoeriol-O-rutinoside/neohesperidoside compounds were investigated all the aglycones containing either 
sugar moeities were investigated separately. 
 


































A: Mangiferin 0.11 -2.57 -4.28 0.42 422.3 11 8 0.13±1.29 2 10 197.37 -0.36 
Isomangiferin 1.22 -3.97 -4.37 0.22 422.3 11 8 0.223 2 10 197.37 -0.36 
B: Eriodictyol-O-glucoside 0.09 -2.23 -2.21 0.44 450.4 11 7 0.22±0.83 2 11 186.37 0.26 
Eriocitrin (eriodictyol-7-O-
rutinoside)  
-0.8 -2.44 3.26 0.59 596.5 15 10 2.089 3 16 256.29 -0.64 
Naringenin-O-dihexoside             
Hesperidin (hesperetin-7-O-
rutinoside)  
0.02 -3.21 3.65 0.55 610.6 15 8 1.78±0.72 3 15 234.29 -0.31 
C: Apigenin-6,8-di-C-glucoside 
(vicenin-2) 
-2.57 -1.68 -1.26 0.13 594.5 15 11 -0.10±0.94 3 16 267.29 -2.81 
Scolymoside (luteolin-7-O-
rutinoside)  
-0.61 -2.65 2.41 0.34 594.5 15 9 2.02±0.85 3 15 245.29 -0.94 
Apigenin-7-O-rutinoside
# 
-0.31 -2.95 3.18 0.21 578.5 14 8 1.055 3 14 225.06 -0.29 
Apigenin-O-neohesperidoside
# 
-0.31 -2.95 1.94 0.2 578.5 14 8 1.72±0.82 3 14 225.06 -0.29 
Chrysoeriol-O-rutinoside
#
 -0.42 -2.97 1.64 0.31 NA NA NA NA NA NA NA NA 
Chrysoeriol-O-
neohesperidoside
# -0.42 -2.97 2.21 0.33 NA NA NA NA NA NA NA NA 
Luteolin 2.4 -2.56 1.9 0.32 286.2 6 4 2.40±0.65 0 5 107.22 2.40 
D: Iriflophenone-3-C-glucoside -0.58 -1.95 -1.7 0.49 NA NA NA NA NA NA NA NA 
E: 3-Hydroxyphloretin-3',5'-di-C-
hexoside 
-3.12 -1.05 -1.89 0.34 NA NA NA NA NA NA NA NA 
Phloretin-3', 5'-di-C-glucoside -2.82 -1.35 -2.27 0.32 NA NA NA NA NA NA NA NA 
F: Quercetin-O-rutinoside
# 
-0.95 -2.4 3.31 0.22 610.5 16 10 1.76±1.48 3 16 265.52 -0.87 
Quercetin-O-
neohesperidoside
# -0.95 -2.4 2.06 0.21 610.5 16 10 -0.356 3 16 155.52 -0.87 
G: p-Coumaric acid 1.33 -1.7 0.58 0.38 NA NA NA NA NA NA NA NA 
Protocatechuic acid 0.9 -1.04 -0.12 0.43 154.1 4 3 1.16±0.24 0 3 77.76 1.02 
A refers to the xanthones compound class 
B refers to the flavanones compound class 
C refers to the flavones compound class 
D refers to the benzophenone compound class 
E refers to the dihydrochalcone compound class 
F refers to the flavanol compound class 
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G refers to the polyphenolic acid compound class 
a
 CH refers to the ChemAxon open source software program used 
b 
CLP refers to cLogP  
c
 SOL refers to the solubility coefficient in percentage  
d
 DL refers to the drug-likeness score 
e 
DS refers to the overall drug score 
f




HBA refers to the number of hydrogen bond acceptors 
h 
HBD refers to the number of hydrogen bond donors
 
i 
VI refers to the number of Lipinski rule violations
 
j 
RB refers to the number of rotating bonds
 
k 
PSA refers the polar surface area in Å
2 
#
 refers to the uncertainty of which sugar moiety belongs to the aglycone 
NA refers to the absence of polyphenol information from the source program 
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In conclusion, the OSIRIS program indicated that all of the investigated polyphenols would display 
relatively high permeability, as indicated by cLogP values < 5, and also high solubility (directly 
proportional to high permeability), as indicated by solubility coefficient values > -4, accompanied 
by the fact that most of the polyphenols displayed a positive druglikeness value. However, the 
toxicity risks of these compounds as well as the negative druglikeness of some polyphenols resulted 
in a lower overall druglikeness score for most polyphenols. Only two compounds, namely eriocitrin 
and hesperidin displayed an overall drug score above 50%. In contrast the ACD/labs program 
indicated that all of the polyphenols investigated, with the exception of luteolin, would display poor 
absorption in the human body due to the fact that these compounds exceeded the allowed Lipinski 
―Rule-of-5‖ violation limit of 1. 
4.4 Discussion 
As phytoestrogenic nutraceuticals are seen as a safer alternative to traditional HRT for women in 
menopause [51-57] this has become a topic of interest in recent years. Even though Cyclopia 
species have shown potential for the development of a phytoestrogenic nutraceutical [10,11], a 
more recent study identified a specific Cyclopia subternata sequential methanol extract, SM6Met, 
as displaying the highest potency of tested Cyclopia extracts in terms of phytoestrogenic properties 
[12]. In addition, SM6Met displayed the positive estrogenic attributes of ERα antagonism, ERβ 
agonism and antagonism of E2-induced breast cancer cell proliferation [13]. In the current study we 
evaluated the permeability of porcine small and large intestine for SM6Met polyphenols using the 
flow-through diffusion assay. This would assist in the search for polyphenols that may be absorbed 
through the human intestinal lining post oral intake and would be crucial for the development of a 
future oral phytoestrogenic nutraceutical containing select polyphenols originating from the 
SM6Met extract. 
The most common in vitro assay evaluating intestinal permeability is performed using Caco-2 cells 
[58-61], which are adenocarcinoma cells derived from the colon, although some in situ perfusion 




studies have been performed using rat intestines [62,63] and studies using oral administration in 
rats, pigs and rabbits [14,15,17,18,29,30,38-40,64]. We, however, made use of the flow-through 
diffusion assay, which has also been used for several absorption studies [23,65,66], albeit not for 
polyphenolic compounds such as investigated in the present study. Thus we for the first time 
evaluated the permeability of these two porcine tissue types a using the flow-through diffusion 
assay for polyphenols originating from SM6Met at concentrations present in the extract. The pig is 
regarded as an excellent model for human absorption due to its physiology being more similar to 
those of humans than any other non-primate mammalian models [67]. 
Even though previous studies have been performed on the absorption of some of the xanthones, 
flavanones, flavones, dihydrochalcones and benzophenones present in SM6Met, these studies had a 
more holistic approach as they considered not only intestinal absorption but also metabolism of 
these polyphenols in a more complex mice, rat or pig in vivo system [14,15,17,18,29,30,36,38-
40,64]. In most of these studies the polyphenols that were orally administered were not detected in 
the blood plasma or urine, however, metabolites or conjugates of these polyphenols were present, 
which is indicative of absorption [14,15,17,18]. In some cases, mostly studies in rats, intact 
molecules not affected by hepatic metabolism or intestinal degradation were found in the plasma 
[17,18,38-40]. In our study we showed that even though we did not detect absorption of 
polyphenols from porcine large intestine, we detected all of the SM6Met polyphenols, with the 
exception of luteolin and quercitin rutinoside/neohesperidoside, in fractions collected from the 
small porcine intestine experiment. We postulate that the reason permeation of polyphenols through 
the large intestine was not observed may be due to the fact that in an in vivo system the large 
intestine polyphenols are hydrolysed by intestinal microflora yielding small polyphenolic acids 
followed by circulatory absorption, and as the microflora is not present in the ex vivo flow-through 
diffusion assay, the unmodified polyphenols might not physically be able to permeate the large 
intestinal barrier. For the small intestine experiment, results obtained suggest that during the 24 h 
period an average of 7.1 % of the xanthones found in the SM6Met extract moved across the porcine 




small intestine, while for the flavanones and flavones this was 4.8 % and 3.1 %, respectively, and 
for the dihydrochalcones and benzophenones it was 10.1 % and 8.0 %, respectively. As all of the 
above mentioned compounds are glycosides, with the exception of luteolin, it is important to note 
that in an in vivo system C-glycosides are less frequently hydrolysed by intestinal glucosidases than 
O-glycosides [20], whereas a compound with a rutinoside moiety is commonly not hydrolysed in 
the small intestine, but by the colonic microflora, resulting in less optimal absorption of the 
aglycone as a whole due to partial polyphenol degradation [68]. In contrast, results obtained in the 
ex vivo flow-through diffusion assay indicated that compound classes with the highest permeation 
percentages were the classes with compounds containing C-glycosides, the dihydrochalcones, 
benzophenones and the xanthones. Furthermore, compounds with a rutinoside moeity did not 
generally exhibit lower permeation percentages.  
An important factor that has not been accounted for in the current study is the role of UDP-
glucuronosyltransferases (UGTs) in the absorption of polyphenols. These enzymes are mainly 
expressed in the liver and intestine, and they are responsible for compound glucoronidation [69,70]. 
It has been shown that glucoronidation of phenolic compounds, such as the polyphenols 
investigated in the current study, results not only in impaired absorption of these compounds 
[69,71], but also in some instances in the lowering of their biological activities [72]. Furthermore, 
UGTs has been shown to catalyze the glucuronidation of phenolic compounds in a species-, gender-
, organ-, and isoform-dependent manner [69]. The current absorption study did not incorporate 
detection parameters for glucoronidated polyphenol conjugates, and as such we did not investigate 
the effect of intestinal UDP-glucuronosyltransferases on the permeation of the relevant polyphenols. 
Most in vitro intestinal permeation studies previously performed on some of the polyphenols 
present in SM6Met used Caco-2 cells [41-43] as they resemble human small intestinal cells 
morphologically and functionally. Some disadvantages are, however, coupled with the use of this 
model which might alter intestinal performance. These disadvantages include the lack of cell 




heterogeneity, the lack of the mucus layer of the intestinal wall and the absence of expression of 
some intestinal enzymes and transporters [73,74]. Thus the use of excised porcine small intestine in 
the current in vitro model should overcome these limitations and enabled us to obtain Papp values for 
all major polyphenols and polyphenols of interest in the SM6Met extract. The Papp values we 




correlating with good absorption in the human body 
[47]. In contrast to the in vitro absorption study, evaluation of the physicochemical properties of the 
polyphenols in SM6Met using the ACD/Labs computational program predicted more than two 
Lipinski ―Rule-of-5‖ violations for all polyphenols investigated, except for luteolin, suggesting that 
these polyphenols would be poorly absorbed in the human body, whereas luteolin may be absorbed 
well. In addition, even though the OSIRIS and ChemAxon programs indicated good permeability 
(cLogP values < 5) coupled to high polyphenol solubility (log S > -4), the OSIRIS program 
predicted, considering most commercially available drugs as reference, a low to moderate overall 
drug score for all the investigated polyphenols. As predicted polyphenol physicochemical properties 
vary between programs, it is evident that one should enrol as many different programs as possible 
and compare the results obtained to physiologically more relevant models for a more accurate 
prediction of the absorption of a compound in the human body. 
Future work should investigate less complex extracts of SM6Met, as discussed in the previous 
chapter, which could include CCC-obtained F1, F2 and F3 where the investigated polyphenols are 
already linked to a specific estrogenic activity, as these permeation studies would serve as a 
preliminary qualification step for these compounds to form part of an intelligent mixture as an oral 
nutraceutical. In vivo studies after oral gavage of these less complex mixtures should also be 
performed for correlation of these results with a preliminary permeation study, as an in vivo study 
would not only investigate permeability but also metabolism of the polyphenols of interest. A recent 
in vivo study, completed with SM6Met (Appendix 1), indicated that SM6Met polyphenols were 
absorbed. Oral gavage administration of the extract resulted in a delay of rat vaginal opening, and 




also a decrease in uterus size in rats treated with the extract and E2, compared to uterus size of rats 
treated with E2 alone [13]  
In conclusion, even though not seen for the porcine large intestine, all of the polyphenols present in 
quantifiable concentrations in the SM6Met extract permeated through the porcine small intestine, 
demonstrating that no structural or physicochemical deterrent exists for these polyphenols to do so. 
This paves the way for future studies, where a more holistic approach could be taken by evaluating 
the absorption of these compounds in an in vivo animal model similar to that of the human system. 
As mentioned in the previous chapter, it seems unlikely that one compound could explain all of the 
positive estrogenic attributes of SM6Met. Furthermore, the concept of formulations consisting of 
intelligent mixtures of natural products to treat diseases has become a popular focus of recent 
studies [75-80]. Thus the formulation of an intelligent mixture from SM6Met is probably needed, 
where after this mixture would need to be evaluated for intestinal absorption. 
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1) Blank (distilled 
water (dH2O)) 
2) Replicate 2, 4 h 
3) Replicate 2, 10 h 
Chromatograms (2-19) of fractions 
obtained from the small intestine 
flow-through diffusion assay at 
21°C investigating SM6Met. 
Replicates 2 and 7 were analysed, 
using LC-MS/MS. 















































































4) Replicate 2, 12 h 
5) Replicate 2, 14 h 
6) Replicate 2, 16 h 
7) Replicate 2, 18 h 

































































































































8) Replicate 2, 20 h 
9) Replicate 2, 22 h 
10) Replicate 2, 24 h 
11) Replicate 5, 4 h 
























































































12) Replicate 5, 10 h 
13) Replicate 5, 12 h 
14) Replicate 5, 14 h 
15) Replicate 5, 16 h 



















































































16) Replicate 5, 18 h 
17) Replicate 5, 20 h 
18) Replicate 5, 22 h 
19) Replicate 5, 24 h 





Supplementary Figure 1. Chromatograms obtained from 21°C small intestine flow-through diffusion 
assay fractions LC-MS/MS analysis of fractions collected every two hours for 24 h for replicates two and 
five. Chromatograms 2-19 represent replicates two and five at the 12, 2 h time intervals for 24 h, represented 
as % base peak intensity over time. Chromatogram 1 represented the blank (distilled H2O) and 
chromatogram 20 the positive control (244 mg/mL, 10 x diluted) containing 9.1 mg/mL ascorbic acid. 
Supplementary Table 1. Polyphenols present in a postive control sample for the flow-through diffusion 






1 1.8 569 Iriflophenone-di-O, C-hexoside 
2 3.5 611 (S)-Eriodictyol-di-C-hexoside 
3 3.6 611 (R)-Eriodictyol-di-C-hexoside 
4 4.2 407 Iriflophenone-3-C-glucoside 
5 6.4 595 Naringenin-di-C-hexoside 
6 7.5 421 Mangiferin 
7 7.6 421 Isomangiferin 
8 9.0 593 Apigenin-6,8-di-C-glucoside (vicenin-2) 
9 10.0 449 Eriodictyol-O-glucoside 
10 12.2 613 3-Hydroxyphloretin-3',5'-di-C-hexoside 
11 12.9 595 Eriocitrin (eriodictyol-7-O-rutinoside ) 
12 13.6 593 Scolymoside (luteolin-7-O-rutinoside) 
13 14.3 597 Phloretin-3',5'-di-C-glucoside 
14 14.6 447 Luteolin-O-hexoside 
15 15.1 579 Naringenin-O-dihexoside 
16 15.4 577 Apigenin-O-rutinoside/neohesperidoside 
17 16.2 609 Hesperidin (hesperetin-7-O-rutinoside ) 
18 16.4 607 Chrysoeriol-O-rutinoside /neohesperidoside 
19 NA 609 Quercetin-O-rutinoside/neohesperidoside 
20 19.8 285 Luteolin 
NA refers to the fact that the compound could not be detected in this SM6Met positive control 
[M-H]
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MM_Bioc_130820_1 1: TOF MS ES- 
BPI
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2) Replicate 2, 2 h 
1) Blank dH2O 
3) Replicate 2, 4 h 
4) Replicate 2, 6 h 
5) Replicate 2, 8 h 
6) Replicate 2, 10 h 
Chromatograms (2-73) of fractions 
obtained from the small intestine flow-
through diffusion assay at 37°C 
investigating SM6Met. Replicate 1 leaked, 
thus replicates 2-7 were analysed, using 
LC-MS/MS 
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8) Replicate 2, 14 h 
7) Replicate 2, 12 h 
9) Replicate 2, 16 h 
10) Replicate 2, 18 h 
11) Replicate 2, 20 h 
12) Replicate 2, 22 h 
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13) Replicate 2, 24 h 
14) Replicate 3, 2 h 
15) Replicate 3, 4 h 
16) Replicate 3, 6h 
17) Replicate 3, 8h 









1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1





























































































































1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1





































































































































1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1

































































































































18) Replicate 3, 10h 
22) Replicate 3, 18h 
23) Replicate 3, 20h 
19) Replicate 3, 12h 
20) Replicate 3, 14h 
21) Replicate 3, 16h 
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24) Replicate 3, 22h 
27) Replicate 4, 4h 
28) Replicate 4, 6h 
25) Replicate 3, 24h 
26) Replicate 4, 2h 
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29) Replicate 4, 8h 
30) Replicate 4, 10h 
31) Replicate 4, 12h 
32) Replicate 4, 14h 
33) Replicate 4, 16h 
34) Replicate 4, 18h 
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35) Replicate 4, 20h 
36) Replicate 4, 22h 
37) Replicate 4, 24h 
38) Replicate 5, 2h 
39) Replicate 5, 4h 
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40) Replicate 5, 6h 
41) Replicate 5, 8h 
42) Replicate 5, 10h 
43) Replicate 5, 12h 
44) Replicate 5, 14h 
45) Replicate 5, 16h 
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46) Replicate 5, 18h 
47) Replicate 5, 20h 
48) Replicate 5, 22h 
49) Replicate 5, 24h 
50) Replicate 6, 2h 
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51) Replicate 6, 4h 
52) Replicate 6, 6h 
53) Replicate 6, 8h 
54) Replicate 6, 10h 
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55) Replicate 6, 12h 
56) Replicate 6, 14h 
57) Replicate 6, 16h 
58) Replicate 6, 18h 
59) Replicate 6, 20h 
60) Replicate 6, 22h 
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61) Replicate 6, 24h 
62) Replicate 7, 2h 
65) Replicate 7, 8h 
66) Replicate 7, 10h 
63) Replicate 7, 4h 
64) Replicate 7, 6h 
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67) Replicate 7, 12h 
71) Replicate 7, 20h 
72) Replicate 7, 22h 
68) Replicate 7, 14h 
69) Replicate 7, 16h 
70) Replicate 7, 18h 





Supplementary Figure 2. Chromatograms obtained from 37°C small intestine flow-through diffusion 
assay fractions LC-MS/MS analysis of fractions collected every two hours for 24 hours for replicates two 
and five. Chromatograms 2-73 represent replicates two to seven at the 12, 2 h time intervals for 24 h, 
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73) Replicate 7, 24h 
Blank dH2O 







Negative Control (PBS+ascorbic acid)
Time
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Positive control 10x diluted (SM6Met)
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Chromatograms (3-50) of fractions obtained from the 
large intestine flow-through diffusion assay at 37°C 
investigating SM6Met. Replicates 2, 5 and 7 leaked thus 
replicates 1, 3, 4 and 6 were analysed using LC-MS/MS. 
1) Blank (PBS + 9.1 mg/ml ascorbic acid)  
3) Replicate 1, 2h 
2) Positive control 10x diluted (24.4 
mg/mL SM6Met + 9.1 mg/mL ascorbic 
acid)  
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4) Replicate 1, 4h 
5) Replicate 1, 6h 
7) Replicate 1, 10h 
6) Replicate 1, 8h 
9) Replicate 1, 14h 
8) Replicate 1, 12h 
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11) Replicate 1, 18h 
10) Replicate 1, 16h 
13) Replicate 1, 22h 
12) Replicate 1, 20h 
15) Replicate 3, 2h 
14) Replicate 1, 24h 
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17) Replicate 3, 6h 
16) Replicate 3, 4h 
19) Replicate 3, 10h 
18) Replicate 3, 8h 
21) Replicate 3, 14h 
20) Replicate 3, 12h 
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23) Replicate 3, 18h 
22) Replicate 3, 16h 
25) Replicate 3, 22h 
24) Replicate 3, 20h 
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27) Replicate 4, 2h 
26) Replicate 3, 24h 
29) Replicate 4, 6h 
28) Replicate 4, 4h 
31) Replicate 4, 10h 
30) Replicate 4, 8h 
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33) Replicate 4, 14h 
32) Replicate 4, 12h 
35) Replicate 4, 18h 
34) Replicate 4, 16h 
37) Replicate 4, 22h 
36) Replicate 4, 20h 
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39) Replicate 6, 2h 
38) Replicate 4, 24h 
41) Replicate 6, 6h 
40) Replicate 6, 4h 
43) Replicate 6, 10h 
42) Replicate 6, 8h 
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45) Replicate 6, 14h 
44) Replicate 6, 12h 
47) Replicate 6, 18h 
46) Replicate 6, 16h 
49) Replicate 6, 22h 
48) Replicate 6, 20h 





Supplementary Figure 3. Chromatograms obtained from 37°C large intestine flow-through diffusion 
assay fractions LC-MS/MS analysis of fractions collected every two hours for 24 hours for replicates two 
and five. Chromatograms 3-50 represent replicates one, three, four and six at the 12 2 h time intervals for 24 
h, represented as % base peak intensity over time. Chromatogram 1 represented the blank (PBS with 9.1 
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50) Replicate 6, 24h 
Blank dH2O 








































































































































































Supplementary Figure 4 Diffusion analysis of the xanthones originating from SM6Met via porcine 
small intestine by means of comparing accumulated polyphenol small intestinal cross-over. The 
permeability assay was performed at 37°C, over 24 h, using the flow-through diffusion system [22], where 
after fractions were analysed using LC-MS/MS to determine the presence of polyphenols originating from 
SM6Met. A) individual replicate cumulative peak area of mangiferin; B) average replicate cumulative peak 
area of mangiferin; C) individual replicate cumulative peak area of isomangiferin; D) average replicate 
cumulative peak area of isomangiferin. Replicates five and six where excluded in all instances. 
  
































































































































































































































































































































































































































































































































































































Supplementary Figure 5 Diffusion analysis of the flavanones originating from SM6Met via porcine 
small intestine by means of comparing accumulated polyphenol small intestinal cross-over. The 
permeability assay was performed at 37°C, over 24 h, using the flow-through diffusion system [16], where 
after fractions were analysed using LC-MS/MS to determine the presence of polyphenols originating from 
SM6Met. A) individual replicate cumulative peak area of (S)-eriodictyol-di-C-hexoside; B) average replicate 
cumulative peak area of (S)-eriodictyol-di-C-hexoside; C) individual replicate cumulative peak area of (R)-
eriodictyol-di-C-hexoside; D) average replicate cumulative peak area of (R)-eriodictyol-di-C-hexoside; E) 
individual replicate cumulative peak area of naringenin-O-dihexoside; F) average replicate cumulative peak 
area of to naringenin-O-dihexoside; G) individual replicate cumulative peak area of naringenin-di-C-
hexoside; H) average replicate cumulative peak area of naringenin-di-C-hexoside; I) individual replicate 
cumulative peak area of hesperidin; J) average replicate cumulative peak area of hesperidin; K) individual 
replicate cumulative peak area of eriocitrin; L) average replicate cumulative peak area of eriocitrin; M) 
individual replicate cumulative peak area of eriodictyol-O-glucoside; N) average replicate cumulative peak 
area of eriodictyol-O-glucoside diffusion across the small intestine over time. Replicates five and six where 
excluded in all instances. 

























































































































































































































































































































































































































Supplementary Figure 6 Diffusion analysis of the flavones originating from SM6Met via porcine small 
intestine by means of comparing accumulated polyphenol small intestinal cross-over. The permeability 
assay was performed at 37°C, over 24 h, using the flow-through diffusion system [16], where after fractions 
were analysed using LC-MS/MS to determine the presence of polyphenols originating from SM6Met. A) 
individual replicate cumulative peak area of apigenin-O-rutinoside; B) average replicate cumulative peak 
area of apigenin-O-rutinoside; C) individual replicate cumulative peak area of scolymoside; D) average 
replicate cumulative peak area of scolymoside; E) individual replicate cumulative peak area of chrysoeriol-
O-rutinoside; F) average replicate cumulative peak area of chrysoeriol-O-rutinoside; G) individual replicate 
cumulative peak area of luteolin-O-hexoside; H) average replicate cumulative peak area of luteolin-O-
hexoside; I) individual replicate cumulative peak area of apigenin-6,8 di-C-glucoside; J) average replicate 
cumulative peak area of apigenin-6,8 di-C-glucoside. Replicates five and six where excluded in all instances. 









































































































































































Supplementary Figure 7 Diffusion analysis of the dihydrochalcones originating from SM6Met via 
porcine small intestine by means of comparing accumulated polyphenol small intestinal cross-over 
relative to its starting concentration. The permeability assay was performed at 37°C, over 24 h, using the 
flow-through diffusion system [16], where after fractions were analysed using LC-MS/MS to determine the 
presence of polyphenols originating from SM6Met. A) individual replicate cumulative peak area of 
phloretin-3',5'-di-C-glucoside; B) average replicate cumulative peak area of phloretin-3',5'-di-C-glucoside; 
C) ) individual replicate cumulative peak area of 3-hydroxyphloretin-3',5'-di-C-hexoside; D) average 
replicate cumulative peak area of 3-hydroxyphloretin-3',5'-di-C-hexoside. Replicates five and six where 
excluded in all instances. 




































































































































































Supplementary Figure 8 Diffusion analysis of the benzophenones originating from SM6Met via 
porcine small intestine by means of comparing accumulated polyphenol small intestinal cross-over 
relative to its starting concentration. The permeability assay was performed at 37°C, over 24 h, using the 
flow-through diffusion system [16], where after fractions were analysed using LC-MS/MS to determine the 
presence of polyphenols originating from SM6Met. A) individual replicate cumulative peak area of 
iriflophenone-di-O,C-hexoside; B) average replicate cumulative peak area of iriflophenone-di-O,C-hexoside; 
C) individual replicate cumulative peak area of iriflophenone-3-C-glucoside; D) average replicate cumulative 
peak area of iriflophenone-3-C-glucoside. Replicates five and six where excluded in all instances. 




Supplementary Table 2. Calculated flux and Papp values from quantified SM6Met polyphenols pre and post-exclusion of replicates five and six 




Cumm peak area 







   








Xanthone Mangiferin 1.899 4.634 2.317 5.28 7.56 4.34 6.21 1.56 2.23 
 Isomangiferin 0.645 1.574 0.787 4.52 6.47 1.26 1.80 1.33 1.91 
           
Flavanone Eriocitrin (eriodictyol-7-O-
rutinoside) 
0.846 2.064 1.032 4.85 6.86 1.77 2.51 1.43 2.03 
 Hesperidin (hesperetin-7-O-
rutinoside) 
2.049 5.000 2.500 8.23 11.73 7.29 10.38 2.43 3.46 
           
Flavone Scolymoside (luteolin-7-O-
rutinoside)  
1.289 3.150 1.573 7.96 11.48 4.43 6.40 2.35 3.39 
           
Dihydrochalcone Phloretin-3',5'-di-C-glucoside 1.278 3.118 1.560 9.04 12.68 5.00 7.01 2.67 3.74 
 3-Hydroxyphloretin-3',5'-di-C-
hexoside 
0.700 1.708 0.854 5.35 7.48 1.62 2.26 1.58 2.21 
           
Benzophenone Iriflophenone-3-C-glucoside 0.669 1.632 0.817 6.48 8.93 1.87 2.58 1.91 2.64 
           
a
 refers to accumulated polyphenol peak area at 24 h relative to the polyphenol peak area in the positive control  
b





















1.899g/100g was the concentration of mangiferin present in SM6Met 
7.56 % was the accumulated peak area of mangiferin at 24 h relative to the mangiferin peak area in the positive control  
0.122 g was the amount of SM6Met loaded onto each replicate 
1440 min = 24 h x 60 min  
A=0.196 cm
2 











Calculation of Q and Co was performed as described in section 4.2.6 
Co is represented in mg/mL 
Q is represented as x 10
6  
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General discussion and conclusion 
  




Women in menopause have shown great interest in phytoestrogenic nutraceuticals as a safer 
alternative to conventional HRT [1-7], more specifically a nutraceutical that would effectively 
address menopausal symptoms, whilst, as a positive side effect, prevent breast cancer [8,9]. As 
phytoestrogens binds to both ERα and ERβ, with a higher binding affinity for ERβ than ERα [10-
13], phytoestrogenic preparations may serve as a source of ER subtype specific ligands [14]. This is 
promising for the future development of a nutraceutical as ERα activation is linked to breast cancer 
cell proliferation, whilst ERβ activation inhibits ERα mediated cell proliferation [15]. ERβ subtype 
specific ligands may thus serve as possible phytoestrogenic nutraceutical candidates, as they would 
be useful in the prevention and treatment of breast cancer [16-18] whilst alleviating menopausal 
symptoms [19-21]. 
A possible source of such ER subtype specific compounds has recently been identified by 
Mfenyana et al. [22] as the C. subternata sequential methanol extract, SM6Met. SM6Met acted as 
the most potent estrogenic extract compared to other Cyclopia extracts, with activity comparable to 
that of commercially available oral phytoestrogenic nutraceuticals. Subsequently the specific 
estrogenic profile of SM6Met was evaluated by Visser et al. [23] and three estrogenic traits well-
suited for the future development of an effective oral phytoestrogenic nutraceutical were 
highlighted. These desirable traits were selective ERβ activation, antagonism of ERα activity, and 
antagonism of E2-induced breast cancer cell proliferation, suggesting that either a compound or 
compounds in SM6Met may be suitable for the treatment of menopausal symptoms, while as a 
positive side effect preventing the development of breast cancer [15-18]. 
As part of an investigation into the possibility of SM6Met serving as a candidate source in the 
development of an oral phytoestrogenic nutraceutical, various drug development factors should be 
considered. Apart from identifying the active ingredient, determining a therapeutic dose, and 
establishing pharmacological properties, these factors include, amongst others, screening the 
compounds of interest for intestinal absorption, evaluating the effect of hepatic metabolism on 




compound stability, assessing compound interaction with other drugs, and calculating compound 
toxicity [24-27]. In addition, the compound administered should ideally have a high therapeutic 
index, so that the plasma level required to exert a toxic effect would be significantly higher than that 
required for therapeutic efficacy [24]. 
The first of the two main aims of the current study was to identify the estrogenic compounds in the 
SM6Met extract responsible for its desired estrogenic traits. Identification of the polyphenolic 
compounds was approached through specific estrogenic activity-guided fractionation of the extract. 
Successful identification of the bioactive compound(s) would be useful not only for quality control 
of a future nutraceutical, but also to screen prospective Cyclopia harvestings destined for 
nutraceutical production. In addition, such a marker compound(s) could in future be used to direct 
plant breeding programs. The second of the two main aims of the study was to determine whether 
the compounds of interest can indeed permeate the intestine in order to become bioavailable. 
Bioavailability is a crucial factor for compounds to have a desired therapeutic effect upon oral 
administration, and as such, absorption of SM6Met compounds were evaluated through analysis of 
SM6Met compound intestinal permeability using the ex vivo flow-through diffusion assay. 
The flow-through diffusion assay was the assay of choice for the evaluation of intestinal absorption 
of SM6Met polyphenols, as this approach has successfully been used in other absorption studies 
[28-30], and it allows for the use of intact porcine intestine. Porcine intestine has been shown to be 
physiologically more similar to human intestines than any other non-primate mammalian models 
[31]. As pharmacokinetic studies have shown that absorption may occur along the entire length of 
the intestine [32], our approach allowed investigation of both small and large intestinal tissue. The 
results from the ex vivo flow-through diffusion study were complemented by commonly used 
human absorption prediction software analysis, which are based on physicochemical profiling of the 
investigated compounds. 




Evaluation of large intestinal permeation of SM6Met polyphenols revealed an unexpected result, 
which was that none of the polyphenols could penetrate this barrier. The reason for this result was 
attributed to the absence of colonic microflora in the investigated absorption model. Colonic 
microflora are responsible for degradation of polyphenols to smaller polyphenolic acids, and as a 
result these compounds are then more readily absorbed [33]. Small intestinal permeation, however, 
did occur for all compounds, except for luteolin and quercetin rutinoside/neohesperidoside, and it 
was found that permeation of compounds occured in a concentration-dependent manner, which is 
commonly seen in absorption studies [34-36]. SM6Met compound classes allowed categorisation of 
preferential small intestinal permeation. It was found that when considering the compound 
concentration in the starting mixture and comparing it to the concentration thereof in collected 
fractions, on average the compound classes in order from high to low permeation preference were: 
dihydrochalcones, benzophenones, xanthones, flavanones, and flavones.  
It has been shown that C-glycosides are usually absorbed to a lesser extent than O-glycosides, as 
colonic microflora are less efficient in hydrolysing the more stable C-C bonds [37], however, the 
current study indicated that the compound classes with the highest degree of permeation were the 
classes containing C-glycosides, the dihydrochalcones, benzophenones and the xanthones. In 
addition, compounds containing a rutinoside moiety have been suggested to generally exhibit a 
lower degree of permeation compared to similar compounds containing a glucoside moiety [38], 
which was not found in the current study. 
In an attempt to predict human intestinal absorption of SM6Met polyphenols, both experimental 
and computational data were used. Papp values were calculated from experimental data, and software 
programs OSIRIS [39], ACD/Labs and ChemAxon [40], based on the physicochemical profiling of 





 correlating with good absorption in the human body [41,42]. In contrast, the 
ACD/Labs program predicted more than two Lipinski ―Rule-of-5‖ violations for all polyphenols 




investigated, except for luteolin, suggesting that these polyphenols would be poorly absorbed in the 
human body. The OSIRIS and ChemAxon programs, on the other hand, predicted good absorption 
of all compounds based on their individual cLogP values (< 5) and solubility (> -4). In addition, the 
OSIRIS program, considering most commercially available drugs as reference, calculated a low to 
moderate overall drug score for the respective compounds. 
Analysis of computational prediction data obtained from the various programs employed in this 
study revealed large variations between programs, as well as a divergence from experimental 
results. For future investigations experimental data should thus take priority, which could be 
accompanied by results obtained from a variety of commonly used, and well-established, software 
programs in order to obtain a more accurate prediction of the human intestinal absorption of a 
compound of interest. Even though the current study did not cater for the role of a number of factors 
that could alter the absorption of an active compound, such as the role of intestinal microflora, and 
compound metabolism and excretion, it did evaluate intestinal permeation, a prerequisite for orally-
administered compounds to become bioavailable. If the compounds evaluated for intestinal 
permeation in the current study are thus re-evaluated for absorption in the future, a more holistic 
test-system that incorporates the role of the intestinal microflora, and compound metabolism, and 
excretion should be used, in an attempt to more accurately predict human absorption of these 
compounds. However, the variable of compound permeation has now been established in the 
current thesis and can therefore be incorptorated in the evaluation of results from future absorption 
studies. 
Activity-guided fractionation combined with qHPLC was used in the isolation and identification of 
compounds contributing to the specific estrogenic activity of SM6Met. This approach is commonly 
used in the identification of compounds responsible for the specific activity of a mixture [19,43,44]. 
In contrast to most studies, the source of interest for the current study, SM6Met, has three attributes 
contributing to the holistic activity, of which two characteristics, ERα antagonism, and ERβ 




agonism, are most responsible for antagonism of E2-induced breast cancer cell-proliferation [15-
18], and as such, it made for a more complex investigation. Despite the complexity of the current 
study, it has previously been demonstrated that one compound could display more than one 
estrogenic attribute. For example, R,R-THC has been shown to be both an ERα agonist and an ERβ 
antagonist [45-47]. However, the possibility that one compound could be responsible for both the 
ERα antagonism and ERβ agonism displayed by SM6Met now seems unlikely, as HPCCC 
fractionation of the SM6Met derived NPF and subsequent activity tests revealed that HPCCC 
fractions F1 and F2 acted as ERα antagonists, while HPCCC fraction F3 acted as an ERβ agonist. It 
is thus evident that fractionation separated the two main desired estrogenic attributes of SM6Met, 
which dismisses the idea that a single compound combines both attributes. 
The activity-guided fractionation procedure followed in the current study included preliminary 
liquid-liquid fractionation of SM6Met to form two fractions, dissimilar based on their polarity, 
namely NPF and the PF. qHPLC analysis revealed that this procedure concentrated the compounds 
of SM6Met into NPF, and subsequent activity tests revealed that all of the desired estrogenic traits 
were consequently enhanced in NPF, but not in PF. NPF was therefore fractionated by HPCCC into 
fractions F1, F2, and F3. qHPLC analysis revealed that during this fractionation a differential 
distribution of NPF compounds into the HPCCC fractions occurred. Consequently the estrogenic 
traits were also separated as mentioned above, where F1 and F2 acted as ERα antagonists, and F3 
acted as the ERβ agonist. In addition, only F2 antagonised E2-induced breast cancer cell-
proliferation. This process not only revealed that more than one compound is most probably 
responsible for the estrogenic attributes of interest in SM6Met, but also that future studies should 
focus on NPF as the reference source of these traits, as all the traits of interest are present in this 
crude fraction. Furthermore, assessment of the synergistic, additive or antagonistic effects of the 
mixture of compounds present in NPF, not exhibited by the polyphenols individually, could be 
productive.  




Comparing the activity of the HPCCC fractions to literature data suggests that the only compound 
likely accountable for the ERα antagonism observed for HPCCC fractions F1 and F2, is eriocitrin, 
as this compound has been shown to bind ERα [48], and is present as a major compound in HPCCC 
fractions F1 and F2, but not in F3 (Fig. 6C & Table 4). However, the fact that F2 contains ten times 
more eriocitrin than F1, and results in the same degree of activity, suggests that, either the eriocitrin 
is not the only candidate responsible for ERα antagonism, or, that the degree of antagonism induced 
by the lower amount of eriocitrin cannot be exceeded. Interestingly, even though our own results 
suggested that the iriflophenone-3-C-glucoside-enriched (Fig. S4) fraction or the suite of minor 
compounds accompanying iriflophenone-3-C-glucoside in the enriched fraction (Fig. S4), could act 
as ERα and ERβ antagonists (Figs 8C&D), other studies have shown that iriflophenone-3-C-
glucoside induces proliferation of breast cancer cells [49,50]. 
In the current study it was shown that the most likely candidate responsible for the robust ERβ 
agonism of HPCCC fraction F3 is scolymoside, as the scolymoside-enriched fraction (Fig. S3) was 
solely responsible for the ERβ agonist activity of HPCCC fraction F3 (Fig. 8B). However, one 
cannot exclude the fact that the minor compounds present in the scolymoside-enriched fraction, 
could also have had an influence on ERβ agonist activity, and as such future studies should 
investigate pure scolymoside in order to obtain more conclusive results, as this compound has 
recently become commercially available. Interestingly, the aglycone of scolymoside, luteolin, which 
is a known phytoestrogen [51], has previously been shown to antagonise E2-induced breast cancer 
cell proliferation [51-53]. In contrast, our study did not show antagonism of E2-induced breast 
cancer cell proliferation (Fig. 9B) in the presence of luteolin, at the concentration present in 
HPCCC fraction F3. This result is in accordance with the antagonism of both ERα and ERβ induced 
by luteolin established in the current study (Figs. 8B&D). 
In a study by Li et al. [54] it was shown that the xanthone, mangiferin, has anti-tumour properties 
against MCF-7 breast cancer cells not mediated via the ER, but rather by regulating matrix 




metalloproteinases, the epithelial to mesenchymal transition, and the β-catenin signalling pathway. 
E2-induced breast cancer proliferation antagonism was, however, not exhibited by mangiferin in the 
current study at the concentration of mangiferin in HPCCC fraction F3 (Fig. 9B), despite the fact 
that our results indicated that mangiferin acts as an ERα antagonist, but not an ERβ antagonist 
(Figs. 8C&D). Interestingly, a novel result suggested that the regio-isomer of mangiferin, 
isomangiferin, acted as an ERβ antagonist. Another interesting result observed was that both 
investigated phenolic acids, p-coumaric acid and protocatechuic acid, displayed ERβ antagonism, 
while in addition, protocatechuic acid displayed ERα antagonism (Fig. 8C) and antagonism of E2-
induced breast cancer cell proliferation (Fig. 9B). 
In conclusion, activity-guided fractionation of SM6Met suggests that the desired estrogenic traits of 
the extract cannot be explained by only one compound. Compounds present in SM6Met or NPF 
might thus display additive, antagonistic, and/or synergistic activities in conferring these estrogenic 
traits. Previous studies have shown that iriflophenone-3-C-glucoside, present in HPCCC fractions 
F2 and F3, may exert synergistic effects on other compounds present in SM6Met and NPF [55,56]. 
These compounds include mangiferin and hesperidin, which has been linked to anti-diabetic and 
cholesterol-lowering effects seen in rat models [57]. Investigation of the synergistic estrogenic 
effects of iriflophenone-3-C-glucoside and hesperidin could be interesting as both compounds are 
present in NPF, the iriflophenone-3-C-glucoside enriched fraction (Fig. S4), and in HPCCC fraction 
F2. Also, interestingly, it has recently been demonstrated by Bartoszewski et al. [58] that even 
though hesperidin has been shown to elicit cell growth arrest and apoptosis in various cancer cell 
lines including pancreatic cancer cells, colon cells, and breast cancer cells [59-62], the presence of 
mangiferin results in an additive apoptotic effect compared to the effect seen by hesperidin alone. 
A shortcoming of the current study is that reconstitution of HPCCC fractions only included the 
major quantifiable compounds, and not the minor compounds, and as such, future work could 
include the reconstitution of HPCCC fractions F1-F3 for comparison with the original fractions 




using not only pure quantifiable compounds for reconstitution, but also pure minor compounds. 
This will allow for a more specific and definite correlation of compounds and their related 
activities. Furthermore, the estrogenic assays used in the current study could be expanded to allow 
for a more stringent activity-guidance procedure. In vitro assays that could for example be included 
are, whole cell binding, determination of ERα and ERβ levels, ERα and ERβ hetero- and homo-
dimerization, and microarray analyses to evaluate effects on endogenous genes. In vivo absorption 
analysis of the less complex HPCCC fractions F1-F3, for comparison with the current in vitro 
absorption study, and also blood samples from a previously performed in vivo immature rat 
uterotrophic study investigating SM6Met [23] (Appendix 1), can also be investigated.  
The idea of intelligent mixtures in the investigation of activity, induced by a mixture of compounds, 
has become increasingly popular [63-68], and as NPF more prominently displays all the desired 
estrogenic traits of SM6Met, future work will focus on the identification and production of an 
intelligent mixture where NPF will serve as a reference extract. Activity analysis of intelligent 
mixtures would allow the investigator to establish whether synergistic, additive or antagonistic 
effects contribute to the desired estrogenic traits. Furthermore, it has been shown that absorption of 
a compound can either be increased or decreased in the presence of other compounds. For example, 
it has been shown that a polyphenol-based matrix, due to the presence of specific polyphenols, can 
result in an increase [69,70], decrease [71,72] or have no effect, on the absorption of other 
polyphenols [73]. In addition, polyphenols can increase drug absorption [74] through the inhibition 
of CYP3A4 [75,76] or the inhibition of monocarboxylate transporter 1 (MCT1) activity [77]. 
Absorption analysis of intelligent mixtures both in vivo and in vitro, and comparison of these results 
to the results obtained with the individual polyphenols, and with NPF, would reveal permeation 
accelarating or permeation retarding effects present in NPF, and also the compounds responsible for 
these effects.  




In summary, the current study illustrated that it is unlikely that one compound is responsible for the 
desired estrogenic attributes displayed by SM6Met, but rather that multiple polyphenols contribute 
to the activity of the extract, either individually, or by eliciting an additive, synergistic or 
antagonistic effect in the presence of other SM6Met polyphenols. Furthermore, the current study 
established that most of the polyphenols in SM6Met could penetrate the human small intestine, and 
as such, these compounds could become bioavailable in order to elicit biological effects. By 
attempting to identify the compounds conferring phytoestrogenic activity to SM6Met, and to predict 
whether these compounds are able to penetrate the human intestinal barrier, valuable information 
was gained. Thus the current study could serve as a stepping stone in the possible future 
development of a uniquely South African honeybush-derived oral phytoestrogenic nutraceutical. 
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